Horizon Technology Finance (HRZN) 10-Q 1 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 01, 2022
Document Information [Line Items]
Entity Central Index Key	0001487428
Entity Registrant Name	Horizon Technology Finance Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	814-00802
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-2114934
Entity Address, Address Line One	312 Farmington Avenue
Entity Address, City or Town	Farmington
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06032
City Area Code	860
Local Phone Number	676‑8654
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,401,476
The 6.25% Notes due 2027 [Member]
Document Information [Line Items]
Title of 12(b) Security	6.25% Notes due 2027
Trading Symbol	HTFC
Security Exchange Name	NYSE
The 4.875% Notes due 2026 [Member]
Document Information [Line Items]
Title of 12(b) Security	4.875% Notes due 2026
Trading Symbol	HTFB
Security Exchange Name	NYSE
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	HRZN
Security Exchange Name	NASDAQ

Consolidated Statements of Asse

Consolidated Statements of Assets and Liabilities (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Assets
Investments at fair value	$ 634,624	$ 458,075
Cash	23,839	38,054
Investments in money market funds	7,732	7,868
Restricted investments in money market funds	1,617	1,359
Interest receivable	10,975	6,154
Other assets	2,602	2,450
Total assets	681,389	513,960
Liabilities
Borrowings (Note 7)	359,011	257,613
Distributions payable	7,918	6,365
Base management fee payable (Note 3)	1,870	706
Incentive fee payable (Note 3)	2,784	2,015
Other accrued expenses	2,119	1,926
Total liabilities	373,702	268,625
Commitments and contingencies (Note 8)
Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 26,561,238 and 21,384,925 shares issued and 26,393,773 and 21,217,460 shares outstanding as of September 30, 2022 and December 31, 2021, respectively	27	22
Paid-in capital in excess of par	369,334	301,359
Distributable earnings	(61,674)	(56,046)
Total net assets	307,687	245,335
Total liabilities and net assets	$ 681,389	$ 513,960
Net asset value per common share (in dollars per share)	$ 11.66	$ 11.56
Non-affiliate [Member]
Assets
Investments at fair value	$ 634,624	$ 458,075
Affiliate [Member]
Assets
Investments at fair value	$ 0	$ 0

Consolidated Statements of As_2

Consolidated Statements of Assets and Liabilities (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Investments at cost	$ 629,216	$ 453,837
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares oustanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	26,561,238	21,384,925
Common stock, shares outstanding (in shares)	26,393,773	21,217,460
Non-affiliate [Member]
Investments at cost	$ 629,216	$ 452,387
Affiliate [Member]
Investments at cost	$ 0	$ 1,450

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Investment income
Interest income on investments	$ 22,745	$ 14,035	$ 54,317	$ 39,178
Total fee income	509	2,332	1,729	3,892
Total investment income	23,254	16,367	56,046	43,070
Expenses
Interest expense	5,339	3,112	12,987	8,781
Base management fee (Note 3)	2,788	1,997	7,555	5,595
Performance based incentive fee (Note 3)	2,784	2,012	6,353	5,040
Administrative fee (Note 3)	412	251	1,147	829
Professional fees	314	559	1,163	1,348
General and administrative	381	333	1,088	1,142
Total expenses	12,018	8,264	30,293	22,735
Net investment income before excise tax	11,236	8,103	25,753	20,335
Provision for excise tax	100	56	306	174
Net investment income	11,136	8,047	25,447	20,161
Net realized and unrealized (loss) gain
Net realized (loss) gain on investments	(8,585)	1,344	(9,484)	(2,372)
Net realized loss on extinguishment of debt	0	0	0	(395)
Net realized (loss) gain	(8,585)	1,344	(9,484)	(2,767)
Net unrealized (depreciation) appreciation on investments	3,442	3,376	1,169	8,122
Net realized and unrealized (loss) gain	(5,143)	4,720	(8,315)	5,355
Net increase in net assets resulting from operations	$ 5,993	$ 12,767	$ 17,132	$ 25,516
Net investment income per common share (in dollars per share)	$ 0.43	$ 0.40	$ 1.06	$ 1.02
Net increase in net assets resulting from operations per common share (in dollars per share)	0.23	0.63	0.71	1.29
Distributions declared per share (in dollars per share)	$ 0.30	$ 0.30	$ 0.90	$ 0.90
Weighted average shares outstanding (in shares)	25,738,054	20,269,813	23,995,369	19,826,790
Non-affiliate [Member]
Investment income
Interest income on investments	$ 22,745	$ 14,035	$ 54,317	$ 38,965
Prepayment fee income on non-affiliate investments	450	1,204	1,542	2,460
Success fee income on non-affiliate investments	0	1,100	0	1,100
Fee income on investments	59	28	187	320
Net realized and unrealized (loss) gain
Net realized (loss) gain on investments	(8,665)	1,344	(8,364)	(2,372)
Net unrealized (depreciation) appreciation on investments	3,442	3,929	(281)	10,314
Affiliate [Member]
Investment income
Interest income on investments	0	0	0	213
Fee income on investments	0	0	0	12
Non-controlled Affiliate [Member]
Net realized and unrealized (loss) gain
Net realized (loss) gain on investments	30	0	30	0
Net unrealized (depreciation) appreciation on investments	0	(228)	0	(1,867)
Controlled Affiliate [Member]
Net realized and unrealized (loss) gain
Net realized (loss) gain on investments	50	0	(1,150)	0
Net unrealized (depreciation) appreciation on investments	$ 0	$ (325)	$ 1,450	$ (325)

Consolidated Statements of Chan

Consolidated Statements of Changes in Net Assets (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Common Stock Outstanding [Member]
Balance (in shares)	24,857,104	20,024,241	21,217,460	19,286,356	19,286,356
Issuance of common stock, net of offering costs (in shares)	1,523,519	395,068	5,141,920	1,122,516
Issuance of common stock under dividend reinvestment plan (in shares)	13,150	5,866	34,393	16,303
Balance (in shares)	26,393,773	20,425,175	26,393,773	20,425,175	21,217,460
Common Stock [Member]
Balance	$ 26	$ 20	$ 22	$ 19	$ 19
Issuance of common stock, net of offering costs	1	1	5	2
Net investment income, net of excise tax	0	0	0	0
Net realized gain on investments	0	0	0	0
Unrealized Gain (Loss) on Investments	0	0	0	0
Issuance of common stock under dividend reinvestment plan	0	0	0	0
Distributions declared	0	0	0	0
Net unrealized appreciation on investments	0	0	0	0
Net realized loss on extinguishment of debt				0
Balance	27	21	27	21	22
Additional Paid-in Capital [Member]
Balance	350,173	282,136	301,359	271,287	271,287
Issuance of common stock, net of offering costs	18,995	6,624	67,519	17,312
Net investment income, net of excise tax	0	0	0	0
Net realized gain on investments	0	0	0	0
Unrealized Gain (Loss) on Investments	0	0	0	0
Issuance of common stock under dividend reinvestment plan	166	101	456	262
Distributions declared	0	0	0	0
Net unrealized appreciation on investments	0	0	0	0
Net realized loss on extinguishment of debt				0
Balance	369,334	288,861	369,334	288,861	301,359
Retained Earnings [Member]
Balance	(59,594)	(57,892)	(56,046)	(58,709)	(58,709)
Issuance of common stock, net of offering costs	0	0	0	0
Net investment income, net of excise tax	11,136	8,047	25,447	20,161
Net realized gain on investments	(8,585)	1,344	(9,484)	(2,372)
Unrealized Gain (Loss) on Investments	3,442	3,376	1,169	8,122
Issuance of common stock under dividend reinvestment plan	0	0	0	0
Distributions declared	(8,073)	(6,167)	(22,760)	(18,099)
Net unrealized appreciation on investments	3,442	3,376	1,169	8,122
Net realized loss on extinguishment of debt				(395)
Balance	(61,674)	(51,292)	(61,674)	(51,292)	(56,046)
Balance	290,605	224,264	245,335	212,597	212,597
Issuance of common stock, net of offering costs	18,996	6,625	67,524	17,314
Net investment income, net of excise tax	11,136	8,047	25,447	20,161
Net realized gain on investments	(8,585)	1,344	(9,484)	(2,372)
Unrealized Gain (Loss) on Investments	3,442	3,376	1,169	8,122
Issuance of common stock under dividend reinvestment plan	166	101	456	262
Distributions declared	(8,073)	(6,167)	(22,760)	(18,099)
Net unrealized appreciation on investments	3,442	3,376	1,169	8,122
Net realized loss on extinguishment of debt	0	0	0	(395)
Balance	$ 307,687	$ 237,590	$ 307,687	$ 237,590	$ 245,335

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net increase in net assets resulting from operations	$ 5,993	$ 12,767	$ 17,132	$ 25,516
Adjustments to reconcile net increase in net assets resulting from operations to net cash used in operating activities:
Amortization of debt issuance costs	400	200	1,142	744
Net realized loss on investments			9,484	2,372
Net realized loss on extinguishment of debt	0	0	0	395
Net unrealized appreciation on investments	(3,442)	(3,376)	(1,169)	(8,122)
Purchase of investments			(348,347)	(217,252)
Principal payments received on investments			114,433	119,260
Proceeds from sale of investments			49,681	5,285
Changes in assets and liabilities:
Increase in interest receivable			(2,175)	(661)
Increase in end-of-term payments			(3,003)	(1,100)
Decrease in unearned income			(274)	(854)
Decrease (increase) in other assets			115	(507)
Increase in other accrued expenses			193	76
Increase in base management fee payable			1,164	135
Increase in incentive fee payable			769	1,037
Net cash used in operating activities			(160,855)	(73,676)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs			67,525	17,312
Advances on Credit Facilities			119,000	89,000
Repayment of Credit Facilities			(47,000)	(36,000)
Debt issuance costs			(2,470)	(2,648)
Distributions paid			(20,752)	(17,493)
Net cash provided by financing activities			146,762	70,296
Net decrease in cash, cash equivalents and restricted cash			(14,093)	(3,380)
Cash, cash equivalents and restricted cash:
Beginning of period			47,281	47,758	$ 47,758
End of period	33,188	44,378	33,188	44,378	47,281
Supplemental disclosure of cash flow information:
Cash paid for interest			11,543	7,785
Supplemental non-cash investing and financing activities:
Warrant investments received and recorded as unearned income			2,969	2,924
Distributions payable	7,918	6,128	7,918	6,128	6,365
End-of-term payments receivable			8,240	4,993
Non-cash income			4,504	3,523
Cash	23,839	20,817	23,839	20,817	38,054
Investments in money market funds	7,732	22,057	7,732	22,057	$ 7,868
Restricted investments in money market funds	1,617	1,504	1,617	1,504
Total cash, cash equivalents and restricted cash	$ 33,188	$ 44,378	33,188	44,378
The 2027 Notes [Member]
Cash flows from financing activities:
Proceeds from issuance of notes			57,500	0
The 2026 Notes [Member]
Cash flows from financing activities:
Proceeds from issuance of notes			0	57,500
Asset-Backed Notes [Member]
Cash flows from financing activities:
Repayment of notes			(27,041)	0
The 2022 Notes [Member]
Cash flows from financing activities:
Repayment of notes			$ 0	$ (37,375)

Consolidated Schedule of Invest

Consolidated Schedule of Investments (Unaudited)	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Investment Holdings, Schedule of Investments [Text Block]	September 30, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 206.2% Non-Affiliate Debt Investments — 197.9% Non-Affiliate Debt Investments — Life Science — 83.0% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,885 $ 2,817 $ 2,765 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,885 2,817 2,765 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,442 1,435 1,410 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,813 2,763 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,813 2,763 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,404 1,379 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,404 1,379 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,887 4,887 Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,959 4,959 Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,976 2,976 Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,959 4,959 Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,959 4,959 Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,975 2,975 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 10.45 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 2,188 2,168 2,168 Term Loan 10.45 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 2,188 2,169 2,169 Term Loan 10.45 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,000 4,916 4,916 Term Loan 10.45 % Libor 7.90 % 9.75 % - 5.00 % May 1, 2026 5,000 4,902 4,902 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % April 1, 2025 2,500 2,473 2,473 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,471 2,471 Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 12.00 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 5,000 4,843 4,843 Term Loan 12.00 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 2,500 2,423 2,423 IMV Inc. (2)(5)(12) Biotechnology Term Loan 12.00 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 5,000 4,942 4,942 Term Loan 12.00 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 2,500 2,470 2,470 Term Loan 12.00 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,942 4,942 Term Loan 12.00 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,941 4,941 KSQ Therapeutics, Inc. (2) (12) Biotechnology Term Loan 11.00 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,071 6,071 Term Loan 11.00 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,172 6,172 LogicBio, Inc. (2)(5)(12) Biotechnology Term Loan 8.80 % Libor 6.25 % 8.75 % - 4.50 % June 1, 2024 2,778 2,766 2,766 Native Microbials, Inc (2) (12) Biotechnology Term Loan 11.50 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,633 3,633 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 12.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,688 9,688 Term Loan 12.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,692 3,692 Term Loan 12.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,692 3,692 Provivi, Inc. (2)(12) Biotechnology Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,666 4,618 4,618 Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,666 4,618 4,618 Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,288 2,288 Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,288 2,288 Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,281 2,281 Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,281 2,281 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Stealth Biotherapeutics Inc. (2)(5)(12) Biotechnology Term Loan 11.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 5,000 4,906 4,906 Term Loan 11.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,500 2,453 2,453 Aerobiotix, LLC (2)(12) Medical Device Term Loan 12.50 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,462 2,366 Term Loan 12.50 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,462 2,365 Canary Medical Inc. (2)(12) Medical Device Term Loan 11.25 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,438 2,438 Term Loan 11.25 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,486 2,486 Term Loan 11.25 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,466 2,466 Ceribell, Inc. (2)(12) Medical Device Term Loan 9.00 % Prime 3.75 % 8.25 % - 5.50 % October 1, 2024 5,000 4,965 4,965 Term Loan 9.00 % Prime 3.75 % 8.25 % - 5.50 % October 1, 2024 5,000 4,969 4,969 Term Loan 9.00 % Prime 3.75 % 8.25 % - 5.50 % October 1, 2024 2,500 2,475 2,475 Term Loan 9.00 % Prime 3.75 % 8.25 % - 5.50 % October 1, 2024 2,500 2,475 2,475 Cognoa, Inc. (2)(12) Medical Device Term Loan 11.75 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 5,000 4,924 4,924 Term Loan 11.75 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,500 2,462 2,462 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 10.55 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,892 3,892 Term Loan 10.55 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,892 3,892 Corinth Medtech, Inc. (2)(12) Medical Device Term Loan 10.75 % Prime 5.25 % 8.50 % - 20.00 % September 15, 2022 2,500 2,500 2,500 Term Loan 10.75 % Prime 5.25 % 8.50 % - 20.00 % September 15, 2022 2,500 2,500 2,500 CSA Medical, Inc. (2)(12) Medical Device Term Loan 10.75 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 2,000 1,981 1,981 Term Loan 10.75 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 133 132 132 Term Loan 10.75 % Libor 8.20 % 10.00 % - 5.00 % March 1, 2024 2,400 2,379 2,379 Embody, Inc. (2)(12) Medical Device Term Loan 12.75 % Prime 6.50 % 9.75 % - 28.00 % August 1, 2026 2,500 2,461 2,461 InfoBionic, Inc. (2)(12) Medical Device Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 3,500 3,425 3,425 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 971 971 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 10.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,810 4,810 Term Loan 10.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,932 4,932 Term Loan 10.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,925 4,925 Term Loan 10.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,926 4,926 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 10.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,593 3,593 Term Loan 10.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,702 3,702 Sonex Health, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 6.50 % 9.75 % - 5.00 % June 1, 2025 2,500 2,428 2,428 Term Loan 12.00 % Prime 6.50 % 9.75 % - 5.00 % June 1, 2025 2,500 2,473 2,473 Term Loan 12.00 % Prime 6.50 % 9.75 % - 5.00 % June 1, 2025 2,500 2,473 2,473 Term Loan 12.00 % Prime 6.50 % 9.75 % - 8.00 % April 1, 2026 2,500 2,455 2,455 Spineology, Inc. (2)(12) Medical Device Term Loan 13.25 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,963 4,963 Term Loan 13.25 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,479 2,479 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Swift Health Systems Inc. (2)(12) Medical Device Term Loan 10.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,345 3,345 Term Loan 10.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,451 3,451 Total Non-Affiliate Debt Investments — Life Science 255,997 255,525 Non-Affiliate Debt Investments — Sustainability — 24.7% Dream Holdings, Inc. (2)(12) Other Sustainability Term Loan 13.00 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,692 3,692 Term Loan 13.00 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,692 3,692 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Term Loan 13.25 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,359 7,359 Term Loan 13.25 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,359 7,359 Term Loan 13.25 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,359 7,359 Term Loan 13.25 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,893 4,893 Term Loan 13.25 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,893 4,893 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,919 4,919 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,313 2,313 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,916 4,916 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,458 2,458 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,694 3,694 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,713 3,713 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 7,500 7,417 7,417 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,709 3,709 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,709 3,709 Total Non-Affiliate Debt Investments — Sustainability 76,095 76,095 Non-Affiliate Debt Investments — Technology — 80.2% Axiom Space, Inc. (2)(12) Communications Term Loan 11.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,452 7,452 Term Loan 11.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,452 7,452 Term Loan 11.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,452 7,452 Convertible Note 3.00 % July 1, 2023 250 250 250 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Term Loan 12.25 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 5,000 4,961 4,961 Term Loan 12.25 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 5,000 4,961 4,961 Term Loan 12.25 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 3,000 2,977 2,977 Term Loan 12.25 % Prime 6.75 % 10.00 % - 3.00 % December 1, 2025 1,000 974 974 Term Loan 12.25 % Prime 6.75 % 10.00 % - 3.00 % February 1, 2026 1,000 974 974 Better Place Forests Co. (2)(12) Consumer-related Technologies Term Loan 12.50 % Prime 6.25 % 9.50 % - 1.85 % July 1, 2025 5,000 4,944 4,944 Term Loan 12.50 % Prime 6.25 % 9.50 % - 1.85 % October 1, 2025 2,500 2,474 2,474 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 13.50 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,458 3,458 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,500 2,481 2,481 Term Loan 11.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,500 2,481 2,481 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,397 3,397 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,237 1,237 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,712 3,712 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,237 1,237 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,712 3,712 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,237 1,237 Interior Define, Inc. (2)(12) Consumer-related Technologies Term Loan 12.75 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 6,500 6,417 5,215 Term Loan 12.75 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 6,000 5,858 4,760 Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 13.00 % Prime 6.75 % 10.00 % - 9.75 % January 1, 2024 2,500 2,585 2,219 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 13.00 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 5,000 4,947 4,947 Term Loan 13.00 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,500 2,474 2,474 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 5,000 4,947 4,947 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 2,000 1,979 1,979 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 2,500 2,474 2,474 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 3,000 2,968 2,968 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 2,500 2,453 2,453 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 2,500 2,453 2,453 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 5,000 4,904 4,904 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 2,500 2,450 2,450 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,339 2,339 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 12.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,900 2,870 2,870 Term Loan 12.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,900 2,870 2,870 Term Loan 12.75 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 3,000 2,964 2,964 Unagi, Inc. (2)(12) Consumer-related Technologies Term Loan 14.00 % Prime 7.25 % 11.00 % - - July 1, 2025 2,500 2,471 2,317 Term Loan 14.00 % Prime 7.25 % 11.00 % - - July 1, 2025 1,250 1,235 1,158 Term Loan 14.00 % Prime 7.25 % 11.00 % - - July 1, 2025 1,250 1,234 1,157 Liqid, Inc. (2)(12) Networking Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 3,833 3,779 3,779 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 3,833 3,779 3,779 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,917 1,887 1,887 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,917 1,887 1,887 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,917 1,855 1,855 BriteCore Holdings, Inc. (2)(12) Software Term Loan 12.25 % Prime 6.75 % 10.00 % - 4.00 % October 1, 2024 2,500 2,420 2,420 Term Loan 12.25 % Prime 6.75 % 10.00 % - 4.00 % October 1, 2024 2,500 2,486 2,486 Decisyon, Inc. (12) Software Term Loan 15.68 % Prime 9.43 % 12.68 % - 50.43 % December 31, 2022 3,313 3,313 3,313 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 12.75 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,500 6,147 6,147 Term Loan 12.75 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,000 5,847 5,847 Term Loan 12.75 % Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,500 2,431 2,431 Engage3, LLC (2)(12) Software Term Loan 12.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,675 3,675 Term Loan 11.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,715 3,715 Kodiak Robotics, Inc. (2)(12) Software Term Loan 11.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,809 9,809 Term Loan 11.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,809 9,809 Term Loan 11.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,904 4,904 Term Loan 11.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,904 4,904 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 12.75 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,941 4,941 Term Loan 12.75 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,471 2,471 Lytics, Inc. (2)(12) Software Term Loan 11.50 % Prime 6.00 % 9.25 % - 3.00 % July 1, 2025 2,500 2,472 2,472 Reputation Institute, Inc. (2)(12) Software Term Loan 12.75 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 5,000 4,926 4,926 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 12.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,927 4,927 Term Loan 12.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,927 4,927 Term Loan 12.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,863 4,863 Term Loan 12.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,927 4,927 Supply Network Visiblity Holdings LLC (2)(12) Software Term Loan 12.00 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,500 3,469 3,469 Term Loan 12.00 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,500 3,469 3,469 Term Loan 12.00 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,470 2,470 Term Loan 12.00 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,470 2,470 Total Non-Affiliate Debt Investments — Technology 249,694 246,720 Non-Affiliate Debt Investments — Healthcare information and services — 10.0% Hound Labs inc. (2) (12) Diagnostics Term Loan 12.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,383 2,383 Term Loan 12.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,470 2,470 Term Loan 12.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,940 4,940 Secure Transfusion Services, Inc. (2)(12) Other Healthcare Term Loan 12.00 % Prime 5.75 % 9.00 % - 4.00 % October 1, 2025 5,000 4,934 4,934 Term Loan 12.00 % Prime 5.75 % 9.00 % - 4.00 % December 31, 2025 2,500 2,463 2,463 BrightInsight, Inc. (2)(12) Software Term Loan 11.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,612 6,612 Term Loan 11.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,445 3,445 Term Loan 11.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,445 3,445 Total Non-Affiliate Debt Investments — Healthcare information and services 30,692 30,692 Total Non- Affiliate Debt Investments 612,478 609,032 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2022 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 7.2% Non-Affiliate Warrants — Life Science — 1.8% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,442 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 5,372 214 104 Corvium, Inc. (2)(12) Biotechnology Preferred Stock Warrant 661,956 52 — Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 176 244 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 21,120 35 — Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 71,292 366 5 Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 16,502 65 — IMV Inc. (2)(5)(12) Biotechnology Common Stock Warrant 397,726 67 4 KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,077 50 54 LogicBio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 7,843 8 — Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 252,161 146 — Native Microbials, Inc (2) (12) Biotechnology Preferred Stock Warrant 94,253 52 59 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 160 160 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 164,608 278 513 Rocket Pharmaceuticals Corporation (5)(12) Biotechnology Common Stock Warrant 7,051 17 1 Stealth Biotherapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 795,455 264 — vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 2 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 23 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 64 1,187 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 27,330 46 52 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 85 1,865 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 204 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 775,000 148 167 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 221 209 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,375,727 153 134 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 47 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 111 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2022 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 699,485 141 135 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 221,510 82 142 Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 19,662 39 43 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 605,313 97 113 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 — Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 79 Total Non-Affiliate Warrants — Life Science 3,869 5,634 Non-Affiliate Warrants — Sustainability — 0.5% Dream Holdings, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 70,539 61 68 LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,539 39 45 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Common Stock Warrant 209,669 489 888 Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 345 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 35,906 126 259 Total Non-Affiliate Warrants — Sustainability 929 1,605 Non-Affiliate Warrants — Technology — 4.2% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 47 52 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 138 3,219 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 92 193 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 57 Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Better Place Forests Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 10,690 27 32 Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 68 1,068 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 17,605 24 61 Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 31 378 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 25,758 30 35 Getaround, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 651,040 450 199 Interior Define, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,710 103 — MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 143 29 33 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 630,626 188 116 Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,600 104 104 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 425 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 324 525 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 38 Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 12 CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 895 Silk, Inc. (2)(12) Data Storage Preferred Stock Warrant 442,110 234 316 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 — Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 500 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 799 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 226 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,254 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrants 6,081 56 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 77,828 21 64 Decisyon, Inc. (12) Software Common Stock Warrant 82,967 46 — Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 187 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 152,908 60 1 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 273 273 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 34 38 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 288,115 22 306 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 26,733 11 14 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 56 35 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 498,241 47 81 Riv Data Corp. (2)(12) Software Preferred Stock Warrant 321,428 12 296 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Skyword, Inc. (12) Software Preferred and Common Stock Warrants 301,055 48 9 Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 123 Supply Network Visiblity Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 74 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 135 — xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 2 Total Non-Affiliate Warrants — Technology 6,685 13,040 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2022 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 159,893 47 51 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 103 1,217 Watermark Medical, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 27,373 73 — Secure Transfusion Services, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 77,690 48 68 BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 80,544 157 157 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 60 341 Total Non-Affiliate Warrants — Healthcare information and services 488 1,834 Total Non-Affiliate Warrants 11,971 22,113 Non-Affiliate Other Investments — 0.4% Lumithera, Inc. (2) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — 200 Total Non-Affiliate Other Investments 1,200 1,300 Non-Affiliate Equity — 0.7% Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 829,674 8 83 Lumithera, Inc. (2) Medical Device Common Stock 392,651 2,000 1,700 Branded Online, Inc. (5)(12) Software Common Stock 108,004 1,079 146 Decisyon, Inc. (12) Software Preferred and Common Stock 72,638,663 230 — Total Non-Affiliate Equity 3,567 2,179 Total Non-Affiliate Portfolio Investment Assets $ 629,216 $ 634,624 Total Portfolio Investment Assets — 206.3% $ 629,216 $ 634,624 Short Term Investments — Unrestricted Investments — 2.5% US Bank Money Market Deposit Account $ 7,732 $ 7,732 Total Short Term Investments — Unrestricted Investments $ 7,732 $ 7,732 Short Term Investments — Restricted Investments — 0.5% US Bank Money Market Deposit Account $ 1,617 $ 1,617 Total Short Term Investments — Restricted Investments $ 1,617 $ 1,617 ( 1 All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States. ( 2 Has been pledged as collateral under the revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), the Note Funding Agreement (the “NYL Facility” and, together with the Key Facility, the “Credit Facilities”) with several entities owned or affiliated with New York Life Insurance Company (“NYL Noteholders”) and/or the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjunction with the $160.0 million securitization of secured loans the Company completed on August 13, 2019 ( ( 3 All non-affiliate investments are investments in which the Company owns less than 5% 5% not 25% 25% ( 4 All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not one September 30, 2022 ( 5 Portfolio company is a public company. ( 6 For debt investments, represents principal balance less unearned income. ( 7 Warrants, Equity and Other Investments are non-income producing. ( 8 Value as a percent of net assets. ( 9 As of September 30, 2022 55 1940, “1940 may not 70% ( 10 ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may not ( 11 Debt investment has a payment-in-kind (“PIK”) feature. ( 12 The fair value of the investment was valued using significant unobservable inputs. See Notes to Consolidated Financial Statements Consolidated Schedule of Investments December 31, 2021 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 186.7% Non-Affiliate Debt Investments — 178.3% Non-Affiliate Debt Investments — Life Science — 77.3% Castle Creek Pharmaceuticals Holdings, Inc. (2)(12) Biotechnology Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 $ 5,000 $ 4,957 $ 4,957 Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 5,000 4,957 4,957 Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 5,000 4,957 4,957 Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 5,000 4,957 4,957 Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 5,000 4,909 4,909 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 5,000 4,909 4,909 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,500 2,454 2,454 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 5,000 4,906 4,906 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 5,000 4,906 4,906 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 2,500 2,451 2,451 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 2,500 2,451 2,451 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 9.75 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 2,500 2,420 2,420 Term Loan 9.75 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 2,500 2,472 2,472 Term Loan 9.75 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,000 4,896 4,896 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % April 1, 2025 2,500 2,465 2,465 Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,463 2,463 Greenlight Biosciences, Inc. (2)(12) Biotechnology Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 5,000 4,850 4,850 Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,475 2,475 IMV Inc. (2)(5)(12) Biotechnology Term Loan 9.00 % Prime 6.25 % 9.00 % - 5.00 % July 1, 2025 5,000 4,799 4,799 Term Loan 9.00 % Prime 6.25 % 9.00 % - 5.00 % July 1, 2025 2,500 2,462 2,462 LogicBio, Inc. (2)(5)(12) Biotechnology Term Loan 8.75 % Libor 6.25 % 8.75 % - 4.50 % June 1, 2024 4,028 4,011 4,011 Provivi, Inc. (2)(12) Biotechnology Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 5,000 4,935 4,935 Term Loan 9.50 % Libo

Note 1 - Organization

Note 1 - Organization	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 1940 1986, not On October 28, 2010, Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, not The Company formed Horizon Funding 2019‑1 “2019‑1 May 2, 2019 2019‑1 May 15, 2019 “2019‑1 2019‑1 “2019‑1 2019‑1 2019‑1 The Company and Arena Sunset SPV, LLC (“Arena”) formed Horizon Funding I, LLC (“HFI”) as a Delaware limited liability company on May 9, 2018, not On April 21, 2020, April 21, 2020, The Company has also established an additional wholly owned subsidiary, which is structured as a Delaware limited liability company, to hold the assets of a portfolio company acquired in connection with foreclosure or bankruptcy, which is a separate legal entity from the Company. The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company. On March 14, 2022,

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 2. The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑Q 6 10 X X” 1933, not may December 31, 2021 Principles of consolidation As required under GAAP and Regulation S- X, Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 not Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments. Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment. Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may September 30, 2022 December 31, 2021 one three nine September 30, 2022 not three September 30, 2021 not nine September 30, 2021 one The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not three September 30, 2022 2021 not nine September 30, 2022 2021 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 three September 30, 2022 2021 nine September 30, 2022 2021 Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no December 31, 2021 Depending on the level of taxable income earned in a tax year, the Company may three nine September 30, 2022 three nine September 30, 2021 The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not September 30, 2022 December 31, 2021 2021, 2020 2019 Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may Stockholders Equity On July 30, 2020, “2020 2020 may On August 2, 2021, 2020 “2021 2020 no 2021 may may 415 During the three September 30, 2022 2021 During the three September 30, 2021 2020 2021 During the nine September 30, 2022 2021 During the nine September 30, 2021 2020 2021 The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of September 30, 2022 Stock Repurchase Program On April 29, 2022, may, not 10b‑18 1934, 1940 June 30, 2023 $5.0 three nine September 30, 2022 2021 not September 30, 2022 Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not Recently issued accounting pronouncements In March 2020, No. 2020 04, 848 2020 04” 2020 04 2020 04 March 12, 2020 December 31, 2022. 2020 04 In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 3. Investment Management Agreement At a special meeting of the stockholders on October 30, 2018, March 7, 2019. October 28, 2010 July 1, 2014. October 28, 2022, The Advisor’s services under the Investment Management Agreement are not not two The base management fee will be calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 $250 The base management fee payable at September 30, 2022 December 31, 2021 three September 30, 2022 2021 nine September 30, 2022 2021 The incentive fee has two The first zero not no 1.75%, 2.1875% 20.00% not Pre-Incentive Fee Net Investment Income does not may 2.00% three The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three 11 may 20.00% zero not three The second 20.00% not The performance based incentive fee expense was $2.8 million and $2.0 million for the three September 30, 2022 2021 nine September 30, 2022 2021 not three nine September 30, 2022 2021 September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 one Administration Agreement The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $0.4 million and $0.3 million for the three September 30, 2022 2021 nine September 30, 2022 2021

Note 4 - Investments

Note 4 - Investments	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Investment Holdings [Text Block]	Note 4. The following table shows the Company’s investments as of September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 612,478 $ 609,032 $ 441,885 $ 437,317 Warrants 11,971 22,113 10,023 20,200 Other 1,200 1,300 1,450 200 Equity 3,567 2,179 479 358 Total investments $ 629,216 $ 634,624 $ 453,837 $ 458,075 The following table shows the Company’s investments by industry sector as of September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 148,952 $ 147,442 $ 109,899 $ 107,902 Medical Device 114,364 116,967 88,681 84,567 Technology Communications 22,883 26,070 22,853 25,920 Consumer-Related 109,906 108,301 92,158 93,194 Data Storage 476 1,211 476 1,047 Internet and Media 329 1,299 569 3,305 Networking 13,551 13,413 17,390 17,964 Power Management 1,585 2,254 1,585 2,609 Semiconductors 56 — 101 — Software 108,910 107,441 60,902 60,807 Sustainability Other Sustainability 77,024 77,700 46,595 47,011 Healthcare Information and Services Diagnostics 9,840 9,844 12,393 12,377 Other 7,621 8,682 175 1,177 Software 13,719 14,000 60 195 Total investments $ 629,216 $ 634,624 $ 453,837 $ 458,075

Note 5 - Transactions With Affi

Note 5 - Transactions With Affiliated Companies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	Note 5. A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% not 25% For the three nine September 30, 2022 no Transactions related to investments in non-controlled affiliated companies for the year ended December 31, 2021 Year ended December 31, 2021 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized December 31, Interest Company 2020 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2021 income (In thousands) Decisyon, Inc. (1) $ 1,181 $ — $ — $ (1,181 ) $ — $ — $ — $ — $ 41 626 — — (638 ) 12 — — — 21 227 — — (227 ) — — — — 7 228 — — (228 ) — — — — 7 685 — — (685 ) — — — — 22 276 — — (276 ) — — — — 9 183 — — (183 ) — — — — 6 120 — — (120 ) — — — — — MVI (ABC) LLC fka StereoVision, Inc. 2,382 — (2,783 ) — — — 401 — 139 — 250 (250 ) — — — — — — — 70 (70 ) — — — — — — — 330 (330 ) — — — — — — 150 (150 ) — — — — — — 1,639 — — — — (848 ) (791 ) — — Total non-controlled affiliates $ 7,547 $ 800 $ (3,583 ) $ (3,538 ) $ 12 $ (848 ) $ (390 ) $ — $ 252 ( 1 December 31, 2021 no 5% A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% nine September 30, 2022 Nine months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Dividends unrealized Net realized September 30, Dividend Company 2021 Purchases Sales fair value declared gain/(loss) gain/(loss) 2021 income (In thousands) HESP LLC — — (300 ) — — 1,450 (1,150 ) — — Total controlled affiliates $ — $ — $ (300 ) $ — $ — $ 1,450 $ (1,150 ) $ — $ — Transactions related to investments in controlled affiliated companies for the year ended December 31, 2021 Year ended December 31, 2021 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Dividends unrealized Net realized December 31, Dividend Company 2020 Purchases Sales fair value declared gain/(loss) gain/(loss) 2021 income (In thousands) HESP LLC 1,500 — (50 ) — — (1,450 ) — — — Total controlled affiliates $ 1,500 $ — $ (50 ) $ — $ — $ (1,450 ) $ — $ — $ —

Note 6 - Fair Value

Note 6 - Fair Value	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 6. Prior to July 30, 2022, 2a 5 1940 July 29, 2022, twelve 25% The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no not may not Fair value measurements focus on exit prices in an orderly transaction (that is, not may The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement three Level 1 Quoted prices in active markets for identical assets and liabilities. Level 2 Observable inputs other than Level 1 not Level 3 Unobservable inputs that are supported by little or no 3 Due to the inherent uncertainty of determining the fair value of investments that do not may may may may Cash and interest receivable: not 1 Money market funds: 2 Debt investments: September 30, 2022 December 31, 2021 3 Under certain circumstances, the Company may Warrant investments: ● Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. ● Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven ● The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant. ● Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment. ● Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may Under certain circumstances the Company may may The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 3 Equity investments: third may 3 1 Other investments: 3 The following tables provide a summary of quantitative information about the Company’s Level 3 September 30, 2022 December 31, 2021 may The following table is not 3 September 30, 2022 September 30, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 605,719 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 25% 14 % 3,313 Multiple Probability Weighted Cash Flow Model Probability Weighting 25% 25 % Warrant investments 21,894 Black-Scholes Valuation Model Price Per Share 0.000 –1,89999 $ 64.53 Average Industry Volatility 25% 25 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 4 2 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,033 Last Equity Financing Price Per Share 1.000 –215.0303 $ 30.09 Total Level 3 investments $ 634,259 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 The following table is not 3 December 31, 2021 December 31, 2021 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average (1) (Dollars in thousands, except per share data) Debt investments $ 430,417 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% –23% 12 % 6,900 Multiple Probability Weighted Cash Flow Model Probability Weighting 20% - 50% 33 % Warrant investments 19,837 Black-Scholes Valuation Model Price Per Share 0.000 –980.0000 $ 20.35 Average Industry Volatility 25% 25 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 4 2 Other investments 200 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 0% –100% 100 % Equity investments 203 Last Equity Financing Price Per Share 0.000 –1.0000 $ 0.41 Total Level 3 investments $ 457,557 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 Borrowings: 2 2026 7 September 30, 2022 2026 1 2027 7 September 30, 2022 2027 1 September 30, 2022 3 not Off-balance-sheet instruments: 3 The following tables detail the assets that are carried at fair value and measured at fair value on a recurring basis as of September 30, 2022 December 31, 2021 September 30, 2022 Level 1 Level 2 Level 3 Total (In thousands) Investments in money market funds $ — $ 7,732 $ — $ 7,732 Restricted investments in money market funds $ — $ 1,617 $ — $ 1,617 Debt investments $ — $ — $ 609,032 $ 609,032 Warrant investments — 219 21,894 22,113 Other investments — — 1,300 1,300 Equity investments 146 — 2,033 2,179 Total investments $ 146 $ 219 $ 634,259 $ 634,624 December 31, 2021 Level 1 Level 2 Level 3 Total (In thousands) Investments in money market funds $ — $ 7,868 $ — $ 7,868 Restricted investments in money market funds $ — $ 1,359 $ — $ 1,359 Debt investments $ — $ — $ 437,317 $ 437,317 Warrant investments — 363 19,837 20,200 Other investments — — 200 200 Equity investments 155 — 203 358 Total investments $ 155 $ 363 $ 457,557 $ 458,075 The following table shows a reconciliation of the beginning and ending balances for Level 3 three September 30, 2022 Three months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 551,560 $ 25,167 $ 453 $ 200 $ 577,380 Purchase of investments 94,627 — — — 94,627 Warrants and equity received and classified as Level 3 — 964 — — 964 Principal payments received on investments (26,929 ) — — (31 ) (26,960 ) Proceeds from sale of investments (6,088 ) (38 ) — — (6,126 ) Net realized (loss) gain on investments (8,492 ) 266 — 31 (8,195 ) Unrealized appreciation (depreciation) included in earnings 8,095 (3,348 ) (420 ) (100 ) 4,227 Transfer out of Level 3 — (1,117 ) — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (541 ) — — — (541 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 During the three September 30, 2022 two 3. 3 one 2 3 one 1 The following table shows a reconciliation of the beginning and ending balances for Level 3 three September 30, 2021 Three months ended September 30, 2021 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 385,814 $ 15,102 $ 237 $ 1,700 $ 402,853 Purchase of investments 98,592 — — — 98,592 Warrants and equity received and classified as Level 3 — 1,394 — — 1,394 Principal payments received on investments (53,588 ) — — — (53,588 ) Proceeds from sale of investments (34 ) (1,519 ) — — (1,553 ) Net realized (loss) gain on investments (40 ) 1,384 — — 1,344 Unrealized appreciation (depreciation) included in earnings 798 3,353 149 (375 ) 3,925 Other (1,606 ) — — — (1,606 ) Level 3 assets, end of period $ 429,936 $ 19,714 $ 386 $ 1,325 $ 451,361 During the three September 30, 2021 3. The following table shows a reconciliation of the beginning and ending balances for Level 3 nine September 30, 2022 Nine months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 348,097 — 250 — 348,347 Warrants and equity received and classified as Level 3 — 2,441 — — 2,441 Principal payments received on investments (114,120 ) — — (313 ) (114,433 ) Proceeds from sale of investments (49,088 ) (464 ) — — (49,552 ) Net realized (loss) gain on investments (8,492 ) 535 — (1,137 ) (9,094 ) Unrealized appreciation (depreciation) included in earnings 1,128 662 (420 ) 1,350 2,720 Transfer out of Level 3 — (1,117 ) — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (2,610 ) — — — (2,610 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 During the nine September 30, 2022 two 3. 3 one 2 3 one 1 The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 September 30, 2022 The following table shows a reconciliation of the beginning and ending balances for Level 3 nine September 30, 2021 Nine months ended September 30, 2021 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 333,495 $ 12,736 $ 2,117 $ 1,700 $ 350,048 Purchase of investments 217,252 — — — 217,252 Warrants and equity received and classified as Level 3 — 2,313 — — 2,313 Principal payments received on investments (119,260 ) — — — (119,260 ) Proceeds from sale of investments (135 ) (3,159 ) — (13 ) (3,307 ) Net realized (loss) gain on investments (5,035 ) 2,566 — — (2,469 ) Unrealized appreciation (depreciation) included in earnings 5,609 5,329 (1,682 ) (362 ) 8,894 Transfer out of Level 3 — (71 ) (49 ) — (120 ) Other (1,990 ) — — — (1,990 ) Level 3 assets, end of period $ 429,936 $ 19,714 $ 386 $ 1,325 $ 451,361 During the nine September 30, 2021 two 3. 3 one 2 3 one 1 The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 September 30, 2021 The Company discloses fair value information about financial instruments, whether or not not The fair value amounts have been measured as of the reporting date and have not may As of September 30, 2022 December 31, 2021 Market risk The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may

Note 7 - Borrowings

Note 7 - Borrowings	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 7. The following table shows the Company’s borrowings as of September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 125,000 $ 67,500 $ 57,500 $ 125,000 $ 53,500 $ 71,500 NYL Facility 200,000 136,750 63,250 100,000 78,750 21,250 Asset-Backed Notes 43,461 43,461 — 70,500 70,500 — 2027 Notes 57,500 57,500 — — — — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 483,461 362,711 120,750 353,000 260,250 92,750 Unamortized debt issuance costs attributable to term borrowings — (3,700 ) — — (2,637 ) — Total borrowings outstanding, net $ 483,461 $ 359,011 $ 120,750 $ 353,000 $ 257,613 $ 92,750 As of September 30, 2022 1940 September 30, 2022 The Company entered into the Key Facility with Key effective November 4, 2013. June 22, 2021, may June 22, 2024. June 22, 2026. June 21, 2021, one June 30, 2021, September 30, 2022 December 31, 2021 three September 30, 2022 2021 nine September 30, 2022 2021 September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 On September 29, 2017, 2022 October 11, 2017, 30 “2022 2022 September 15, 2022 September 15, 2019 2022 March 15, June 15, September 15 December 15 2022 2022 April 24, 2021 ( 2022 2022 2022 On March 30, 2021, 2026 “2026 2026 2026 March 30, 2026 may March 30, 2023 2026 4.875% March 30, June 30, September 30 December 30 2026 2026 September 30, 2022 2026 2026 On June 15, 2022, 2027 July 11, 2022, 30 “2027 2027 June 15, 2027 may June 15, 2024 2027 6.25% March 30, June 30, September 30 December 30 September 30, 2022. 2027 2027 September 30, 2022 2027 2027 On August 13, 2019, August 13, 2019. no August 13, 2019. The Asset-Backed Notes were issued by the 2019‑1 August 13, 2019, July 15, 2021 September 15, 2027. At September 30, 2022 December 31, 2021 Under the terms of the Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the Asset-Backed Notes, which may September 30, 2022 December 31, 2021 On April 21, 2020, June 1, 2018, three On February 25, 2022, June 2023 June 2028. $100.0 three There were $136.8 million and $78.8 million in advances made by the NYL Noteholders as of September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021

Note 8 - Financial Instruments

Note 8 - Financial Instruments With Off-balance-sheet Risk	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	Note 8. In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate. The balance of unfunded commitments to extend credit was $214.5 million and $114.5 million as of September 30, 2022 December 31, 2021 may not The following table provides the Company’s unfunded commitments by portfolio company as of September 30, 2022 September 30, 2022 Fair Value of Unfunded Principal Commitment Balance Liability (In thousands) Better Place Forests Co. $ 5,000 $ 6 BrightInsight, Inc. 21,000 278 Britecore Holdings, Inc. 5,000 66 Canary Medical Inc. 2,500 34 Castle Creek Biosciences 4,000 72 Ceribell, Inc. 2,500 4 Divergent Technologies, Inc. 30,000 315 DropOff, Inc. 7,500 188 Embody, Inc. 2,000 20 Engage3, LLC 8,000 40 Hound Labs, Inc. 7,500 87 Interior Define, Inc. 5,000 65 KSQ Therapeutics, Inc. 10,000 100 Lytics, Inc. 1,250 — Magnolia Medical Technologies, Inc. 10,000 122 Native Microbials, Inc. 8,750 64 Optoro, Inc. 15,000 38 PDS Biotechnology Corporation 10,000 158 Scientia Vascular, Inc. 10,000 110 Slingshot Aerospace, Inc. 5,000 64 Soli, Inc. 7,500 147 Sonex Health, Inc. 2,500 45 Swift Health Systems Inc. 25,500 105 Temperpack Technologies, Inc. 9,000 19 Total $ 214,500 $ 2,147 The table above also provides the fair value of the Company’s unfunded commitment liability as of September 30, 2022

Note 9 - Concentrations of Cred

Note 9 - Concentrations of Credit Risk	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 9. The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may may The Company’s largest debt investments may five September 30, 2022 December 31, 2021 No 10% September 30, 2022 December 31, 2021 five three September 30, 2022 2021 five nine September 30, 2022 2021

Note 10 - Distributions

Note 10 - Distributions	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 10. The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the nine September 30, 2022 December 31, 2021 DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Nine Months Ended September 30, 2022 7/29/2022 11/17/22 12/15/22 $ 0.10 $ — — $ — 7/29/2022 10/18/22 11/15/22 0.10 — — — 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 0.90 $ 17,083 32,590 $ 392 Year Ended December 31, 2021 10/22/21 2/18/22 3/16/22 $ 0.10 $ 2,100 3,409 $ 46 10/22/21 1/19/22 2/16/22 0.10 2,096 2,680 43 10/22/21 12/17/21 1/14/22 0.10 2,031 3,417 56 10/22/21 11/18/21 12/15/21 0.05 1,013 1,197 20 7/23/21 11/18/21 12/15/21 0.10 2,027 2,395 38 7/23/21 10/19/21 11/16/21 0.10 2,010 1,907 34 7/23/21 9/17/21 10/15/21 0.10 2,008 2,068 36 4/23/21 8/18/21 9/15/21 0.10 1,996 2,041 34 4/23/21 7/20/21 8/16/21 0.10 1,983 1,937 34 4/23/21 6/17/21 7/16/21 0.10 1,964 1,888 33 2/26/21 5/18/21 6/15/21 0.10 1,964 1,671 29 2/26/21 4/20/21 5/14/21 0.10 1,937 1,794 29 2/26/21 3/18/21 4/16/21 0.10 1,938 1,653 28 $ 1.25 $ 25,067 28,057 $ 460 On October 28, 2022, Monthly distributions Ex-Dividend Date Record Date Payment Date Distributions Declared December 16, 2022 December 19, 2022 January 13, 2023 $ 0.11 January 17, 2023 January 18, 2023 February 15, 2023 $ 0.11 February 16, 2023 February 17, 2023 March 15, 2023 $ 0.11 Special distribution Ex-Dividend Date Record Date Payment Date Distributions Declared November 16, 2022 November 17, 2022 December 15, 2022 $ 0.05 After paying distributions of $0.30 per share and earning net investment income of $0.43 per share for the quarter, the Company’s undistributed spillover income as of September 30, 2022 not

Note 11 - Financial Highlights

Note 11 - Financial Highlights	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Investment Company, Financial Highlights [Text Block]	Note 11. The following table shows financial highlights for the Company: Nine months ended September 30, 2022 2021 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.56 $ 11.02 Net investment income 1.06 1.02 Realized loss (0.40 ) (0.14 ) Unrealized appreciation on investments 0.05 0.41 Net increase in net assets resulting from operations 0.71 1.29 Distributions declared (1) (0.90 ) (0.90 ) From net investment income (0.90 ) (0.90 ) From net realized gain on investments — — Return of capital — — Other (2) 0.29 0.22 Net asset value at end of period $ 11.66 $ 11.63 Per share market value, beginning of period $ 15.92 $ 13.24 Per share market value, end of period $ 10.01 $ 16.26 Total return based on a market value (3) (31.5 )% 29.6 % Shares outstanding at end of period 26,393,773 20,425,175 Ratios to average net assets: Expenses without incentive value (4) 11.4 % 10.6 % Incentive fees (4) 3.0 % 3.0 % Net expenses (4) 14.4 % 13.6 % Net investment income with incentive fees (4) 12.1 % 12.1 % Net assets at the end of the period $ 307,687 $ 237,590 Average net asset value $ 280,904 $ 223,031 Average debt per share $ 13.32 $ 11.07 Portfolio turnover ratio (5) 14.9 % 29.0 % ( 1 Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may ( 2 Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share. ( 3 The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price. ( 4 Annualized. ( 5 Calculated by dividing the lesser of purchases or the sum of ( 1 2

Note 12 - Subsequent Events

Note 12 - Subsequent Events	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12. On October 21, 2022, On October 21, 2022, On October 26, 2022, 2022 1, 2022 1 144A "7.56% November 9, 2022, This disclosure does not On October 28, 2022,

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation As required under GAAP and Regulation S- X, Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 not
Use of Estimates, Policy [Policy Text Block]	Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.
Fair Value Measurement, Policy [Policy Text Block]	Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6
Segment Reporting, Policy [Policy Text Block]	Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.
Investment, Policy [Policy Text Block]	Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may September 30, 2022 December 31, 2021 one three nine September 30, 2022 not three September 30, 2021 not nine September 30, 2021 one The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not three September 30, 2022 2021 not nine September 30, 2022 2021 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not
Deferred Charges, Policy [Policy Text Block]	Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 three September 30, 2022 2021 nine September 30, 2022 2021
Income Tax, Policy [Policy Text Block]	Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no December 31, 2021 Depending on the level of taxable income earned in a tax year, the Company may three nine September 30, 2022 three nine September 30, 2021 The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not September 30, 2022 December 31, 2021 2021, 2020 2019
Distributions [Policy Text Block]	Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may
Stockholders' Equity, Policy [Policy Text Block]	Stockholders Equity On July 30, 2020, “2020 2020 may On August 2, 2021, 2020 “2021 2020 no 2021 may may 415 During the three September 30, 2022 2021 During the three September 30, 2021 2020 2021 During the nine September 30, 2022 2021 During the nine September 30, 2021 2020 2021 The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of September 30, 2022
Stock Repurchase Program [Policy Text Block]	Stock Repurchase Program On April 29, 2022, may, not 10b‑18 1934, 1940 June 30, 2023 $5.0 three nine September 30, 2022 2021 not September 30, 2022
Transfers and Servicing of Financial Assets, Policy [Policy Text Block]	Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently issued accounting pronouncements In March 2020, No. 2020 04, 848 2020 04” 2020 04 2020 04 March 12, 2020 December 31, 2022. 2020 04 In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03

Consolidated Schedule of Inve_2

Consolidated Schedule of Investments (Unaudited) (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Investment [Table Text Block]	Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 206.2% Non-Affiliate Debt Investments — 197.9% Non-Affiliate Debt Investments — Life Science — 83.0% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,885 $ 2,817 $ 2,765 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,885 2,817 2,765 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,442 1,435 1,410 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,813 2,763 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,813 2,763 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,404 1,379 Term Loan 12.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,404 1,379 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,887 4,887 Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,959 4,959 Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,976 2,976 Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,959 4,959 Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,959 4,959 Term Loan 11.55 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,975 2,975 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 10.45 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 2,188 2,168 2,168 Term Loan 10.45 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 2,188 2,169 2,169 Term Loan 10.45 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,000 4,916 4,916 Term Loan 10.45 % Libor 7.90 % 9.75 % - 5.00 % May 1, 2026 5,000 4,902 4,902 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % April 1, 2025 2,500 2,473 2,473 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,471 2,471 Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 12.00 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 5,000 4,843 4,843 Term Loan 12.00 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 2,500 2,423 2,423 IMV Inc. (2)(5)(12) Biotechnology Term Loan 12.00 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 5,000 4,942 4,942 Term Loan 12.00 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 2,500 2,470 2,470 Term Loan 12.00 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,942 4,942 Term Loan 12.00 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,941 4,941 KSQ Therapeutics, Inc. (2) (12) Biotechnology Term Loan 11.00 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,071 6,071 Term Loan 11.00 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,172 6,172 LogicBio, Inc. (2)(5)(12) Biotechnology Term Loan 8.80 % Libor 6.25 % 8.75 % - 4.50 % June 1, 2024 2,778 2,766 2,766 Native Microbials, Inc (2) (12) Biotechnology Term Loan 11.50 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,633 3,633 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 12.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,688 9,688 Term Loan 12.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,692 3,692 Term Loan 12.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,692 3,692 Provivi, Inc. (2)(12) Biotechnology Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,666 4,618 4,618 Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,666 4,618 4,618 Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,288 2,288 Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,288 2,288 Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,281 2,281 Term Loan 11.05 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,281 2,281 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Stealth Biotherapeutics Inc. (2)(5)(12) Biotechnology Term Loan 11.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 5,000 4,906 4,906 Term Loan 11.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,500 2,453 2,453 Aerobiotix, LLC (2)(12) Medical Device Term Loan 12.50 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,462 2,366 Term Loan 12.50 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,462 2,365 Canary Medical Inc. (2)(12) Medical Device Term Loan 11.25 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,438 2,438 Term Loan 11.25 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,486 2,486 Term Loan 11.25 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,466 2,466 Ceribell, Inc. (2)(12) Medical Device Term Loan 9.00 % Prime 3.75 % 8.25 % - 5.50 % October 1, 2024 5,000 4,965 4,965 Term Loan 9.00 % Prime 3.75 % 8.25 % - 5.50 % October 1, 2024 5,000 4,969 4,969 Term Loan 9.00 % Prime 3.75 % 8.25 % - 5.50 % October 1, 2024 2,500 2,475 2,475 Term Loan 9.00 % Prime 3.75 % 8.25 % - 5.50 % October 1, 2024 2,500 2,475 2,475 Cognoa, Inc. (2)(12) Medical Device Term Loan 11.75 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 5,000 4,924 4,924 Term Loan 11.75 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,500 2,462 2,462 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 10.55 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,892 3,892 Term Loan 10.55 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,892 3,892 Corinth Medtech, Inc. (2)(12) Medical Device Term Loan 10.75 % Prime 5.25 % 8.50 % - 20.00 % September 15, 2022 2,500 2,500 2,500 Term Loan 10.75 % Prime 5.25 % 8.50 % - 20.00 % September 15, 2022 2,500 2,500 2,500 CSA Medical, Inc. (2)(12) Medical Device Term Loan 10.75 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 2,000 1,981 1,981 Term Loan 10.75 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 133 132 132 Term Loan 10.75 % Libor 8.20 % 10.00 % - 5.00 % March 1, 2024 2,400 2,379 2,379 Embody, Inc. (2)(12) Medical Device Term Loan 12.75 % Prime 6.50 % 9.75 % - 28.00 % August 1, 2026 2,500 2,461 2,461 InfoBionic, Inc. (2)(12) Medical Device Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 3,500 3,425 3,425 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 971 971 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 10.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,810 4,810 Term Loan 10.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,932 4,932 Term Loan 10.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,925 4,925 Term Loan 10.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,926 4,926 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 10.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,593 3,593 Term Loan 10.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,702 3,702 Sonex Health, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 6.50 % 9.75 % - 5.00 % June 1, 2025 2,500 2,428 2,428 Term Loan 12.00 % Prime 6.50 % 9.75 % - 5.00 % June 1, 2025 2,500 2,473 2,473 Term Loan 12.00 % Prime 6.50 % 9.75 % - 5.00 % June 1, 2025 2,500 2,473 2,473 Term Loan 12.00 % Prime 6.50 % 9.75 % - 8.00 % April 1, 2026 2,500 2,455 2,455 Spineology, Inc. (2)(12) Medical Device Term Loan 13.25 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,963 4,963 Term Loan 13.25 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,479 2,479 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Swift Health Systems Inc. (2)(12) Medical Device Term Loan 10.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,345 3,345 Term Loan 10.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,451 3,451 Total Non-Affiliate Debt Investments — Life Science 255,997 255,525 Non-Affiliate Debt Investments — Sustainability — 24.7% Dream Holdings, Inc. (2)(12) Other Sustainability Term Loan 13.00 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,692 3,692 Term Loan 13.00 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,692 3,692 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Term Loan 13.25 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,359 7,359 Term Loan 13.25 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,359 7,359 Term Loan 13.25 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,359 7,359 Term Loan 13.25 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,893 4,893 Term Loan 13.25 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,893 4,893 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,919 4,919 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,313 2,313 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,916 4,916 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,458 2,458 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,694 3,694 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,713 3,713 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 7,500 7,417 7,417 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,709 3,709 Term Loan 13.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,709 3,709 Total Non-Affiliate Debt Investments — Sustainability 76,095 76,095 Non-Affiliate Debt Investments — Technology — 80.2% Axiom Space, Inc. (2)(12) Communications Term Loan 11.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,452 7,452 Term Loan 11.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,452 7,452 Term Loan 11.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,452 7,452 Convertible Note 3.00 % July 1, 2023 250 250 250 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Term Loan 12.25 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 5,000 4,961 4,961 Term Loan 12.25 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 5,000 4,961 4,961 Term Loan 12.25 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 3,000 2,977 2,977 Term Loan 12.25 % Prime 6.75 % 10.00 % - 3.00 % December 1, 2025 1,000 974 974 Term Loan 12.25 % Prime 6.75 % 10.00 % - 3.00 % February 1, 2026 1,000 974 974 Better Place Forests Co. (2)(12) Consumer-related Technologies Term Loan 12.50 % Prime 6.25 % 9.50 % - 1.85 % July 1, 2025 5,000 4,944 4,944 Term Loan 12.50 % Prime 6.25 % 9.50 % - 1.85 % October 1, 2025 2,500 2,474 2,474 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 13.50 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,458 3,458 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,500 2,481 2,481 Term Loan 11.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,500 2,481 2,481 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,397 3,397 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,237 1,237 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,712 3,712 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,237 1,237 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,712 3,712 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,237 1,237 Interior Define, Inc. (2)(12) Consumer-related Technologies Term Loan 12.75 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 6,500 6,417 5,215 Term Loan 12.75 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 6,000 5,858 4,760 Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 13.00 % Prime 6.75 % 10.00 % - 9.75 % January 1, 2024 2,500 2,585 2,219 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 13.00 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 5,000 4,947 4,947 Term Loan 13.00 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,500 2,474 2,474 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 5,000 4,947 4,947 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 2,000 1,979 1,979 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 2,500 2,474 2,474 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 3,000 2,968 2,968 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 2,500 2,453 2,453 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 2,500 2,453 2,453 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 5,000 4,904 4,904 Term Loan 11.25 % Prime 5.75 % 9.00 % - 2.00 % January 1, 2026 2,500 2,450 2,450 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,339 2,339 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 12.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,900 2,870 2,870 Term Loan 12.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,900 2,870 2,870 Term Loan 12.75 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 3,000 2,964 2,964 Unagi, Inc. (2)(12) Consumer-related Technologies Term Loan 14.00 % Prime 7.25 % 11.00 % - - July 1, 2025 2,500 2,471 2,317 Term Loan 14.00 % Prime 7.25 % 11.00 % - - July 1, 2025 1,250 1,235 1,158 Term Loan 14.00 % Prime 7.25 % 11.00 % - - July 1, 2025 1,250 1,234 1,157 Liqid, Inc. (2)(12) Networking Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 3,833 3,779 3,779 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 3,833 3,779 3,779 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,917 1,887 1,887 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,917 1,887 1,887 Term Loan 11.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,917 1,855 1,855 BriteCore Holdings, Inc. (2)(12) Software Term Loan 12.25 % Prime 6.75 % 10.00 % - 4.00 % October 1, 2024 2,500 2,420 2,420 Term Loan 12.25 % Prime 6.75 % 10.00 % - 4.00 % October 1, 2024 2,500 2,486 2,486 Decisyon, Inc. (12) Software Term Loan 15.68 % Prime 9.43 % 12.68 % - 50.43 % December 31, 2022 3,313 3,313 3,313 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 12.75 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,500 6,147 6,147 Term Loan 12.75 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,000 5,847 5,847 Term Loan 12.75 % Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,500 2,431 2,431 Engage3, LLC (2)(12) Software Term Loan 12.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,675 3,675 Term Loan 11.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,715 3,715 Kodiak Robotics, Inc. (2)(12) Software Term Loan 11.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,809 9,809 Term Loan 11.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,809 9,809 Term Loan 11.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,904 4,904 Term Loan 11.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,904 4,904 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 12.75 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,941 4,941 Term Loan 12.75 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,471 2,471 Lytics, Inc. (2)(12) Software Term Loan 11.50 % Prime 6.00 % 9.25 % - 3.00 % July 1, 2025 2,500 2,472 2,472 Reputation Institute, Inc. (2)(12) Software Term Loan 12.75 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 5,000 4,926 4,926 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 12.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,927 4,927 Term Loan 12.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,927 4,927 Term Loan 12.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,863 4,863 Term Loan 12.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,927 4,927 Supply Network Visiblity Holdings LLC (2)(12) Software Term Loan 12.00 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,500 3,469 3,469 Term Loan 12.00 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,500 3,469 3,469 Term Loan 12.00 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,470 2,470 Term Loan 12.00 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,470 2,470 Total Non-Affiliate Debt Investments — Technology 249,694 246,720 Non-Affiliate Debt Investments — Healthcare information and services — 10.0% Hound Labs inc. (2) (12) Diagnostics Term Loan 12.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,383 2,383 Term Loan 12.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,470 2,470 Term Loan 12.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,940 4,940 Secure Transfusion Services, Inc. (2)(12) Other Healthcare Term Loan 12.00 % Prime 5.75 % 9.00 % - 4.00 % October 1, 2025 5,000 4,934 4,934 Term Loan 12.00 % Prime 5.75 % 9.00 % - 4.00 % December 31, 2025 2,500 2,463 2,463 BrightInsight, Inc. (2)(12) Software Term Loan 11.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,612 6,612 Term Loan 11.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,445 3,445 Term Loan 11.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,445 3,445 Total Non-Affiliate Debt Investments — Healthcare information and services 30,692 30,692 Total Non- Affiliate Debt Investments 612,478 609,032 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 7.2% Non-Affiliate Warrants — Life Science — 1.8% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,442 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 5,372 214 104 Corvium, Inc. (2)(12) Biotechnology Preferred Stock Warrant 661,956 52 — Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 176 244 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 21,120 35 — Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 71,292 366 5 Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 16,502 65 — IMV Inc. (2)(5)(12) Biotechnology Common Stock Warrant 397,726 67 4 KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,077 50 54 LogicBio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 7,843 8 — Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 252,161 146 — Native Microbials, Inc (2) (12) Biotechnology Preferred Stock Warrant 94,253 52 59 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 160 160 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 164,608 278 513 Rocket Pharmaceuticals Corporation (5)(12) Biotechnology Common Stock Warrant 7,051 17 1 Stealth Biotherapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 795,455 264 — vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 2 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 23 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 64 1,187 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 27,330 46 52 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 85 1,865 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 204 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 775,000 148 167 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 221 209 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,375,727 153 134 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 47 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 111 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 699,485 141 135 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 221,510 82 142 Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 19,662 39 43 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 605,313 97 113 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 — Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 79 Total Non-Affiliate Warrants — Life Science 3,869 5,634 Non-Affiliate Warrants — Sustainability — 0.5% Dream Holdings, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 70,539 61 68 LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,539 39 45 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Common Stock Warrant 209,669 489 888 Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 345 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 35,906 126 259 Total Non-Affiliate Warrants — Sustainability 929 1,605 Non-Affiliate Warrants — Technology — 4.2% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 47 52 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 138 3,219 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 92 193 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 57 Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Better Place Forests Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 10,690 27 32 Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 68 1,068 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 17,605 24 61 Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 31 378 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 25,758 30 35 Getaround, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 651,040 450 199 Interior Define, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,710 103 — MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 143 29 33 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 630,626 188 116 Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,600 104 104 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 425 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 324 525 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 38 Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 12 CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 895 Silk, Inc. (2)(12) Data Storage Preferred Stock Warrant 442,110 234 316 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 — Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 500 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 799 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 226 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,254 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrants 6,081 56 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 77,828 21 64 Decisyon, Inc. (12) Software Common Stock Warrant 82,967 46 — Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 187 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 152,908 60 1 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 273 273 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 34 38 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 288,115 22 306 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 26,733 11 14 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 56 35 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 498,241 47 81 Riv Data Corp. (2)(12) Software Preferred Stock Warrant 321,428 12 296 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Skyword, Inc. (12) Software Preferred and Common Stock Warrants 301,055 48 9 Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 123 Supply Network Visiblity Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 74 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 135 — xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 2 Total Non-Affiliate Warrants — Technology 6,685 13,040 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 159,893 47 51 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 103 1,217 Watermark Medical, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 27,373 73 — Secure Transfusion Services, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 77,690 48 68 BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 80,544 157 157 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 60 341 Total Non-Affiliate Warrants — Healthcare information and services 488 1,834 Total Non-Affiliate Warrants 11,971 22,113 Non-Affiliate Other Investments — 0.4% Lumithera, Inc. (2) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — 200 Total Non-Affiliate Other Investments 1,200 1,300 Non-Affiliate Equity — 0.7% Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 829,674 8 83 Lumithera, Inc. (2) Medical Device Common Stock 392,651 2,000 1,700 Branded Online, Inc. (5)(12) Software Common Stock 108,004 1,079 146 Decisyon, Inc. (12) Software Preferred and Common Stock 72,638,663 230 — Total Non-Affiliate Equity 3,567 2,179 Total Non-Affiliate Portfolio Investment Assets $ 629,216 $ 634,624 Total Portfolio Investment Assets — 206.3% $ 629,216 $ 634,624 Short Term Investments — Unrestricted Investments — 2.5% US Bank Money Market Deposit Account $ 7,732 $ 7,732 Total Short Term Investments — Unrestricted Investments $ 7,732 $ 7,732 Short Term Investments — Restricted Investments — 0.5% US Bank Money Market Deposit Account $ 1,617 $ 1,617 Total Short Term Investments — Restricted Investments $ 1,617 $ 1,617 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 186.7% Non-Affiliate Debt Investments — 178.3% Non-Affiliate Debt Investments — Life Science — 77.3% Castle Creek Pharmaceuticals Holdings, Inc. (2)(12) Biotechnology Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 $ 5,000 $ 4,957 $ 4,957 Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 5,000 4,957 4,957 Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 5,000 4,957 4,957 Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 5,000 4,957 4,957 Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 5,000 4,909 4,909 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 5,000 4,909 4,909 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,500 2,454 2,454 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 5,000 4,906 4,906 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 5,000 4,906 4,906 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 2,500 2,451 2,451 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 2,500 2,451 2,451 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 9.75 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 2,500 2,420 2,420 Term Loan 9.75 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 2,500 2,472 2,472 Term Loan 9.75 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,000 4,896 4,896 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % April 1, 2025 2,500 2,465 2,465 Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,463 2,463 Greenlight Biosciences, Inc. (2)(12) Biotechnology Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 5,000 4,850 4,850 Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,475 2,475 IMV Inc. (2)(5)(12) Biotechnology Term Loan 9.00 % Prime 6.25 % 9.00 % - 5.00 % July 1, 2025 5,000 4,799 4,799 Term Loan 9.00 % Prime 6.25 % 9.00 % - 5.00 % July 1, 2025 2,500 2,462 2,462 LogicBio, Inc. (2)(5)(12) Biotechnology Term Loan 8.75 % Libor 6.25 % 8.75 % - 4.50 % June 1, 2024 4,028 4,011 4,011 Provivi, Inc. (2)(12) Biotechnology Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 5,000 4,935 4,935 Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 5,000 4,935 4,935 Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,500 2,440 2,440 Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,500 2,440 2,440 Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,500 2,430 2,430 Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,500 2,430 2,430 Stealth Biotherapeutics Inc. (2)(5)(12) Biotechnology Term Loan 8.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 5,000 4,631 4,631 Term Loan 8.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,500 2,441 2,441 Canary Medical Inc. (2)(12) Medical Device Term Loan 9.00 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,394 2,394 Ceribell, Inc. (2)(12) Medical Device Term Loan 8.25 % Libor 6.70 % 8.25 % - 5.50 % October 1, 2024 5,000 4,926 4,926 Term Loan 8.25 % Libor 6.70 % 8.25 % - 5.50 % October 1, 2024 5,000 4,957 4,957 Term Loan 8.25 % Libor 6.70 % 8.25 % - 5.50 % October 1, 2024 2,500 2,466 2,466 Term Loan 8.25 % Libor 6.70 % 8.25 % - 5.50 % October 1, 2024 2,500 2,466 2,466 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 9.25 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 4,056 4,009 4,009 Term Loan 9.25 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 4,056 4,009 4,009 Corinth Medtech, Inc. (2)(12) Medical Device Term Loan 8.50 % Prime 5.25 % 8.50 % - 20.00 % April 1, 2022 2,500 2,495 2,495 Term Loan 8.50 % Prime 5.25 % 8.50 % - 20.00 % April 1, 2022 2,500 2,495 2,495 CSA Medical, Inc. (2)(12) Medical Device Term Loan 10.00 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 3,125 3,095 3,095 Term Loan 10.00 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 208 206 206 Term Loan 10.00 % Libor 8.20 % 10.00 % - 5.00 % March 1, 2024 3,600 3,569 3,569 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Embody, Inc. (2)(12) Medical Device Term Loan 9.75 % Prime 6.50 % 9.75 % - 28.00 % August 1, 2026 2,500 2,457 2,457 InfoBionic, Inc. (2)(12) Medical Device Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 3,500 3,397 3,397 Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 963 963 MacuLogix, Inc. (2)(12)(14) Medical Device Term Loan 10.08 % Libor 7.68 % 10.08 % - 6.00 % September 1, 2023 7,500 7,447 4,481 Term Loan 10.08 % Libor 7.68 % 10.08 % - 6.00 % September 1, 2023 4,050 4,022 2,420 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 9.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,952 4,952 Term Loan 9.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,952 4,952 Term Loan 9.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,944 4,944 Term Loan 9.75 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,944 4,944 Sonex Health, Inc. (2)(12) Medical Device Term Loan 9.25 % Prime 6.00 % 9.25 % - 5.00 % June 1, 2024 2,500 2,391 2,391 Term Loan 9.25 % Prime 6.00 % 9.25 % - 5.00 % June 1, 2024 2,500 2,472 2,472 Term Loan 9.25 % Prime 6.00 % 9.25 % - 5.00 % June 1, 2024 2,500 2,472 2,472 Spineology, Inc. (2)(12) Medical Device Term Loan 10.25 % Prime 7.00 % 10.25 % - 1.00 %

Note 4 - Investments (Tables)

Note 4 - Investments (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Investment Holdings, Schedule of Investments [Table Text Block]	September 30, 2022 December 31, 2021 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 612,478 $ 609,032 $ 441,885 $ 437,317 Warrants 11,971 22,113 10,023 20,200 Other 1,200 1,300 1,450 200 Equity 3,567 2,179 479 358 Total investments $ 629,216 $ 634,624 $ 453,837 $ 458,075 September 30, 2022 December 31, 2021 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 148,952 $ 147,442 $ 109,899 $ 107,902 Medical Device 114,364 116,967 88,681 84,567 Technology Communications 22,883 26,070 22,853 25,920 Consumer-Related 109,906 108,301 92,158 93,194 Data Storage 476 1,211 476 1,047 Internet and Media 329 1,299 569 3,305 Networking 13,551 13,413 17,390 17,964 Power Management 1,585 2,254 1,585 2,609 Semiconductors 56 — 101 — Software 108,910 107,441 60,902 60,807 Sustainability Other Sustainability 77,024 77,700 46,595 47,011 Healthcare Information and Services Diagnostics 9,840 9,844 12,393 12,377 Other 7,621 8,682 175 1,177 Software 13,719 14,000 60 195 Total investments $ 629,216 $ 634,624 $ 453,837 $ 458,075

Note 5 - Transactions With Af_2

Note 5 - Transactions With Affiliated Companies (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Investments in and Advances to Affiliates [Table Text Block]	Year ended December 31, 2021 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized December 31, Interest Company 2020 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2021 income (In thousands) Decisyon, Inc. (1) $ 1,181 $ — $ — $ (1,181 ) $ — $ — $ — $ — $ 41 626 — — (638 ) 12 — — — 21 227 — — (227 ) — — — — 7 228 — — (228 ) — — — — 7 685 — — (685 ) — — — — 22 276 — — (276 ) — — — — 9 183 — — (183 ) — — — — 6 120 — — (120 ) — — — — — MVI (ABC) LLC fka StereoVision, Inc. 2,382 — (2,783 ) — — — 401 — 139 — 250 (250 ) — — — — — — — 70 (70 ) — — — — — — — 330 (330 ) — — — — — — 150 (150 ) — — — — — — 1,639 — — — — (848 ) (791 ) — — Total non-controlled affiliates $ 7,547 $ 800 $ (3,583 ) $ (3,538 ) $ 12 $ (848 ) $ (390 ) $ — $ 252 Nine months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Dividends unrealized Net realized September 30, Dividend Company 2021 Purchases Sales fair value declared gain/(loss) gain/(loss) 2021 income (In thousands) HESP LLC — — (300 ) — — 1,450 (1,150 ) — — Total controlled affiliates $ — $ — $ (300 ) $ — $ — $ 1,450 $ (1,150 ) $ — $ — Year ended December 31, 2021 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Dividends unrealized Net realized December 31, Dividend Company 2020 Purchases Sales fair value declared gain/(loss) gain/(loss) 2021 income (In thousands) HESP LLC 1,500 — (50 ) — — (1,450 ) — — — Total controlled affiliates $ 1,500 $ — $ (50 ) $ — $ — $ (1,450 ) $ — $ — $ —

Note 6 - Fair Value (Tables)

Note 6 - Fair Value (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	September 30, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 605,719 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 25% 14 % 3,313 Multiple Probability Weighted Cash Flow Model Probability Weighting 25% 25 % Warrant investments 21,894 Black-Scholes Valuation Model Price Per Share 0.000 –1,89999 $ 64.53 Average Industry Volatility 25% 25 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 4 2 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,033 Last Equity Financing Price Per Share 1.000 –215.0303 $ 30.09 Total Level 3 investments $ 634,259 December 31, 2021 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average (1) (Dollars in thousands, except per share data) Debt investments $ 430,417 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% –23% 12 % 6,900 Multiple Probability Weighted Cash Flow Model Probability Weighting 20% - 50% 33 % Warrant investments 19,837 Black-Scholes Valuation Model Price Per Share 0.000 –980.0000 $ 20.35 Average Industry Volatility 25% 25 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 4 2 Other investments 200 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 0% –100% 100 % Equity investments 203 Last Equity Financing Price Per Share 0.000 –1.0000 $ 0.41 Total Level 3 investments $ 457,557
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	September 30, 2022 Level 1 Level 2 Level 3 Total (In thousands) Investments in money market funds $ — $ 7,732 $ — $ 7,732 Restricted investments in money market funds $ — $ 1,617 $ — $ 1,617 Debt investments $ — $ — $ 609,032 $ 609,032 Warrant investments — 219 21,894 22,113 Other investments — — 1,300 1,300 Equity investments 146 — 2,033 2,179 Total investments $ 146 $ 219 $ 634,259 $ 634,624 December 31, 2021 Level 1 Level 2 Level 3 Total (In thousands) Investments in money market funds $ — $ 7,868 $ — $ 7,868 Restricted investments in money market funds $ — $ 1,359 $ — $ 1,359 Debt investments $ — $ — $ 437,317 $ 437,317 Warrant investments — 363 19,837 20,200 Other investments — — 200 200 Equity investments 155 — 203 358 Total investments $ 155 $ 363 $ 457,557 $ 458,075
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 551,560 $ 25,167 $ 453 $ 200 $ 577,380 Purchase of investments 94,627 — — — 94,627 Warrants and equity received and classified as Level 3 — 964 — — 964 Principal payments received on investments (26,929 ) — — (31 ) (26,960 ) Proceeds from sale of investments (6,088 ) (38 ) — — (6,126 ) Net realized (loss) gain on investments (8,492 ) 266 — 31 (8,195 ) Unrealized appreciation (depreciation) included in earnings 8,095 (3,348 ) (420 ) (100 ) 4,227 Transfer out of Level 3 — (1,117 ) — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (541 ) — — — (541 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 Three months ended September 30, 2021 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 385,814 $ 15,102 $ 237 $ 1,700 $ 402,853 Purchase of investments 98,592 — — — 98,592 Warrants and equity received and classified as Level 3 — 1,394 — — 1,394 Principal payments received on investments (53,588 ) — — — (53,588 ) Proceeds from sale of investments (34 ) (1,519 ) — — (1,553 ) Net realized (loss) gain on investments (40 ) 1,384 — — 1,344 Unrealized appreciation (depreciation) included in earnings 798 3,353 149 (375 ) 3,925 Other (1,606 ) — — — (1,606 ) Level 3 assets, end of period $ 429,936 $ 19,714 $ 386 $ 1,325 $ 451,361 Nine months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 348,097 — 250 — 348,347 Warrants and equity received and classified as Level 3 — 2,441 — — 2,441 Principal payments received on investments (114,120 ) — — (313 ) (114,433 ) Proceeds from sale of investments (49,088 ) (464 ) — — (49,552 ) Net realized (loss) gain on investments (8,492 ) 535 — (1,137 ) (9,094 ) Unrealized appreciation (depreciation) included in earnings 1,128 662 (420 ) 1,350 2,720 Transfer out of Level 3 — (1,117 ) — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (2,610 ) — — — (2,610 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 Nine months ended September 30, 2021 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 333,495 $ 12,736 $ 2,117 $ 1,700 $ 350,048 Purchase of investments 217,252 — — — 217,252 Warrants and equity received and classified as Level 3 — 2,313 — — 2,313 Principal payments received on investments (119,260 ) — — — (119,260 ) Proceeds from sale of investments (135 ) (3,159 ) — (13 ) (3,307 ) Net realized (loss) gain on investments (5,035 ) 2,566 — — (2,469 ) Unrealized appreciation (depreciation) included in earnings 5,609 5,329 (1,682 ) (362 ) 8,894 Transfer out of Level 3 — (71 ) (49 ) — (120 ) Other (1,990 ) — — — (1,990 ) Level 3 assets, end of period $ 429,936 $ 19,714 $ 386 $ 1,325 $ 451,361

Note 7 - Borrowings (Tables)

Note 7 - Borrowings (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Debt [Table Text Block]	September 30, 2022 December 31, 2021 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 125,000 $ 67,500 $ 57,500 $ 125,000 $ 53,500 $ 71,500 NYL Facility 200,000 136,750 63,250 100,000 78,750 21,250 Asset-Backed Notes 43,461 43,461 — 70,500 70,500 — 2027 Notes 57,500 57,500 — — — — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 483,461 362,711 120,750 353,000 260,250 92,750 Unamortized debt issuance costs attributable to term borrowings — (3,700 ) — — (2,637 ) — Total borrowings outstanding, net $ 483,461 $ 359,011 $ 120,750 $ 353,000 $ 257,613 $ 92,750

Note 8 - Financial Instrument_2

Note 8 - Financial Instruments With Off-balance-sheet Risk (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block]	September 30, 2022 Fair Value of Unfunded Principal Commitment Balance Liability (In thousands) Better Place Forests Co. $ 5,000 $ 6 BrightInsight, Inc. 21,000 278 Britecore Holdings, Inc. 5,000 66 Canary Medical Inc. 2,500 34 Castle Creek Biosciences 4,000 72 Ceribell, Inc. 2,500 4 Divergent Technologies, Inc. 30,000 315 DropOff, Inc. 7,500 188 Embody, Inc. 2,000 20 Engage3, LLC 8,000 40 Hound Labs, Inc. 7,500 87 Interior Define, Inc. 5,000 65 KSQ Therapeutics, Inc. 10,000 100 Lytics, Inc. 1,250 — Magnolia Medical Technologies, Inc. 10,000 122 Native Microbials, Inc. 8,750 64 Optoro, Inc. 15,000 38 PDS Biotechnology Corporation 10,000 158 Scientia Vascular, Inc. 10,000 110 Slingshot Aerospace, Inc. 5,000 64 Soli, Inc. 7,500 147 Sonex Health, Inc. 2,500 45 Swift Health Systems Inc. 25,500 105 Temperpack Technologies, Inc. 9,000 19 Total $ 214,500 $ 2,147

Note 10 - Distributions (Tables

Note 10 - Distributions (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Dividends Declared [Table Text Block]	DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Nine Months Ended September 30, 2022 7/29/2022 11/17/22 12/15/22 $ 0.10 $ — — $ — 7/29/2022 10/18/22 11/15/22 0.10 — — — 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 0.90 $ 17,083 32,590 $ 392 Year Ended December 31, 2021 10/22/21 2/18/22 3/16/22 $ 0.10 $ 2,100 3,409 $ 46 10/22/21 1/19/22 2/16/22 0.10 2,096 2,680 43 10/22/21 12/17/21 1/14/22 0.10 2,031 3,417 56 10/22/21 11/18/21 12/15/21 0.05 1,013 1,197 20 7/23/21 11/18/21 12/15/21 0.10 2,027 2,395 38 7/23/21 10/19/21 11/16/21 0.10 2,010 1,907 34 7/23/21 9/17/21 10/15/21 0.10 2,008 2,068 36 4/23/21 8/18/21 9/15/21 0.10 1,996 2,041 34 4/23/21 7/20/21 8/16/21 0.10 1,983 1,937 34 4/23/21 6/17/21 7/16/21 0.10 1,964 1,888 33 2/26/21 5/18/21 6/15/21 0.10 1,964 1,671 29 2/26/21 4/20/21 5/14/21 0.10 1,937 1,794 29 2/26/21 3/18/21 4/16/21 0.10 1,938 1,653 28 $ 1.25 $ 25,067 28,057 $ 460 Ex-Dividend Date Record Date Payment Date Distributions Declared December 16, 2022 December 19, 2022 January 13, 2023 $ 0.11 January 17, 2023 January 18, 2023 February 15, 2023 $ 0.11 February 16, 2023 February 17, 2023 March 15, 2023 $ 0.11 Ex-Dividend Date Record Date Payment Date Distributions Declared November 16, 2022 November 17, 2022 December 15, 2022 $ 0.05

Note 11 - Financial Highlights

Note 11 - Financial Highlights (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Investment Company, Financial Highlights [Table Text Block]	Nine months ended September 30, 2022 2021 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.56 $ 11.02 Net investment income 1.06 1.02 Realized loss (0.40 ) (0.14 ) Unrealized appreciation on investments 0.05 0.41 Net increase in net assets resulting from operations 0.71 1.29 Distributions declared (1) (0.90 ) (0.90 ) From net investment income (0.90 ) (0.90 ) From net realized gain on investments — — Return of capital — — Other (2) 0.29 0.22 Net asset value at end of period $ 11.66 $ 11.63 Per share market value, beginning of period $ 15.92 $ 13.24 Per share market value, end of period $ 10.01 $ 16.26 Total return based on a market value (3) (31.5 )% 29.6 % Shares outstanding at end of period 26,393,773 20,425,175 Ratios to average net assets: Expenses without incentive value (4) 11.4 % 10.6 % Incentive fees (4) 3.0 % 3.0 % Net expenses (4) 14.4 % 13.6 % Net investment income with incentive fees (4) 12.1 % 12.1 % Net assets at the end of the period $ 307,687 $ 237,590 Average net asset value $ 280,904 $ 223,031 Average debt per share $ 13.32 $ 11.07 Portfolio turnover ratio (5) 14.9 % 29.0 %

Consolidated Schedule of Inve_3

Consolidated Schedule of Investments (Unaudited) (Details Textual) - USD ($) $ in Thousands	Oct. 22, 2022	Sep. 30, 2022	Dec. 31, 2021	Aug. 13, 2019
Debt Instrument, Face Amount		$ 483,461	$ 353,000
Percentage of Nonqualifying Assets on a Cost Basis		7.40%	5.80%
Percentage of Nonqualifying Assets on a Fair Value Basis		7.30%	5.80%
Assets of Espero [Member]
Asset Acquisition, Consideration Transferred, Total	$ 7,000
Asset-Backed Notes [Member]
Debt Instrument, Face Amount		$ 43,461	$ 70,500	$ 160,000
Asset-Backed Notes [Member] | Affiliated Entity [Member]
Debt Instrument, Face Amount				$ 100,000

Consolidated Schedule of Inve_4

Consolidated Schedule of Investments (Unaudited) - Investments (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Investments at cost	$ 629,216	$ 453,837
Investments at fair value	634,624	458,075
Non-affiliate [Member]
Investments at cost	629,216	452,387
Investments at fair value	634,624	458,075
Controlled Affiliate [Member]
Investments at cost		1,450
Investments at fair value		0
Debt Securities [Member] | Non-affiliate [Member]
Investments at cost	612,478
Investments at fair value	609,032
Warrant [Member] | Non-affiliate [Member]
Investments at cost	11,971	10,023
Investments at fair value	22,113	20,200
Other Long-Term Investments [Member] | Non-affiliate [Member]
Investments at cost	1,200	0
Investments at fair value	1,300	200
Other Long-Term Investments [Member] | Controlled Affiliate [Member]
Investments at cost		1,450
Investments at fair value		0
Debt Investments [Member] | Non-affiliate [Member]
Investments at cost		441,885
Investments at fair value		437,317
Preferred and Common Stock [Member] | Non-affiliate [Member]
Investments at cost		479
Investments at fair value		358
Equity Securities [Member] | Non-affiliate [Member]
Investments at cost	3,567
Investments at fair value	2,179
Money Market Funds, Unrestricted Investment [Member]
Investments at cost	7,732	7,868
Investments at fair value	7,732	7,868
Unrestricted Short Term Investments [Member]
Investments at cost	7,732	7,868
Investments at fair value	7,732	7,868
Money Market Funds, Restricted Investments [Member]
Investments at cost	1,617	1,359
Investments at fair value	1,617	1,359
Restricted Short Term Investments [Member]
Investments at cost	1,617	1,359
Investments at fair value	1,617	1,359
Biotechnology Sector [Member]
Investments at cost	148,952	109,899
Investments at fair value	147,442	107,902
Biotechnology Sector [Member] | Common Stock Warrants [Member] | Avalo Therapeutics, Inc. [Member]
Investments at cost	311	311
Investments at fair value	$ 0	$ 27
Number of Shares (in shares)	26,442	317,306
Biotechnology Sector [Member] | Common Stock Warrants [Member] | Stealth BioTherapeutics Inc. [Member]
Investments at cost	$ 264	$ 264
Investments at fair value	$ 0	$ 45
Number of Shares (in shares)	795,455	795,455
Biotechnology Sector [Member] | Common Stock Warrants [Member] | Celsion Corporation [Member]
Investments at cost		$ 65
Investments at fair value		$ 1
Number of Shares (in shares)		295,053
Biotechnology Sector [Member] | Common Stock Warrants [Member] | F-Star Therapeutics, Inc [Member]
Investments at cost	$ 35	$ 36
Investments at fair value	$ 0	$ 3
Number of Shares (in shares)	21,120	21,120
Biotechnology Sector [Member] | Common Stock Warrants [Member] | IMV Inc [Member]
Investments at cost	$ 67	$ 64
Investments at fair value	$ 4	$ 64
Number of Shares (in shares)	397,726	284,090
Biotechnology Sector [Member] | Common Stock Warrants [Member] | Greenlight Biosciences, Inc [Member]
Investments at cost	$ 366
Investments at fair value	$ 5
Number of Shares (in shares)	71,292
Biotechnology Sector [Member] | Common Stock Warrants [Member] | LogicBio, Inc [Member]
Investments at cost	$ 8	$ 8
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	7,843	7,843
Biotechnology Sector [Member] | Common Stock Warrants [Member] | Imunon, Inc [Member]
Investments at cost	$ 65
Investments at fair value	$ 0
Number of Shares (in shares)	16,502
Biotechnology Sector [Member] | Common Stock Warrants [Member] | Mustang Bio, Inc [Member]
Investments at cost	$ 146	$ 146
Investments at fair value	$ 0	$ 5
Number of Shares (in shares)	252,161	252,161
Biotechnology Sector [Member] | Common Stock Warrants [Member] | Rocket Pharmaceuticals Corporation [Member]
Investments at cost	$ 17	$ 17
Investments at fair value	$ 1	$ 9
Number of Shares (in shares)	7,051	7,051
Biotechnology Sector [Member] | Common Stock Warrants [Member] | Strongbridge U.S. Inc [Member]
Investments at cost		$ 72
Investments at fair value		$ 110
Number of Shares (in shares)		160,714
Biotechnology Sector [Member] | Common Stock Warrants [Member] | vTv Therapeutics Inc [Member]
Investments at cost	$ 44	$ 44
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	95,293	95,293
Biotechnology Sector [Member] | Common Stock Warrants [Member] | PDS Biotechnology Corporation [Member]
Investments at cost	$ 160
Investments at fair value	$ 160
Number of Shares (in shares)	299,848
Biotechnology Sector [Member] | Common Stock Warrants [Member] | Xeris Pharmaceuticals, Inc [Member]
Investments at cost	$ 72
Investments at fair value	$ 2
Number of Shares (in shares)	126,000
Biotechnology Sector [Member] | Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25) One [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 2,885
Investments at cost	2,817
Investments at fair value	$ 2,765
Biotechnology Sector [Member] | Term Loan (11.75% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 10/1/25) One [Member] | Stealth BioTherapeutics Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0%
ETP	6%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,906
Investments at fair value	4,906
Biotechnology Sector [Member] | Term Loan (9.30% cash (Libor + 7.50%; Floor 9.30%), 5.00% ETP, Due 3/1/24) One [Member] | Castle Creek Pharmaceuticals Holdings, Inc. [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0%
ETP		5%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		4,957
Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | Castle Creek Biosciences, Inc [Member]
Investments at cost	214	142
Investments at fair value	$ 104	$ 148
Number of Shares (in shares)	5,372	2,428
Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | Corvium, Inc [Member]
Investments at cost	$ 52	$ 54
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	661,956	661,956
Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | Emalex Biosciences, Inc. [Member]
Investments at cost	$ 176	$ 139
Investments at fair value	$ 244	$ 162
Number of Shares (in shares)	110,402	92,002
Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | Provivi, Inc. [Member]
Investments at cost	$ 278	$ 278
Investments at fair value	$ 513	$ 519
Number of Shares (in shares)	164,608	164,608
Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | KSQ Therapeutics, Inc. [Member]
Investments at cost	$ 50
Investments at fair value	$ 54
Number of Shares (in shares)	48,077
Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | Native Microbials, Inc. [Member]
Investments at cost	$ 52
Investments at fair value	$ 59
Number of Shares (in shares)	94,253
Biotechnology Sector [Member] | Term Loan (11.00% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25), Two [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 2,885
Investments at cost	2,817
Investments at fair value	$ 2,765
Biotechnology Sector [Member] | Term Loan (10.25% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 10/1/25) Two [Member] | Stealth BioTherapeutics Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0%
ETP	6%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,453
Investments at fair value	$ 2,453
Biotechnology Sector [Member] | Term Loan (9.30% cash (Libor + 7.50%; Floor 9.30%), 5.00% ETP, Due 3/1/24) Two [Member] | Castle Creek Pharmaceuticals Holdings, Inc. [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0%
ETP		5%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] | Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25) Three [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 1,442
Investments at cost	1,435
Investments at fair value	$ 1,410
Biotechnology Sector [Member] | Term Loan (9.30% cash (Libor + 7.50%; Floor 9.30%), 5.00% ETP, Due 3/1/24) Three [Member] | Castle Creek Pharmaceuticals Holdings, Inc. [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0%
ETP		5%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] | Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 2/1/25) One [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Feb. 01, 2025
Principal Amount	$ 2,885
Investments at cost	2,813
Investments at fair value	$ 2,763
Biotechnology Sector [Member] | Term Loan (9.30% cash (Libor + 7.50%; Floor 9.30%), 5.00% ETP, Due 3/1/24) Four [Member] | Castle Creek Pharmaceuticals Holdings, Inc. [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0%
ETP		5%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] | Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 2/1/25) Two [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Feb. 01, 2025
Principal Amount	$ 2,885
Investments at cost	2,813
Investments at fair value	$ 2,763
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25) One [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,909
Investments at fair value		$ 4,909
Biotechnology Sector [Member] | Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 4/1/25) One [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Apr. 01, 2025
Principal Amount	$ 1,442
Investments at cost	1,404
Investments at fair value	$ 1,379
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25) Two [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,909
Investments at fair value		$ 4,909
Biotechnology Sector [Member] | Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 4/1/25) Two [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Apr. 01, 2025
Principal Amount	$ 1,442
Investments at cost	1,404
Investments at fair value	$ 1,379
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25) Three [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,454
Investments at fair value		$ 2,454
Biotechnology Sector [Member] | Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) One [Member] | Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,887
Investments at fair value	$ 4,887
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 2/1/25) Four [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Feb. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,906
Investments at fair value		$ 4,906
Biotechnology Sector [Member] | Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) Two [Member] | Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,959
Investments at fair value	$ 4,959
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 2/1/25) Five [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Feb. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,906
Investments at fair value		$ 4,906
Biotechnology Sector [Member] | Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) Three [Member] | Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 3,000
Investments at cost	2,976
Investments at fair value	$ 2,976
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 4/1/25) Six [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Apr. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,451
Investments at fair value		$ 2,451
Biotechnology Sector [Member] | Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) Four [Member] | Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,959
Investments at fair value	$ 4,959
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 4/1/25) Seven [Member] | Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Apr. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,451
Investments at fair value		2,451
Biotechnology Sector [Member] | Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) Five [Member] | Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,959
Investments at fair value	$ 4,959
Biotechnology Sector [Member] | Other Long-Term Investments [Member] | HESP LLC [Member]
Investments at cost		1,450
Investments at fair value		$ 0
Biotechnology Sector [Member] | Term Loan (9.75% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 6/1/24), One [Member] | Emalex Biosciences, Inc. [Member]
Cash Rate		9.75%
Margin		7.90%
Floor		9.75%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,420
Investments at fair value		$ 2,420
Biotechnology Sector [Member] | Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) Six [Member] | Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 3,000
Investments at cost	2,975
Investments at fair value	2,975
Biotechnology Sector [Member] | Preferred Stock [Member] | Castle Creek Biosciences, Inc [Member]
Investments at cost	250
Investments at fair value	$ 250
Number of Shares (in shares)	1,162
Biotechnology Sector [Member] | Term Loan (9.75% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 6/1/24), Two [Member] | Emalex Biosciences, Inc. [Member]
Cash Rate		9.75%
Margin		7.90%
Floor		9.75%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,472
Investments at fair value		$ 2,472
Biotechnology Sector [Member] | Term Loan (10.45% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 6/1/24) One [Member] | Emalex Biosciences, Inc. [Member]
Cash Rate	10.45%
Margin	7.90%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jun. 01, 2024
Principal Amount	$ 2,188
Investments at cost	2,168
Investments at fair value	$ 2,168
Biotechnology Sector [Member] | Term Loan (9.75% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 11/1/25) One [Member] | Emalex Biosciences, Inc. [Member]
Cash Rate		9.75%
Margin		7.90%
Floor		9.75%
Ceiling Rate		0%
ETP		5%
Maturity Date		Nov. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,896
Investments at fair value		$ 4,896
Biotechnology Sector [Member] | Term Loan (10.45% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 6/1/24) Two [Member] | Emalex Biosciences, Inc. [Member]
Cash Rate	10.45%
Margin	7.90%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jun. 01, 2024
Principal Amount	$ 2,188
Investments at cost	2,169
Investments at fair value	$ 2,169
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 4/1/25) One [Member] | F-Star Therapeutics, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Apr. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,465
Investments at fair value		$ 2,465
Biotechnology Sector [Member] | Term Loan (10.45% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 11/1/25) [Member] | Emalex Biosciences, Inc. [Member]
Cash Rate	10.45%
Margin	7.90%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Nov. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,916
Investments at fair value	$ 4,916
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 7/1/25) Two [Member] | F-Star Therapeutics, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,463
Investments at fair value		$ 2,463
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 7/1/25) Two [Member] | Greenlight Biosciences, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,475
Investments at fair value		$ 2,475
Biotechnology Sector [Member] | Term Loan (10.45% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 5/1/26) [Member] | Emalex Biosciences, Inc. [Member]
Cash Rate	10.45%
Margin	7.90%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,902
Investments at fair value	$ 4,902
Biotechnology Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 7/1/25) One [Member] | Greenlight Biosciences, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,850
Investments at fair value		$ 4,850
Biotechnology Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 4/1/25) [Member] | F-Star Therapeutics, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Apr. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,473
Investments at fair value	$ 2,473
Biotechnology Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 7/1/25) [Member] | F-Star Therapeutics, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,471
Investments at fair value	$ 2,471
Biotechnology Sector [Member] | Term Loan (9.00% cash (Prime + 6.25%; Floor 9.00%), 5.00% ETP, Due 7/1/25) One [Member] | IMV Inc [Member]
Cash Rate		9%
Margin		6.25%
Floor		9%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,799
Investments at fair value		$ 4,799
Biotechnology Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 3.00% ETP, Due 7/1/25) One [Member] | Greenlight Biosciences, Inc [Member]
Cash Rate	12%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	3%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,843
Investments at fair value	$ 4,843
Biotechnology Sector [Member] | Term Loan (9.00% cash (Prime + 6.25%; Floor 9.00%), 5.00% ETP, Due 7/1/25) Two [Member] | IMV Inc [Member]
Cash Rate		9%
Margin		6.25%
Floor		9%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,462
Investments at fair value		$ 2,462
Biotechnology Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 3.00% ETP, Due 7/1/25) Two [Member] | Greenlight Biosciences, Inc [Member]
Cash Rate	12%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	3%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,423
Investments at fair value	$ 2,423
Biotechnology Sector [Member] | Term Loan (8.75% cash (Libor + 6.25%; Floor 8.75%), 4.50% ETP, Due 6/1/24) One [Member] | LogicBio, Inc [Member]
Cash Rate		8.75%
Margin		6.25%
Floor		8.75%
Ceiling Rate		0%
ETP		4.50%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 4,028
Investments at cost		4,011
Investments at fair value		$ 4,011
Biotechnology Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 5.00% ETP, Due 7/1/25) One [Member] | IMV Inc [Member]
Cash Rate	12%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,942
Investments at fair value	$ 4,942
Biotechnology Sector [Member] | Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), One [Member] | Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,935
Investments at fair value		$ 4,935
Biotechnology Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 5.00% ETP, Due 7/1/25) Two [Member] | IMV Inc [Member]
Cash Rate	12%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,470
Investments at fair value	$ 2,470
Biotechnology Sector [Member] | Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), Two [Member] | Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,935
Investments at fair value		$ 4,935
Biotechnology Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 5.00% ETP, Due 1/1/26) One [Member] | IMV Inc [Member]
Cash Rate	12%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,942
Investments at fair value	$ 4,942
Biotechnology Sector [Member] | Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), Three [Member] | Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,440
Investments at fair value		$ 2,440
Biotechnology Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 5.00% ETP, Due 1/1/26) Two [Member] | IMV Inc [Member]
Cash Rate	12%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,941
Investments at fair value	$ 4,941
Biotechnology Sector [Member] | Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), Four [Member] | Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,440
Investments at fair value		$ 2,440
Biotechnology Sector [Member] | Term Loan (11.00% cash (Prime + 4.75%; Floor 8.50%), 5.50% ETP, Due 5/1/27) One [Member] | KSQ Therapeutics, Inc. [Member]
Cash Rate	11%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	May 01, 2027
Principal Amount	$ 6,250
Investments at cost	6,071
Investments at fair value	$ 6,071
Biotechnology Sector [Member] | Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), Five [Member] | Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,430
Investments at fair value		$ 2,430
Biotechnology Sector [Member] | Term Loan (11.00% cash (Prime + 4.75%; Floor 8.50%), 5.50% ETP, Due 5/1/27) Two [Member] | KSQ Therapeutics, Inc. [Member]
Cash Rate	11%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	May 01, 2027
Principal Amount	$ 6,250
Investments at cost	6,172
Investments at fair value	$ 6,172
Biotechnology Sector [Member] | Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), Six [Member] | Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,430
Investments at fair value		$ 2,430
Biotechnology Sector [Member] | Term Loan (8.80% cash (Libor + 6.25%; Floor 8.75%), 4.50% ETP, Due 6/1/24) [Member] | LogicBio, Inc [Member]
Cash Rate	8.80%
Margin	6.25%
Floor	8.75%
Ceiling Rate	0%
ETP	4.50%
Maturity Date	Jun. 01, 2024
Principal Amount	$ 2,778
Investments at cost	2,766
Investments at fair value	$ 2,766
Biotechnology Sector [Member] | Term Loan (8.75% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 10/1/25) One [Member] | Stealth BioTherapeutics Inc. [Member]
Cash Rate		8.75%
Margin		5.50%
Floor		8.75%
Ceiling Rate		0%
ETP		6%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,631
Investments at fair value		$ 4,631
Biotechnology Sector [Member] | Term Loan (11.50% cash (Prime + 5.25%; Floor 8.50%), 5.00% ETP, Due 11/1/26) [Member] | Native Microbials, Inc. [Member]
Cash Rate	11.50%
Margin	5.25%
Floor	8.50%
Ceiling Rate	0%
ETP	5%
Maturity Date	Nov. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,633
Investments at fair value	$ 3,633
Biotechnology Sector [Member] | Term Loan (8.75% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 10/1/25) Two [Member] | Stealth BioTherapeutics Inc. [Member]
Cash Rate		8.75%
Margin		5.50%
Floor		8.75%
Ceiling Rate		0%
ETP		6%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,441
Investments at fair value		2,441
Biotechnology Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.75%), 3.75% ETP, Due 9/1/26) One [Member] | PDS Biotechnology Corporation [Member]
Cash Rate	12%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,688
Investments at fair value	$ 9,688
Biotechnology Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.75%), 3.75% ETP, Due 9/1/26) Two [Member] | PDS Biotechnology Corporation [Member]
Cash Rate	12%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,692
Investments at fair value	$ 3,692
Biotechnology Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.75%), 3.75% ETP, Due 9/1/26) Three [Member] | PDS Biotechnology Corporation [Member]
Cash Rate	12%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,692
Investments at fair value	$ 3,692
Biotechnology Sector [Member] | Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) One [Member] | Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 4,666
Investments at cost	4,618
Investments at fair value	$ 4,618
Biotechnology Sector [Member] | Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) Two [Member] | Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 4,666
Investments at cost	4,618
Investments at fair value	$ 4,618
Biotechnology Sector [Member] | Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) Three [Member] | Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 2,333
Investments at cost	2,288
Investments at fair value	$ 2,288
Biotechnology Sector [Member] | Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) Four [Member] | Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 2,333
Investments at cost	2,288
Investments at fair value	$ 2,288
Biotechnology Sector [Member] | Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) Five [Member] | Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 2,333
Investments at cost	2,281
Investments at fair value	$ 2,281
Biotechnology Sector [Member] | Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) Six [Member] | Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 2,333
Investments at cost	2,281
Investments at fair value	2,281
Communications Sector [Member]
Investments at cost	22,883	22,853
Investments at fair value	26,070	25,920
Communications Sector [Member] | Common Stock Warrants [Member] | Axiom Space, Inc [Member]
Investments at cost	47	45
Investments at fair value	$ 52	$ 42
Number of Shares (in shares)	1,991	1,991
Communications Sector [Member] | Preferred Stock Warrants [Member] | Intelepeer Holdings, Inc [Member]
Investments at cost	$ 138	$ 140
Investments at fair value	$ 3,219	$ 3,141
Number of Shares (in shares)	2,936,535	2,936,535
Communications Sector [Member] | Preferred Stock Warrants [Member] | PebblePost, Inc [Member]
Investments at cost	$ 92	$ 92
Investments at fair value	$ 193	$ 161
Number of Shares (in shares)	598,850	598,850
Communications Sector [Member] | Term Loan (11.50% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26) One [Member] | Axiom Space, Inc [Member]
Cash Rate	11.50%
Margin	6%
Floor	9.25%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 7,500
Investments at cost	7,452
Investments at fair value	$ 7,452
Communications Sector [Member] | Term Loan (11.50% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26) Two [Member] | Axiom Space, Inc [Member]
Cash Rate	11.50%
Margin	6%
Floor	9.25%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 7,500
Investments at cost	7,452
Investments at fair value	$ 7,452
Communications Sector [Member] | Term Loan (11.50% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26) Three [Member] | Axiom Space, Inc [Member]
Cash Rate	11.50%
Margin	6%
Floor	9.25%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 7,500
Investments at cost	7,452
Investments at fair value	$ 7,452
Communications Sector [Member] | Convertible Note (3.00%, Due 7/1/23) [Member] | Axiom Space, Inc [Member]
Cash Rate	3%	3%
Maturity Date	Jul. 01, 2023	Jul. 01, 2023
Principal Amount	$ 250	$ 250
Investments at cost	250	250
Investments at fair value	250	$ 250
Communications Sector [Member] | Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26), One [Member] | Axiom Space, Inc [Member]
Cash Rate		9.25%
Margin		6%
Floor		9.25%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Jun. 01, 2026
Principal Amount		$ 7,500
Investments at cost		7,442
Investments at fair value		$ 7,442
Communications Sector [Member] | Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26), Two [Member] | Axiom Space, Inc [Member]
Cash Rate		9.25%
Margin		6%
Floor		9.25%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Jun. 01, 2026
Principal Amount		$ 7,500
Investments at cost		7,442
Investments at fair value		$ 7,442
Communications Sector [Member] | Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26), Three [Member] | Axiom Space, Inc [Member]
Cash Rate		9.25%
Margin		6%
Floor		9.25%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Jun. 01, 2026
Principal Amount		$ 7,500
Investments at cost		7,442
Investments at fair value		7,442
Medical Device Sector [Member]
Investments at cost	114,364	88,681
Investments at fair value	116,967	84,567
Medical Device Sector [Member] | Common Stock Warrants [Member] | AccuVein Inc [Member]
Investments at cost	23	24
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	1,175	1,175
Medical Device Sector [Member] | Common Stock Warrants [Member] | CVRx, Inc [Member]
Investments at cost	$ 76	$ 80
Investments at fair value	$ 47	$ 90
Number of Shares (in shares)	47,410	47,410
Medical Device Sector [Member] | Term Loan (10.75% cash (Prime + 5.25%; Floor 9.00%), 5.00% ETP, Due 7/1/27) One [Member] | Swift Health Systems Inc. [Member]
Cash Rate	10.75%
Margin	5.25%
Floor	9%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,345
Investments at fair value	3,345
Medical Device Sector [Member] | Term Loan (9.30% cash (Libor + 7.50%; Floor 9.30%), 5.00% ETP, Due 3/1/24) One [Member] | CSA Medical, Inc [Member]
Cash Rate		10%
Margin		8.20%
Floor		10%
Ceiling Rate		0%
ETP		5%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 3,600
Investments at cost		3,569
Investments at fair value		$ 3,569
Medical Device Sector [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 28.00% ETP, Due 8/1/26) One [Member] | Embody, Inc. [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		28%
Maturity Date		Aug. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,457
Investments at fair value		2,457
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Swift Health Systems Inc. [Member]
Investments at cost	71
Investments at fair value	$ 79
Number of Shares (in shares)	135,484
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Magnolia Medical Technologies, Inc [Member]
Investments at cost	$ 141	91
Investments at fair value	$ 135	$ 112
Number of Shares (in shares)	699,485	441,780
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | InfoBionic, Inc [Member]
Investments at cost	$ 124	$ 124
Investments at fair value	$ 111	$ 121
Number of Shares (in shares)	317,647	317,647
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Aerobiotix, LLC [Member]
Investments at cost	$ 46
Investments at fair value	$ 52
Number of Shares (in shares)	27,330
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Meditrina, Inc [Member]
Investments at cost	$ 82	$ 83
Investments at fair value	$ 142	$ 122
Number of Shares (in shares)	221,510	221,510
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Scientia Vascular, Inc. [Member]
Investments at cost	$ 39
Investments at fair value	$ 43
Number of Shares (in shares)	19,662
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | MacuLogix, Inc [Member]
Investments at cost		$ 238
Investments at fair value		$ 0
Number of Shares (in shares)		454,460
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Canary Medical Inc. [Member]
Investments at cost	$ 85	$ 53
Investments at fair value	$ 1,865	$ 45
Number of Shares (in shares)	12,153	7,292
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Sonex Health, Inc. [Member]
Investments at cost	$ 97	$ 77
Investments at fair value	$ 113	$ 75
Number of Shares (in shares)	605,313	484,250
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | VERO Biotech LLC [Member]
Investments at cost	$ 53	$ 53
Investments at fair value	$ 0	$ 30
Number of Shares (in shares)	408	408
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Ceribell, Inc. [Member]
Investments at cost	$ 69	$ 61
Investments at fair value	$ 204	$ 172
Number of Shares (in shares)	145,483	134,299
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Cognoa, Inc. [Member]
Investments at cost	$ 148
Investments at fair value	$ 167
Number of Shares (in shares)	775,000
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Conventus Orthopaedics, Inc [Member]
Investments at cost	$ 221	$ 149
Investments at fair value	$ 209	$ 169
Number of Shares (in shares)	7,972,222	6,361,111
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | Aerin Medical, Inc [Member]
Investments at cost	$ 64	$ 66
Investments at fair value	$ 1,187	$ 463
Number of Shares (in shares)	1,818,183	1,818,183
Medical Device Sector [Member] | Preferred Stock Warrants [Member] | CSA Medical, Inc [Member]
Investments at cost	$ 153	$ 154
Investments at fair value	$ 134	$ 108
Number of Shares (in shares)	1,375,727	1,375,727
Medical Device Sector [Member] | Term Loan (10.00% cash (Prime + 5.25%; Floor 9.00%), 5.00% ETP, Due 7/1/27), Two [Member] | Swift Health Systems Inc. [Member]
Cash Rate	10.75%
Margin	5.25%
Floor	9%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,451
Investments at fair value	$ 3,451
Medical Device Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 10/1/24) One [Member] | InfoBionic, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 3,500
Investments at cost		3,397
Investments at fair value		$ 3,397
Medical Device Sector [Member] | Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 6.0% ETP, Due 4/1/26) One [Member] | Aerobiotix, LLC [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	6%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,462
Investments at fair value	$ 2,366
Medical Device Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 6/1/25) One [Member] | InfoBionic, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Jun. 01, 2025
Principal Amount		$ 1,000
Investments at cost		963
Investments at fair value		$ 963
Medical Device Sector [Member] | Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 6.0% ETP, Due 4/1/26) Two [Member] | Aerobiotix, LLC [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	6%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,462
Investments at fair value	$ 2,365
Medical Device Sector [Member] | Term Loan (10.08% cash (Libor + 7.68%; Floor 10.08%), 6.00% ETP, Due 9/1/23) One [Member] | MacuLogix, Inc [Member]
Cash Rate		10.08%
Margin		7.68%
Floor		10.08%
Ceiling Rate		0%
ETP		6%
Maturity Date		Sep. 01, 2023
Principal Amount		$ 7,500
Investments at cost		7,447
Investments at fair value		$ 4,481
Medical Device Sector [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 7.00% ETP, Due 11/1/24) One [Member] | Canary Medical Inc. [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	7%
Maturity Date	Nov. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,438
Investments at fair value	$ 2,438
Medical Device Sector [Member] | Term Loan (10.08% cash (Libor + 7.68%; Floor 10.08%), 6.00% ETP, Due 9/1/23) Two [Member] | MacuLogix, Inc [Member]
Cash Rate		10.08%
Margin		7.68%
Floor		10.08%
Ceiling Rate		0%
ETP		6%
Maturity Date		Sep. 01, 2023
Principal Amount		$ 4,050
Investments at cost		4,022
Investments at fair value		$ 2,420
Medical Device Sector [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 7.00% ETP, Due 11/1/24) Two [Member] | Canary Medical Inc. [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	7%
Maturity Date	Nov. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,486
Investments at fair value	$ 2,486
Medical Device Sector [Member] | Term Loan (9.75% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) One [Member] | Magnolia Medical Technologies, Inc [Member]
Cash Rate		9.75%
Margin		5%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,952
Investments at fair value		$ 4,952
Medical Device Sector [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 7.00% ETP, Due 11/1/24) Three [Member] | Canary Medical Inc. [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	7%
Maturity Date	Nov. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,466
Investments at fair value	$ 2,466
Medical Device Sector [Member] | Term Loan (9.75% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Two [Member] | Magnolia Medical Technologies, Inc [Member]
Cash Rate		9.75%
Margin		5%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,952
Investments at fair value		$ 4,952
Medical Device Sector [Member] | Term Loan (9.00% cash (Prime + 3.75%; Floor 8.25%), 5.50% ETP, Due 10/1/24) One [Member] | Ceribell, Inc. [Member]
Cash Rate	9%
Margin	3.75%
Floor	8.25%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 5,000
Investments at cost	4,965
Investments at fair value	$ 4,965
Medical Device Sector [Member] | Term Loan (9.75% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Three [Member] | Magnolia Medical Technologies, Inc [Member]
Cash Rate		9.75%
Margin		5%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,944
Investments at fair value		$ 4,944
Medical Device Sector [Member] | Term Loan (9.00% cash (Prime + 3.75%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Two [Member] | Ceribell, Inc. [Member]
Cash Rate	9%
Margin	3.75%
Floor	8.25%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 5,000
Investments at cost	4,969
Investments at fair value	$ 4,969
Medical Device Sector [Member] | Term Loan (9.75% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Four [Member] | Magnolia Medical Technologies, Inc [Member]
Cash Rate		9.75%
Margin		5%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,944
Investments at fair value		4,944
Medical Device Sector [Member] | Term Loan (9.00% cash (Prime + 3.75%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Three [Member] | Ceribell, Inc. [Member]
Cash Rate	9%
Margin	3.75%
Floor	8.25%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,475
Investments at fair value	2,475
Medical Device Sector [Member] | Royalty Agreement [Member] | Lumithera, Inc. [Member]
Investments at cost	1,200
Investments at fair value	1,100
Medical Device Sector [Member] | Royalty Agreement [Member] | ZetrOZ, Inc [Member]
Investments at cost	0	0
Investments at fair value	$ 200	$ 200
Medical Device Sector [Member] | Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 5.00% ETP, Due 6/1/24) One [Member] | Sonex Health, Inc. [Member]
Cash Rate		9.25%
Margin		6%
Floor		9.25%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,391
Investments at fair value		$ 2,391
Medical Device Sector [Member] | Term Loan (9.00% cash (Prime + 3.75%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Four [Member] | Ceribell, Inc. [Member]
Cash Rate	9%
Margin	3.75%
Floor	8.25%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,475
Investments at fair value	$ 2,475
Medical Device Sector [Member] | Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 5.00% ETP, Due 6/1/24) Two [Member] | Sonex Health, Inc. [Member]
Cash Rate		9.25%
Margin		6%
Floor		9.25%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,472
Investments at fair value		$ 2,472
Medical Device Sector [Member] | Term Loan (11.75% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 8/1/26) One [Member] | Cognoa, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0%
ETP	6%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,924
Investments at fair value	$ 4,924
Medical Device Sector [Member] | Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 5.00% ETP, Due 6/1/24) Three [Member] | Sonex Health, Inc. [Member]
Cash Rate		9.25%
Margin		6%
Floor		9.25%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,472
Investments at fair value		$ 2,472
Medical Device Sector [Member] | Term Loan (11.75% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 8/1/26) Two [Member] | Cognoa, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0%
ETP	6%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,462
Investments at fair value	$ 2,462
Medical Device Sector [Member] | Term Loan (10.25% cash (Prime + 7.00%; Floor 10.25%), 1.00% ETP, Due 10/1/25) One [Member] | Spineology, Inc [Member]
Cash Rate		10.25%
Margin		7%
Floor		10.25%
Ceiling Rate		0%
ETP		1%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,928
Investments at fair value		$ 4,928
Medical Device Sector [Member] | Term Loan (10.55% cash (Libor + 8.00%; Floor 9.25%), 10.36% ETP, Due 7/1/25) One [Member] | Conventus Orthopaedics, Inc [Member]
Cash Rate	10.55%
Margin	8%
Floor	9.25%
Ceiling Rate	0%
ETP	10.36%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 3,960
Investments at cost	3,892
Investments at fair value	3,892
Medical Device Sector [Member] | Common Stock [Member] | Lumithera, Inc. [Member]
Investments at cost	2,000
Investments at fair value	$ 1,700
Number of Shares (in shares)	392,651
Medical Device Sector [Member] | Term Loan (10.55% cash (Libor + 8.00%; Floor 9.25%), 10.36% ETP, Due 7/1/25) Two [Member] | Conventus Orthopaedics, Inc [Member]
Cash Rate	10.55%
Margin	8%
Floor	9.25%
Ceiling Rate	0%
ETP	10.36%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 3,960
Investments at cost	3,892
Investments at fair value	$ 3,892
Medical Device Sector [Member] | Term Loan (10.75% cash (Prime + 5.25%; Floor 8.50%), 20.00% ETP, Due 9/15/22) One [Member] | Corinth Medtech, Inc [Member]
Cash Rate	10.75%
Margin	5.25%
Floor	8.50%
Ceiling Rate	0%
ETP	20%
Maturity Date	Sep. 15, 2022
Principal Amount	$ 2,500
Investments at cost	2,500
Investments at fair value	$ 2,500
Medical Device Sector [Member] | Term Loan (10.75% cash (Prime + 5.25%; Floor 8.50%), 20.00% ETP, Due 9/15/22) Two [Member] | Corinth Medtech, Inc [Member]
Cash Rate	10.75%
Margin	5.25%
Floor	8.50%
Ceiling Rate	0%
ETP	20%
Maturity Date	Sep. 15, 2022
Principal Amount	$ 2,500
Investments at cost	2,500
Investments at fair value	$ 2,500
Medical Device Sector [Member] | Term Loan (10.75% cash (Libor + 8.20%; Floor 10.00%), 5.00% ETP, Due 1/1/24) One [Member] | CSA Medical, Inc [Member]
Cash Rate	10.75%
Margin	8.20%
Floor	10%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jan. 01, 2024
Principal Amount	$ 2,000
Investments at cost	1,981
Investments at fair value	$ 1,981
Medical Device Sector [Member] | Term Loan (10.75% cash (Libor + 8.20%; Floor 10.00%), 5.00% ETP, Due 1/1/24) Two [Member] | CSA Medical, Inc [Member]
Cash Rate	10.75%
Margin	8.20%
Floor	10%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jan. 01, 2024
Principal Amount	$ 133
Investments at cost	132
Investments at fair value	$ 132
Medical Device Sector [Member] | Term Loan (10.75% cash (Libor + 8.20%; Floor 10.00%), 5.00% ETP, Due 3/1/24) [Member] | CSA Medical, Inc [Member]
Cash Rate	10.75%
Margin	8.20%
Floor	10%
Ceiling Rate	0%
ETP	5%
Maturity Date	Mar. 01, 2024
Principal Amount	$ 2,400
Investments at cost	2,379
Investments at fair value	$ 2,379
Medical Device Sector [Member] | Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 28.00% ETP, Due 8/1/26) [Member] | Embody, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	28%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,461
Investments at fair value	$ 2,461
Medical Device Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 10/1/24) [Member] | InfoBionic, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 3,500
Investments at cost	3,425
Investments at fair value	$ 3,425
Medical Device Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 6/1/25) [Member] | InfoBionic, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 1,000
Investments at cost	971
Investments at fair value	$ 971
Medical Device Sector [Member] | Term Loan (10.50% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) One [Member] | Magnolia Medical Technologies, Inc [Member]
Cash Rate	10.50%
Margin	5%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,810
Investments at fair value	$ 4,810
Medical Device Sector [Member] | Term Loan (10.50% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Two [Member] | Magnolia Medical Technologies, Inc [Member]
Cash Rate	10.50%
Margin	5%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,932
Investments at fair value	$ 4,932
Medical Device Sector [Member] | Term Loan (10.50% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Three [Member] | Magnolia Medical Technologies, Inc [Member]
Cash Rate	10.50%
Margin	5%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,925
Investments at fair value	$ 4,925
Medical Device Sector [Member] | Term Loan (10.50% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Four [Member] | Magnolia Medical Technologies, Inc [Member]
Cash Rate	10.50%
Margin	5%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,926
Investments at fair value	$ 4,926
Medical Device Sector [Member] | Term Loan (10.25% cash (Prime + 4.75%; Floor 8.50%), 5.00% ETP, Due 1/1/27) One [Member] | Scientia Vascular, Inc. [Member]
Cash Rate	10.25%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,593
Investments at fair value	$ 3,593
Medical Device Sector [Member] | Term Loan (10.25% cash (Prime + 4.75%; Floor 8.50%), 5.00% ETP, Due 1/1/27) Two [Member] | Scientia Vascular, Inc. [Member]
Cash Rate	10.25%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,702
Investments at fair value	$ 3,702
Medical Device Sector [Member] | Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 5.00% ETP, Due 6/1/25) One [Member] | Sonex Health, Inc. [Member]
Cash Rate	12%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,428
Investments at fair value	$ 2,428
Medical Device Sector [Member] | Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 7.00% ETP, Due 11/1/24) One [Member] | Canary Medical Inc. [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		7%
Maturity Date		Nov. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,394
Investments at fair value		$ 2,394
Medical Device Sector [Member] | Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 5.00% ETP, Due 6/1/25) Two [Member] | Sonex Health, Inc. [Member]
Cash Rate	12%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,473
Investments at fair value	$ 2,473
Medical Device Sector [Member] | Term Loan (8.25% cash (Libor + 6.70%; Floor 8.25%), 5.50% ETP, Due 10/1/24) One [Member] | Ceribell, Inc. [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,926
Investments at fair value		$ 4,926
Medical Device Sector [Member] | Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 5.00% ETP, Due 6/1/25) Three [Member] | Sonex Health, Inc. [Member]
Cash Rate	12%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,473
Investments at fair value	$ 2,473
Medical Device Sector [Member] | Term Loan (8.25% cash (Libor + 6.70%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Two [Member] | Ceribell, Inc. [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Medical Device Sector [Member] | Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 8.00% ETP, Due 4/1/26) [Member] | Sonex Health, Inc. [Member]
Cash Rate	12%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	8%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,455
Investments at fair value	$ 2,455
Medical Device Sector [Member] | Term Loan (8.25% cash (Libor + 6.70%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Three [Member] | Ceribell, Inc. [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,466
Investments at fair value		$ 2,466
Medical Device Sector [Member] | Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 1.00% ETP, Due 10/1/25) [Member] | Spineology, Inc [Member]
Cash Rate	13.25%
Margin	7%
Floor	10.25%
Ceiling Rate	0%
ETP	1%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,963
Investments at fair value	$ 4,963
Medical Device Sector [Member] | Term Loan (8.25% cash (Libor + 6.70%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Four [Member] | Ceribell, Inc. [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,466
Investments at fair value		$ 2,466
Medical Device Sector [Member] | Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 1.00% ETP, Due 4/1/26) [Member] | Spineology, Inc [Member]
Cash Rate	13.25%
Margin	7%
Floor	10.25%
Ceiling Rate	0%
ETP	1%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,479
Investments at fair value	2,479
Medical Device Sector [Member] | Term Loan (9.25% cash (Libor + 8.00%; Floor 9.25%), 10.36% ETP, Due 7/1/25) One [Member] | Conventus Orthopaedics, Inc [Member]
Cash Rate		9.25%
Margin		8%
Floor		9.25%
Ceiling Rate		0%
ETP		10.36%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 4,056
Investments at cost		4,009
Investments at fair value		$ 4,009
Medical Device Sector [Member] | Term Loan (9.25% cash (Libor + 8.00%; Floor 9.25%), 10.36% ETP, Due 7/1/25) Two [Member] | Conventus Orthopaedics, Inc [Member]
Cash Rate		9.25%
Margin		8%
Floor		9.25%
Ceiling Rate		0%
ETP		10.36%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 4,056
Investments at cost		4,009
Investments at fair value		$ 4,009
Medical Device Sector [Member] | Term Loan (8.50% cash (Prime + 5.25%; Floor 8.50%), 20.00% ETP, Due 4/1/22) One [Member] | Corinth Medtech, Inc [Member]
Cash Rate		8.50%
Margin		5.25%
Floor		8.50%
Ceiling Rate		0%
ETP		20%
Maturity Date		Apr. 01, 2022
Principal Amount		$ 2,500
Investments at cost		2,495
Investments at fair value		$ 2,495
Medical Device Sector [Member] | Term Loan (8.50% cash (Prime + 5.25%; Floor 8.50%), 20.00% ETP, Due 4/1/22) Two [Member] | Corinth Medtech, Inc [Member]
Cash Rate		8.50%
Margin		5.25%
Floor		8.50%
Ceiling Rate		0%
ETP		20%
Maturity Date		Apr. 01, 2022
Principal Amount		$ 2,500
Investments at cost		2,495
Investments at fair value		$ 2,495
Medical Device Sector [Member] | Term Loan (10.00% cash (Libor + 8.20%; Floor 10.00%), 5.00% ETP, Due 1/1/24) One [Member] | CSA Medical, Inc [Member]
Cash Rate		10%
Margin		8.20%
Floor		10%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jan. 01, 2024
Principal Amount		$ 3,125
Investments at cost		3,095
Investments at fair value		$ 3,095
Medical Device Sector [Member] | Term Loan (10.00% cash (Libor + 8.20%; Floor 10.00%), 5.00% ETP, Due 1/1/24) Two [Member] | CSA Medical, Inc [Member]
Cash Rate		10%
Margin		8.20%
Floor		10%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jan. 01, 2024
Principal Amount		$ 208
Investments at cost		206
Investments at fair value		206
Consumer-related Technologies [Member] | Common Stock Warrants [Member] | Aterian, Inc [Member]
Investments at cost	195	195
Investments at fair value	$ 0	$ 1
Number of Shares (in shares)	76,923	76,923
Consumer-related Technologies [Member] | Common Stock Warrants [Member] | Updater, Inc [Member]
Investments at cost	$ 34	$ 34
Investments at fair value	$ 12	$ 31
Number of Shares (in shares)	108,333	108,333
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) One [Member] | Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,397
Investments at fair value	3,397
Consumer-related Technologies [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 1/1/26), Two [Member] | Interior Define, Inc. [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 6,000
Investments at cost		5,775
Investments at fair value		5,775
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Divergent Technologies, Inc. [Member]
Investments at cost	30
Investments at fair value	$ 35
Number of Shares (in shares)	25,758
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Interior Define, Inc. [Member]
Investments at cost	$ 103	103
Investments at fair value	$ 0	$ 103
Number of Shares (in shares)	553,710	553,710
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | NextCar Holding Company, Inc [Member]
Investments at cost	$ 188	$ 47
Investments at fair value	$ 116	$ 47
Number of Shares (in shares)	630,626	310,463
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Alula Holdings, Inc [Member]
Investments at cost	$ 93	$ 93
Investments at fair value	$ 57	$ 70
Number of Shares (in shares)	20,000	20,000
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Primary Kids, Inc [Member]
Investments at cost	$ 57	$ 57
Investments at fair value	$ 425	$ 51
Number of Shares (in shares)	553,778	553,778
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Better Place Forests Co. [Member]
Investments at cost	$ 27	$ 23
Investments at fair value	$ 32	$ 23
Number of Shares (in shares)	10,690	9,353
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Caastle, Inc [Member]
Investments at cost	$ 68	$ 68
Investments at fair value	$ 1,068	$ 823
Number of Shares (in shares)	268,591	268,591
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | CAMP NYC, Inc [Member]
Investments at cost	$ 24	$ 22
Investments at fair value	$ 61	$ 22
Number of Shares (in shares)	17,605	17,605
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Quip NYC Inc [Member]
Investments at cost	$ 324	$ 324
Investments at fair value	$ 525	$ 503
Number of Shares (in shares)	6,191	6,191
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Clara Foods Co [Member]
Investments at cost	$ 31	$ 30
Investments at fair value	$ 378	$ 368
Number of Shares (in shares)	46,745	46,745
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Unagi, Inc [Member]
Investments at cost	$ 32	$ 25
Investments at fair value	$ 38	$ 24
Number of Shares (in shares)	171,081	134,421
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Getaround, Inc [Member]
Investments at cost	$ 450	$ 450
Investments at fair value	$ 199	$ 367
Number of Shares (in shares)	651,040	651,040
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | MyForest Foods Co [Member]
Investments at cost	$ 29
Investments at fair value	$ 33
Number of Shares (in shares)	143
Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | Optoro, Inc. [Member]
Investments at cost	$ 104
Investments at fair value	$ 104
Number of Shares (in shares)	6,600
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) Two [Member] | Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,237
Investments at fair value	$ 1,237
Consumer-related Technologies [Member] | Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 9.75% ETP, Due 1/1/24) [Member] | Lyrical Foods, Inc [Member]
Cash Rate		10%
Margin		6.75%
Floor		10%
Ceiling Rate		0%
ETP		9.75%
Maturity Date		Jan. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,480
Investments at fair value		$ 2,480
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) Three [Member] | Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,712
Investments at fair value	$ 3,712
Consumer-related Technologies [Member] | Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 10.10% ETP, Due 1/1/26), One [Member] | NextCar Holding Company, Inc [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		10.10%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 5,000
Investments at cost		4,935
Investments at fair value		$ 4,935
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) Four [Member] | Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,237
Investments at fair value	$ 1,237
Consumer-related Technologies [Member] | Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 10.10% ETP, Due 1/1/26), Two [Member] | NextCar Holding Company, Inc [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		10.10%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 2,000
Investments at cost		1,920
Investments at fair value		$ 1,920
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) Five [Member] | Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,712
Investments at fair value	$ 3,712
Consumer-related Technologies [Member] | Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 3/1/25), One [Member] | Primary Kids, Inc [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,961
Investments at fair value		$ 2,961
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) Six [Member] | Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,237
Investments at fair value	$ 1,237
Consumer-related Technologies [Member] | Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 3/1/25), Two [Member] | Primary Kids, Inc [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,961
Investments at fair value		$ 2,961
Consumer-related Technologies [Member] | Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 1/1/26) One [Member] | Interior Define, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 6,500
Investments at cost	6,417
Investments at fair value	$ 5,215
Consumer-related Technologies [Member] | Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 9/1/25) [Member] | Primary Kids, Inc [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Sep. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,955
Investments at fair value		$ 2,955
Consumer-related Technologies [Member] | Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 1/1/26) Two [Member] | Interior Define, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 6,000
Investments at cost	5,858
Investments at fair value	$ 4,760
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 8.00%; Floor 11.25%), 3.00% ETP, Due 4/1/26) [Member] | Quip NYC Inc [Member]
Cash Rate		11.25%
Margin		8%
Floor		11.25%
Ceiling Rate		0%
ETP		3%
Maturity Date		Apr. 01, 2026
Principal Amount		$ 10,000
Investments at cost		9,639
Investments at fair value		$ 9,639
Consumer-related Technologies [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 9.75% ETP, Due 1/1/24) [Member] | Lyrical Foods, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	9.75%
Maturity Date	Jan. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,585
Investments at fair value	$ 2,219
Consumer-related Technologies [Member] | Term Loan (11.00% cash (Prime + 7.75%; Floor 11.00%), Due 7/1/25), One [Member] | Unagi, Inc [Member]
Cash Rate		11%
Margin		7.75%
Floor		11%
Ceiling Rate		0%
ETP		0%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,446
Investments at fair value		$ 2,446
Consumer-related Technologies [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 10/1/25) One [Member] | MyForest Foods Co [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,947
Investments at fair value	$ 4,947
Consumer-related Technologies [Member] | Term Loan (11.00% cash (Prime + 7.75%; Floor 11.00%), Due 7/1/25), Two [Member] | Unagi, Inc [Member]
Cash Rate		11%
Margin		7.75%
Floor		11%
Ceiling Rate		0%
ETP		0%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 1,250
Investments at cost		1,234
Investments at fair value		$ 1,234
Consumer-related Technologies [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 10/1/25) Two [Member] | MyForest Foods Co [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,474
Investments at fair value	$ 2,474
Consumer-related Technologies [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 12.00%, Ceiling 14.00%),0.56% ETP, Due 12/20/24), One [Member] | Updater, Inc [Member]
Cash Rate		12%
Margin		5.75%
Floor		12%
Ceiling Rate		14%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 5,000
Investments at cost		4,961
Investments at fair value		$ 4,961
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) One [Member] | NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,947
Investments at fair value	$ 4,947
Consumer-related Technologies [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 12.00%, Ceiling 14.00%),0.56% ETP, Due 12/20/24), Two [Member] | Updater, Inc [Member]
Cash Rate		12%
Margin		5.75%
Floor		12%
Ceiling Rate		14%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 5,000
Investments at cost		4,961
Investments at fair value		$ 4,961
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Two [Member] | NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 2,000
Investments at cost	1,979
Investments at fair value	$ 1,979
Consumer-related Technologies [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 12.00%, Ceiling 14.00%),0.56% ETP, Due 12/20/24), Three [Member] | Updater, Inc [Member]
Cash Rate		12%
Margin		5.75%
Floor		12%
Ceiling Rate		14%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 10,000
Investments at cost		9,922
Investments at fair value		9,922
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Three [Member] | NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,474
Investments at fair value	2,474
Consumer-related Technologies [Member] | Common Stock [Member] | SnagAJob.com, Inc [Member]
Investments at cost	8	9
Investments at fair value	$ 83	$ 83
Number of Shares (in shares)	829,674	82,974
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Four [Member] | NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 3,000
Investments at cost	2,968
Investments at fair value	$ 2,968
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Five [Member] | NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,453
Investments at fair value	$ 2,453
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Six [Member] | NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,453
Investments at fair value	$ 2,453
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Seven [Member] | NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,904
Investments at fair value	$ 4,904
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Eight [Member] | NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,450
Investments at fair value	$ 2,450
Consumer-related Technologies [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 8/1/27) [Member] | Optoro, Inc. [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 2,500
Investments at cost	2,339
Investments at fair value	$ 2,339
Consumer-related Technologies [Member] | Term Loan (12.75% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 3/1/25) One [Member] | Primary Kids, Inc [Member]
Cash Rate	12.75%
Margin	7.25%
Floor	10.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 2,900
Investments at cost	2,870
Investments at fair value	$ 2,870
Consumer-related Technologies [Member] | Term Loan (12.75% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 3/1/25) Two [Member] | Primary Kids, Inc [Member]
Cash Rate	12.75%
Margin	7.25%
Floor	10.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 2,900
Investments at cost	2,870
Investments at fair value	$ 2,870
Consumer-related Technologies [Member] | Term Loan (12.75% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 9/1/25) [Member] | Primary Kids, Inc [Member]
Cash Rate	12.75%
Margin	7.25%
Floor	10.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Sep. 01, 2025
Principal Amount	$ 3,000
Investments at cost	2,964
Investments at fair value	$ 2,964
Consumer-related Technologies [Member] | Term Loan (14.00% cash (Prime + 7.75%; Floor 11.00%), Due 7/1/25) One [Member] | Unagi, Inc [Member]
Cash Rate	14%
Margin	7.25%
Floor	11%
Ceiling Rate	0%
ETP	0%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,471
Investments at fair value	$ 2,317
Consumer-related Technologies [Member] | Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25) One [Member] | Alula Holdings, Inc [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,961
Investments at fair value	$ 4,961
Consumer-related Technologies [Member] | Term Loan (14.00% cash (Prime + 7.75%; Floor 11.00%), Due 7/1/25) Two [Member] | Unagi, Inc [Member]
Cash Rate	14%
Margin	7.25%
Floor	11%
Ceiling Rate	0%
ETP	0%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 1,250
Investments at cost	1,235
Investments at fair value	$ 1,158
Consumer-related Technologies [Member] | Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25) Two [Member] | Alula Holdings, Inc [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,961
Investments at fair value	$ 4,961
Consumer-related Technologies [Member] | Term Loan (14.00% cash (Prime + 7.75%; Floor 11.00%), Due 7/1/25) Three [Member] | Unagi, Inc [Member]
Cash Rate	14%
Margin	7.25%
Floor	11%
Ceiling Rate	0%
ETP	0%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 1,250
Investments at cost	1,234
Investments at fair value	$ 1,157
Consumer-related Technologies [Member] | Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25) Three [Member] | Alula Holdings, Inc [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 3,000
Investments at cost	2,977
Investments at fair value	$ 2,977
Consumer-related Technologies [Member] | Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 12/1/25) [Member] | Alula Holdings, Inc [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Dec. 01, 2025
Principal Amount	$ 1,000
Investments at cost	974
Investments at fair value	$ 974
Consumer-related Technologies [Member] | Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 2/1/26) [Member] | Alula Holdings, Inc [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Feb. 01, 2026
Principal Amount	$ 1,000
Investments at cost	974
Investments at fair value	$ 974
Consumer-related Technologies [Member] | Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25), One [Member] | Alula Holdings, Inc [Member]
Cash Rate		10%
Margin		6.75%
Floor		10%
Ceiling Rate		0%
ETP		3%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,935
Investments at fair value		$ 4,935
Consumer-related Technologies [Member] | Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 1.85% ETP, Due 7/1/25) [Member] | Better Place Forests Co. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	1.85%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,944
Investments at fair value	$ 4,944
Consumer-related Technologies [Member] | Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25), Two [Member] | Alula Holdings, Inc [Member]
Cash Rate		10%
Margin		6.75%
Floor		10%
Ceiling Rate		0%
ETP		3%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,949
Investments at fair value		$ 4,949
Consumer-related Technologies [Member] | Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 1.85% ETP, Due 10/1/25) [Member] | Better Place Forests Co. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	1.85%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,474
Investments at fair value	$ 2,474
Consumer-related Technologies [Member] | Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25), Three [Member] | Alula Holdings, Inc [Member]
Cash Rate		10%
Margin		6.75%
Floor		10%
Ceiling Rate		0%
ETP		3%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,969
Investments at fair value		$ 2,969
Consumer-related Technologies [Member] | Term Loan (13.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 5/1/26) [Member] | CAMP NYC, Inc [Member]
Cash Rate	13.50%
Margin	7.25%
Floor	10.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	May 01, 2026
Principal Amount	$ 3,500
Investments at cost	3,458
Investments at fair value	$ 3,458
Consumer-related Technologies [Member] | Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 12/1/25) [Member] | Alula Holdings, Inc [Member]
Cash Rate		10%
Margin		6.75%
Floor		10%
Ceiling Rate		0%
ETP		3%
Maturity Date		Dec. 01, 2025
Principal Amount		$ 1,000
Investments at cost		968
Investments at fair value		$ 968
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 8/1/25) One [Member] | Clara Foods Co [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Aug. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,481
Investments at fair value	$ 2,481
Consumer-related Technologies [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 1.85% ETP, Due 7/1/25) [Member] | Better Place Forests Co. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		1.85%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,928
Investments at fair value		$ 4,928
Consumer-related Technologies [Member] | Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 8/1/25) Two [Member] | Clara Foods Co [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Aug. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,481
Investments at fair value	2,481
Consumer-related Technologies [Member] | Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 5/1/26) [Member] | CAMP NYC, Inc [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		May 01, 2026
Principal Amount		$ 3,500
Investments at cost		3,430
Investments at fair value		$ 3,430
Consumer-related Technologies [Member] | Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 8/1/25), One [Member] | Clara Foods Co [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Aug. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,476
Investments at fair value		$ 2,476
Consumer-related Technologies [Member] | Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 8/1/25), Two [Member] | Alula Holdings, Inc [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Aug. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,476
Investments at fair value		$ 2,476
Consumer-related Technologies [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 1/1/26), One [Member] | Interior Define, Inc. [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 6,500
Investments at cost		6,397
Investments at fair value		6,397
Software Sector [Member]
Investments at cost	108,910	60,902
Investments at fair value	107,441	60,807
Software Sector [Member] | Common Stock Warrants [Member] | DropOff, Inc. [Member]
Investments at cost	455	397
Investments at fair value	$ 187	$ 395
Number of Shares (in shares)	516,732	482,283
Software Sector [Member] | Common Stock Warrants [Member] | Branded Online, Inc [Member]
Investments at cost		$ 370
Investments at fair value		$ 443
Number of Shares (in shares)		16,678
Software Sector [Member] | Common Stock Warrants [Member] | Decisyon, Inc [Member]
Investments at cost	$ 46	$ 46
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	82,967	82,967
Software Sector [Member] | Common Stock Warrants [Member] | E La Carte, Inc [Member]
Investments at cost	$ 60
Investments at fair value	$ 1
Number of Shares (in shares)	152,908
Software Sector [Member] | Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 3.50% ETP, Due 4/1/26) One [Member] | DropOff, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	3.50%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 6,500
Investments at cost	6,147
Investments at fair value	6,147
Software Sector [Member] | Preferred Stock Warrants [Member] | Kodiak Robotics, Inc. [Member]
Investments at cost	273
Investments at fair value	$ 273
Number of Shares (in shares)	639,918
Software Sector [Member] | Preferred Stock Warrants [Member] | BrightInsight, Inc. [Member]
Investments at cost	$ 157
Investments at fair value	$ 157
Number of Shares (in shares)	80,544
Software Sector [Member] | Preferred Stock Warrants [Member] | Medsphere Systems Corporation [Member]
Investments at cost	$ 60	$ 60
Investments at fair value	$ 341	$ 195
Number of Shares (in shares)	7,097,792	7,097,792
Software Sector [Member] | Preferred Stock Warrants [Member] | Lemongrass Holdings, Inc [Member]
Investments at cost	$ 34
Investments at fair value	$ 38
Number of Shares (in shares)	101,308
Software Sector [Member] | Preferred Stock Warrants [Member] | Lytics, Inc. [Member]
Investments at cost	$ 11	$ 12
Investments at fair value	$ 14	$ 12
Number of Shares (in shares)	26,733	26,733
Software Sector [Member] | Preferred Stock Warrants [Member] | Reputation Institute, Inc [Member]
Investments at cost	$ 56	$ 54
Investments at fair value	$ 35	$ 52
Number of Shares (in shares)	3,731	3,731
Software Sector [Member] | Preferred Stock Warrants [Member] | Slingshot Aerospace, Inc. [Member]
Investments at cost	$ 123
Investments at fair value	$ 123
Number of Shares (in shares)	309,208
Software Sector [Member] | Preferred Stock Warrants [Member] | Supply Network Visiblity Holdings LLC [Member]
Investments at cost	$ 64	$ 64
Investments at fair value	$ 74	$ 62
Number of Shares (in shares)	682	682
Software Sector [Member] | Preferred Stock Warrants [Member] | Britecore Holdings, Inc. [Member]
Investments at cost	$ 21	$ 5
Investments at fair value	$ 64	$ 37
Number of Shares (in shares)	77,828	55,591
Software Sector [Member] | Preferred Stock Warrants [Member] | E La Carte, Inc [Member]
Investments at cost		$ 61
Investments at fair value		$ 53
Number of Shares (in shares)		181,947
Software Sector [Member] | Preferred Stock Warrants [Member] | Lotame Solutions, Inc. [Member]
Investments at cost	$ 22	$ 23
Investments at fair value	$ 306	$ 276
Number of Shares (in shares)	288,115	288,115
Software Sector [Member] | Preferred Stock Warrants [Member] | Revinate Holdings, Inc [Member]
Investments at cost	$ 47	$ 44
Investments at fair value	$ 81	$ 66
Number of Shares (in shares)	498,241	615,475
Software Sector [Member] | Preferred Stock Warrants [Member] | Riv Data Corp [Member]
Investments at cost	$ 12	$ 12
Investments at fair value	$ 296	$ 292
Number of Shares (in shares)	321,428	321,428
Software Sector [Member] | Preferred Stock Warrants [Member] | SIGNiX, Inc [Member]
Investments at cost	$ 225	$ 224
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	186,235	186,235
Software Sector [Member] | Preferred Stock Warrants [Member] | Topia Mobility, Inc [Member]
Investments at cost	$ 135	$ 138
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	3,049,607	3,049,607
Software Sector [Member] | Preferred Stock Warrants [Member] | xAd, Inc [Member]
Investments at cost	$ 177	$ 179
Investments at fair value	$ 2	$ 1
Number of Shares (in shares)	4,343,348	4,343,348
Software Sector [Member] | Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 3.50% ETP, Due 4/1/26) Two [Member] | DropOff, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	3.50%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 6,000
Investments at cost	5,847
Investments at fair value	$ 5,847
Software Sector [Member] | Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 3.50% ETP, Due 8/1/26) [Member] | DropOff, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	3.50%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,431
Investments at fair value	$ 2,431
Software Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.75%), 4.50% ETP, Due 7/1/27) One [Member] | Engage3, LLC [Member]
Cash Rate	12.75%
Margin	6.25%
Floor	9.75%
Ceiling Rate	0%
ETP	4.50%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,675
Investments at fair value	$ 3,675
Software Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.75%), 4.50% ETP, Due 7/1/27) Two [Member] | Engage3, LLC [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.75%
Ceiling Rate	0%
ETP	4.50%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,715
Investments at fair value	$ 3,715
Software Sector [Member] | Term Loan (11.75% cash (Prime + 5.50%; Floor 10.25%), 4.00% ETP, Due 4/1/26) One [Member] | Kodiak Robotics, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0%
ETP	4%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,809
Investments at fair value	$ 9,809
Software Sector [Member] | Term Loan (11.75% cash (Prime + 5.50%; Floor 10.25%), 4.00% ETP, Due 4/1/26) Two [Member] | Kodiak Robotics, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0%
ETP	4%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,809
Investments at fair value	$ 9,809
Software Sector [Member] | Term Loan (11.75% cash (Prime + 5.50%; Floor 10.25%), 4.00% ETP, Due 4/1/26) Three [Member] | Kodiak Robotics, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0%
ETP	4%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,904
Investments at fair value	4,904
Software Sector [Member] | Warrant [Member] | Skyword, Inc [Member]
Investments at cost	48	$ 49
Investments at fair value	$ 9	$ 4
Number of Shares (in shares)	301,055	301,055
Software Sector [Member] | Term Loan (11.75% cash (Prime + 5.50%; Floor 10.25%), 4.00% ETP, Due 4/1/26) Four [Member] | Kodiak Robotics, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0%
ETP	4%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,904
Investments at fair value	$ 4,904
Software Sector [Member] | Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 2.50% ETP, Due 3/1/26) One [Member] | Lemongrass Holdings, Inc [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Mar. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,941
Investments at fair value	$ 4,941
Software Sector [Member] | Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 2.50% ETP, Due 3/1/26) Two [Member] | Lemongrass Holdings, Inc [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Mar. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,471
Investments at fair value	$ 2,471
Software Sector [Member] | Term Loan (11.50% cash (Prime + 6.00%; Floor 9.25%), 3.00% ETP, Due 7/1/25) [Member] | Lytics, Inc. [Member]
Cash Rate	11.50%
Margin	6%
Floor	9.25%
Ceiling Rate	0%
ETP	3%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,472
Investments at fair value	$ 2,472
Software Sector [Member] | Term Loan (12.75% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 8/1/25) [Member] | Reputation Institute, Inc [Member]
Cash Rate	12.75%
Margin	7.25%
Floor	10.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Aug. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,926
Investments at fair value	$ 4,926
Software Sector [Member] | Term Loan (12.00% cash (Prime +5.75%; Floor 9.75%), 5.00% ETP, Due 8/1/26) One [Member] | Slingshot Aerospace, Inc. [Member]
Cash Rate	12%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,927
Investments at fair value	4,927
Software Sector [Member] | Common Stock [Member] | Branded Online, Inc [Member]
Investments at cost	1,079
Investments at fair value	$ 146
Number of Shares (in shares)	108,004
Software Sector [Member] | Term Loan (12.00% cash (Prime +5.75%; Floor 9.75%), 5.00% ETP, Due 8/1/26) Two [Member] | Slingshot Aerospace, Inc. [Member]
Cash Rate	12%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,927
Investments at fair value	$ 4,927
Software Sector [Member] | Term Loan (12.00% cash (Prime +5.75%; Floor 9.75%), 5.00% ETP, Due 8/1/26) Three [Member] | Slingshot Aerospace, Inc. [Member]
Cash Rate	12%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,863
Investments at fair value	$ 4,863
Software Sector [Member] | Term Loan (12.00% cash (Prime +5.75%; Floor 9.75%), 5.00% ETP, Due 8/1/26) Four [Member] | Slingshot Aerospace, Inc. [Member]
Cash Rate	12%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,927
Investments at fair value	4,927
Software Sector [Member] | Preferred and Common Stock [Member] | Decisyon, Inc [Member]
Investments at cost	230	$ 230
Investments at fair value	$ 0	$ 120
Number of Shares (in shares)	72,638,663	72,638,663
Software Sector [Member] | Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 2/1/25) One [Member] | Supply Network Visiblity Holdings LLC [Member]
Cash Rate	12%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Feb. 01, 2025
Principal Amount	$ 3,500
Investments at cost	3,469
Investments at fair value	$ 3,469
Software Sector [Member] | Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 2/1/25) Two [Member] | Supply Network Visiblity Holdings LLC [Member]
Cash Rate	12%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Feb. 01, 2025
Principal Amount	$ 3,500
Investments at cost	3,469
Investments at fair value	$ 3,469
Software Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 6.00% ETP, Due 9/1/26) [Member] | Branded Online, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		6%
Maturity Date		Sep. 01, 2026
Principal Amount		$ 5,000
Investments at cost		4,719
Investments at fair value		$ 4,719
Software Sector [Member] | Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 12/1/25) One [Member] | Supply Network Visiblity Holdings LLC [Member]
Cash Rate	12%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Dec. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,470
Investments at fair value	$ 2,470
Software Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 6.00% ETP, Due 11/1/26) [Member] | Branded Online, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		6%
Maturity Date		Nov. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,355
Investments at fair value		$ 2,355
Software Sector [Member] | Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 12/1/25) Two [Member] | Supply Network Visiblity Holdings LLC [Member]
Cash Rate	12%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Dec. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,470
Investments at fair value	$ 2,470
Software Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 0% ETP, Due 7/1/23) [Member] | Branded Online, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		0%
Maturity Date		Jul. 01, 2023
Principal Amount		$ 5,000
Investments at cost		5,000
Investments at fair value		$ 5,000
Software Sector [Member] | Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 4.00% ETP, Due 10/1/24), One [Member] | Britecore Holdings, Inc. [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,481
Investments at fair value		$ 2,481
Software Sector [Member] | Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 4.00% ETP, Due 10/1/24), Two [Member] | Britecore Holdings, Inc. [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,481
Investments at fair value		$ 2,481
Software Sector [Member] | Term Loan (12.68% cash (Prime + 9.23%; Floor 12.68%), 50.43% ETP, Due 1/1/23) [Member] | Decisyon, Inc [Member]
Cash Rate		12.68%
Margin		9.23%
Floor		12.68%
Ceiling Rate		0%
ETP		50.43%
Maturity Date		Jan. 01, 2023
Principal Amount		$ 3,470
Investments at cost		3,470
Investments at fair value		$ 3,470
Software Sector [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 3.50% ETP, Due 4/1/26), One [Member] | DropOff, Inc. [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		3.50%
Maturity Date		Apr. 01, 2026
Principal Amount		$ 6,500
Investments at cost		6,087
Investments at fair value		$ 6,087
Software Sector [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 3.50% ETP, Due 4/1/26), Two [Member] | DropOff, Inc. [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		3.50%
Maturity Date		Apr. 01, 2026
Principal Amount		$ 6,000
Investments at cost		5,816
Investments at fair value		$ 5,816
Software Sector [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 10/1/25), One [Member] | E La Carte, Inc [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,937
Investments at fair value		$ 2,937
Software Sector [Member] | Term Loan (11.00% cash (Prime + 5.50%; Floor 9.50%), 3.00% ETP, Due 8/1/27) One [Member] | BrightInsight, Inc. [Member]
Cash Rate	11%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 7,000
Investments at cost	6,612
Investments at fair value	$ 6,612
Software Sector [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 10/1/25), Two [Member] | E La Carte, Inc [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,958
Investments at fair value		$ 2,958
Software Sector [Member] | Term Loan (11.00% cash (Prime + 5.50%; Floor 9.50%), 3.00% ETP, Due 8/1/27) Two [Member] | BrightInsight, Inc. [Member]
Cash Rate	11%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,445
Investments at fair value	$ 3,445
Software Sector [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 10/1/25), Three [Member] | E La Carte, Inc [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 1,500
Investments at cost		1,479
Investments at fair value		$ 1,479
Software Sector [Member] | Term Loan (11.00% cash (Prime + 5.50%; Floor 9.50%), 3.00% ETP, Due 8/1/27) Three [Member] | BrightInsight, Inc. [Member]
Cash Rate	11%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,445
Investments at fair value	$ 3,445
Software Sector [Member] | Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 4.00% ETP, Due 7/1/25) [Member] | Lytics, Inc. [Member]
Cash Rate		9.25%
Margin		6%
Floor		9.25%
Ceiling Rate		0%
ETP		4%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,464
Investments at fair value		$ 2,464
Software Sector [Member] | Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 8/1/25) [Member] | Reputation Institute, Inc [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0%
ETP		3%
Maturity Date		Aug. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,905
Investments at fair value		$ 4,905
Software Sector [Member] | Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 4.00% ETP, Due 10/1/24) One [Member] | Britecore Holdings, Inc. [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	4%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,420
Investments at fair value	$ 2,420
Software Sector [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 2/1/25) [Member] | Supply Network Visiblity Holdings LLC [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Feb. 01, 2025
Principal Amount		$ 3,500
Investments at cost		3,458
Investments at fair value		$ 3,458
Software Sector [Member] | Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 4.00% ETP, Due 10/1/24) Two [Member] | Britecore Holdings, Inc. [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	4%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,486
Investments at fair value	$ 2,486
Software Sector [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 2/1/25), Two [Member] | Supply Network Visiblity Holdings LLC [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Feb. 01, 2025
Principal Amount		$ 3,500
Investments at cost		3,458
Investments at fair value		$ 3,458
Software Sector [Member] | Term Loan (15.68% cash (Prime + 9.43%; Floor 12.68%), 50.43% ETP, Due 12/31/22) [Member] | Decisyon, Inc [Member]
Cash Rate	15.68%
Margin	9.43%
Floor	12.68%
Ceiling Rate	0%
ETP	50.43%
Maturity Date	Dec. 31, 2022
Principal Amount	$ 3,313
Investments at cost	3,313
Investments at fair value	3,313
Software Sector [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 12/1/25), One [Member] | Supply Network Visiblity Holdings LLC [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Dec. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,463
Investments at fair value		$ 2,463
Software Sector [Member] | Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 12/1/25), Two [Member] | Supply Network Visiblity Holdings LLC [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Dec. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,463
Investments at fair value		2,463
Diagnostics Sector [Member]
Investments at cost	9,840	12,393
Investments at fair value	9,844	12,377
Diagnostics Sector [Member] | Preferred Stock Warrants [Member] | Hound Labs, Inc. [Member]
Investments at cost	47
Investments at fair value	$ 51
Number of Shares (in shares)	159,893
Diagnostics Sector [Member] | Preferred Stock Warrants [Member] | IDbyDNA, Inc. [Member]
Investments at cost		112
Investments at fair value		$ 95
Number of Shares (in shares)		472,006
Diagnostics Sector [Member] | Term Loan (12.25% cash (Prime + 6.00%; Floor 9.25%), 3.50% ETP, Due 6/1/26) One [Member] | Hound Labs, Inc. [Member]
Cash Rate	12.25%
Margin	6%
Floor	9.25%
Ceiling Rate	0%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,383
Investments at fair value	$ 2,383
Diagnostics Sector [Member] | Term Loan (12.25% cash (Prime + 6.00%; Floor 9.25%), 3.50% ETP, Due 6/1/26) Two [Member] | Hound Labs, Inc. [Member]
Cash Rate	12.25%
Margin	6%
Floor	9.25%
Ceiling Rate	0%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,470
Investments at fair value	$ 2,470
Diagnostics Sector [Member] | Term Loan (12.25% cash (Prime + 6.00%; Floor 9.25%), 3.50% ETP, Due 6/1/26) Three [Member] | Hound Labs, Inc. [Member]
Cash Rate	12.25%
Margin	6%
Floor	9.25%
Ceiling Rate	0%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,940
Investments at fair value	4,940
Diagnostics Sector [Member] | Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 1/1/25), One [Member] | IDbyDNA, Inc. [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,902
Investments at fair value		$ 4,902
Diagnostics Sector [Member] | Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 1/1/25), Two [Member] | IDbyDNA, Inc. [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,936
Investments at fair value		$ 4,936
Diagnostics Sector [Member] | Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 1/1/26) [Member] | IDbyDNA, Inc. [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,444
Investments at fair value		2,444
Life Science [Member] | Debt Securities [Member] | Non-affiliate [Member]
Investments at cost	255,997
Investments at fair value	255,525
Other Healthcare Sector [Member] | Preferred Stock Warrants [Member] | Kate Farms, Inc [Member]
Investments at cost	103	101
Investments at fair value	$ 1,217	$ 1,177
Number of Shares (in shares)	82,965	82,965
Other Healthcare Sector [Member] | Preferred Stock Warrants [Member] | Watermark Medical, Inc [Member]
Investments at cost	$ 73	$ 74
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	27,373	27,373
Other Healthcare Sector [Member] | Preferred Stock Warrants [Member] | Secure Transfusion Services, Inc [Member]
Investments at cost	$ 48
Investments at fair value	$ 68
Number of Shares (in shares)	77,690
Other Healthcare Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 4.00% ETP, Due 10/1/25) [Member] | Secure Transfusion Services, Inc [Member]
Cash Rate	12%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	4%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,934
Investments at fair value	$ 4,934
Other Healthcare Sector [Member] | Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 4.00% ETP, Due 12/31/25) [Member] | Secure Transfusion Services, Inc [Member]
Cash Rate	12%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	4%
Maturity Date	Dec. 31, 2025
Principal Amount	$ 2,500
Investments at cost	2,463
Investments at fair value	2,463
Other Sustainability Sector [Member]
Investments at cost	77,024	$ 46,595
Investments at fair value	77,700	47,011
Other Sustainability Sector [Member] | Common Stock Warrants [Member] | Nexii Building Solutions, Inc [Member]
Investments at cost	489	356
Investments at fair value	$ 888	$ 331
Number of Shares (in shares)	209,669	142,405
Other Sustainability Sector [Member] | Common Stock Warrants [Member] | LiquiGlide, Inc [Member]
Investments at cost	$ 39	$ 39
Investments at fair value	$ 45	$ 36
Number of Shares (in shares)	61,539	61,359
Other Sustainability Sector [Member] | Preferred Stock Warrants [Member] | Dream Holdings, Inc [Member]
Investments at cost	$ 61
Investments at fair value	$ 68
Number of Shares (in shares)	70,539
Other Sustainability Sector [Member] | Preferred Stock Warrants [Member] | Soli Organic, Inc [Member]
Investments at cost	$ 214
Investments at fair value	$ 345
Number of Shares (in shares)	681
Other Sustainability Sector [Member] | Preferred Stock Warrants [Member] | Temperpack Technologies, Inc [Member]
Investments at cost	$ 126	$ 107
Investments at fair value	$ 259	$ 552
Number of Shares (in shares)	35,906	48,756
Other Sustainability Sector [Member] | Debt Securities [Member] | Non-affiliate [Member]
Investments at cost	$ 76,095
Investments at fair value	$ 76,095
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 4/1/26) One [Member] | Dream Holdings, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,692
Investments at fair value	$ 3,692
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 4/1/26) Two [Member] | Dream Holdings, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,692
Investments at fair value	$ 3,692
Other Sustainability Sector [Member] | Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25) One [Member] | Nexii Building Solutions, Inc [Member]
Cash Rate	13.25%
Margin	7%
Floor	10.25%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Sep. 01, 2025
Principal Amount	$ 7,500
Investments at cost	7,359
Investments at fair value	$ 7,359
Other Sustainability Sector [Member] | Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25) Two [Member] | Nexii Building Solutions, Inc [Member]
Cash Rate	13.25%
Margin	7%
Floor	10.25%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Sep. 01, 2025
Principal Amount	$ 7,500
Investments at cost	7,359
Investments at fair value	$ 7,359
Other Sustainability Sector [Member] | Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25) Three [Member] | Nexii Building Solutions, Inc [Member]
Cash Rate	13.25%
Margin	7%
Floor	10.25%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Sep. 01, 2025
Principal Amount	$ 7,500
Investments at cost	7,359
Investments at fair value	$ 7,359
Other Sustainability Sector [Member] | Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 7/1/26) One [Member] | Nexii Building Solutions, Inc [Member]
Cash Rate	13.25%
Margin	7%
Floor	10.25%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Jul. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,893
Investments at fair value	$ 4,893
Other Sustainability Sector [Member] | Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 7/1/26) Two [Member] | Nexii Building Solutions, Inc [Member]
Cash Rate	13.25%
Margin	7%
Floor	10.25%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Jul. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,893
Investments at fair value	$ 4,893
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.75% ETP, Due 4/1/26) One [Member] | Soli Organic, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.75%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,919
Investments at fair value	$ 4,919
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.75% ETP, Due 4/1/26) Two [Member] | Soli Organic, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.75%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,313
Investments at fair value	$ 2,313
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.75% ETP, Due 5/1/26) One [Member] | Soli Organic, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.75%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,916
Investments at fair value	$ 4,916
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.75% ETP, Due 5/1/26) Two [Member] | Soli Organic, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.75%
Maturity Date	May 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,458
Investments at fair value	$ 2,458
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 6/1/25) One [Member] | Temperpack Technologies, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 3,750
Investments at cost	3,694
Investments at fair value	$ 3,694
Other Sustainability Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 5.00% ETP, Due 1/1/25) [Member] | LiquiGlide, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 2,000
Investments at cost		1,928
Investments at fair value		$ 1,928
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 6/1/25) Two [Member] | Temperpack Technologies, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 3,750
Investments at cost	3,713
Investments at fair value	$ 3,713
Other Sustainability Sector [Member] | Term Loan (10.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25), One [Member] | Nexii Building Solutions, Inc [Member]
Cash Rate		10.25%
Margin		7%
Floor		10.25%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Sep. 01, 2025
Principal Amount		$ 7,500
Investments at cost		7,322
Investments at fair value		$ 7,322
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25) One [Member] | Temperpack Technologies, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 7,500
Investments at cost	7,417
Investments at fair value	$ 7,417
Other Sustainability Sector [Member] | Term Loan (10.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25), Two [Member] | Nexii Building Solutions, Inc [Member]
Cash Rate		10.25%
Margin		7%
Floor		10.25%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Sep. 01, 2025
Principal Amount		$ 7,500
Investments at cost		7,322
Investments at fair value		$ 7,322
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25) Two [Member] | Temperpack Technologies, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 3,750
Investments at cost	3,709
Investments at fair value	$ 3,709
Other Sustainability Sector [Member] | Term Loan (10.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25), Three [Member] | Nexii Building Solutions, Inc [Member]
Cash Rate		10.25%
Margin		7%
Floor		10.25%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Sep. 01, 2025
Principal Amount		$ 7,500
Investments at cost		7,322
Investments at fair value		$ 7,322
Other Sustainability Sector [Member] | Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25) Three [Member] | Temperpack Technologies, Inc [Member]
Cash Rate	13%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 3,750
Investments at cost	3,709
Investments at fair value	3,709
Other Sustainability Sector [Member] | Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 6/1/25), One [Member] | Temperpack Technologies, Inc [Member]
Cash Rate		10%
Margin		6.75%
Floor		10%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Jun. 01, 2025
Principal Amount		$ 3,750
Investments at cost		3,703
Investments at fair value		$ 3,703
Other Sustainability Sector [Member] | Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 6/1/25), Two [Member] | Temperpack Technologies, Inc [Member]
Cash Rate		10%
Margin		6.75%
Floor		10%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Jun. 01, 2025
Principal Amount		$ 3,750
Investments at cost		3,703
Investments at fair value		$ 3,703
Other Sustainability Sector [Member] | Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25), One [Member] | Temperpack Technologies, Inc [Member]
Cash Rate		10%
Margin		6.75%
Floor		10%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 7,500
Investments at cost		7,396
Investments at fair value		$ 7,396
Other Sustainability Sector [Member] | Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25), Two [Member] | Temperpack Technologies, Inc [Member]
Cash Rate		10%
Margin		6.75%
Floor		10%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,750
Investments at cost		3,698
Investments at fair value		$ 3,698
Other Sustainability Sector [Member] | Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25), Three [Member] | Temperpack Technologies, Inc [Member]
Cash Rate		10%
Margin		6.75%
Floor		10%
Ceiling Rate		0%
ETP		2.50%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,750
Investments at cost		3,698
Investments at fair value		3,698
Life Science Segment [Member] | Warrant [Member] | Non-affiliate [Member]
Investments at cost	3,869	2,893
Investments at fair value	5,634	$ 2,600
Number of Shares (in shares)
Life Science Segment [Member] | Debt Investments [Member] | Non-affiliate [Member]
Investments at cost		$ 194,237
Investments at fair value		189,669
Healthcare Information and Services Segment [Member] | Debt Securities [Member] | Non-affiliate [Member]
Investments at cost	30,692
Investments at fair value	30,692
Healthcare Information and Services Segment [Member] | Warrant [Member] | Non-affiliate [Member]
Investments at cost	488	347
Investments at fair value	1,834	1,467
Healthcare Information and Services Segment [Member] | Debt Investments [Member] | Non-affiliate [Member]
Investments at cost		12,282
Investments at fair value		12,282
Sustainability Segment [Member] | Warrant [Member] | Non-affiliate [Member]
Investments at cost	929	502
Investments at fair value	1,605	$ 919
Number of Shares (in shares)
Sustainability Segment [Member] | Debt Investments [Member] | Non-affiliate [Member]
Investments at cost		$ 46,092
Investments at fair value		46,092
Networking Sector [Member]
Investments at cost	13,551	17,390
Investments at fair value	13,413	17,964
Networking Sector [Member] | Preferred Stock Warrants [Member] | Liqid, Inc [Member]
Investments at cost	364	364
Investments at fair value	$ 226	$ 938
Number of Shares (in shares)	344,102	344,102
Networking Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24), One [Member] | Liqid, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,770
Investments at fair value		$ 4,770
Networking Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24), Two [Member] | Liqid, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,924
Investments at fair value		$ 4,924
Networking Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24), Three [Member] | Liqid, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,459
Investments at fair value		$ 2,459
Networking Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24), Four [Member] | Liqid, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,459
Investments at fair value		$ 2,459
Networking Sector [Member] | Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24), Five [Member] | Liqid, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		4%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,414
Investments at fair value		2,414
Networking Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24) One [Member] | Liqid, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Sep. 01, 2024
Principal Amount	$ 3,833
Investments at cost	3,779
Investments at fair value	$ 3,779
Networking Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24) Two [Member] | Liqid, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Sep. 01, 2024
Principal Amount	$ 3,833
Investments at cost	3,779
Investments at fair value	$ 3,779
Networking Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24) Three [Member] | Liqid, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Sep. 01, 2024
Principal Amount	$ 1,917
Investments at cost	1,887
Investments at fair value	$ 1,887
Networking Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24) Four [Member] | Liqid, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Sep. 01, 2024
Principal Amount	$ 1,917
Investments at cost	1,887
Investments at fair value	$ 1,887
Networking Sector [Member] | Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24) Five [Member] | Liqid, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Sep. 01, 2024
Principal Amount	$ 1,917
Investments at cost	1,855
Investments at fair value	1,855
Data Storage [Member] | Preferred Stock Warrants [Member] | CPG Beyond, Inc [Member]
Investments at cost		242
Investments at fair value		$ 859
Number of Shares (in shares)		500,000
Data Storage [Member] | Warrant [Member] | Silk, Inc [Member]
Investments at cost		$ 234
Investments at fair value		$ 188
Number of Shares (in shares)		44,211,003
Internet and Media Sector [Member]
Investments at cost	329	$ 569
Investments at fair value	1,299	3,305
Internet and Media Sector [Member] | Preferred Stock Warrants [Member] | Global Worldwide LLC [Member]
Investments at cost	75	75
Investments at fair value	$ 0	$ 6
Number of Shares (in shares)	245,810	245,810
Internet and Media Sector [Member] | Preferred Stock Warrants [Member] | Rocket Lawyer Incorporated [Member]
Investments at cost	$ 92	$ 92
Investments at fair value	$ 500	$ 741
Number of Shares (in shares)	261,721	261,721
Internet and Media Sector [Member] | Preferred Stock Warrants [Member] | Skillshare, Inc [Member]
Investments at cost	$ 162	$ 162
Investments at fair value	$ 799	$ 2,403
Number of Shares (in shares)	139,074	139,074
Internet and Media Sector [Member] | Common Stock [Member] | Zeta Global Holdings Corp [Member]
Investments at cost		$ 240
Investments at fair value		$ 155
Number of Shares (in shares)		18,405
Technology Segment [Member] | Debt Securities [Member] | Non-affiliate [Member]
Investments at cost	$ 249,694
Investments at fair value	246,720
Technology Segment [Member] | Warrant [Member] | Non-affiliate [Member]
Investments at cost	6,685	$ 6,281
Investments at fair value	13,040	15,214
Technology Segment [Member] | Debt Investments [Member] | Non-affiliate [Member]
Investments at cost		189,274
Investments at fair value		189,274
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,254	2,609
Power Management Sector [Member] | Preferred Stock Warrants [Member] | Kinestral, Inc [Member]
Investments at cost		1,585
Investments at fair value		$ 2,609
Number of Shares (in shares)		5,002,574
Power Management Sector [Member] | Preferred Stock Warrants [Member] | Halio, Inc [Member]
Investments at cost	1,585
Investments at fair value	$ 2,254
Number of Shares (in shares)	5,002,574
Semiconductor Sector [Member]
Investments at cost	$ 56	$ 101
Investments at fair value	0	0
Semiconductor Sector [Member] | Warrant [Member] | Avalanche Technology, Inc [Member]
Investments at cost	56	101
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	6,081	6,753
Data Storage Sector [Member]
Investments at cost	$ 476	$ 476
Investments at fair value	1,211	$ 1,047
Data Storage Sector [Member] | Preferred Stock Warrants [Member] | CPG Beyond, Inc [Member]
Investments at cost	242
Investments at fair value	$ 895
Number of Shares (in shares)	500,000
Data Storage Sector [Member] | Warrant [Member] | Silk, Inc [Member]
Investments at cost	$ 234
Investments at fair value	$ 316
Number of Shares (in shares)	442,110

Consolidated Schedule of Inve_5

Consolidated Schedule of Investments (Unaudited) - Investments (Details) (Parentheticals)	Sep. 30, 2022	Dec. 31, 2021
NAV %	206.30%	186.70%
Non-affiliate [Member]
NAV %	206.20%	186.70%
Controlled Affiliate [Member]
NAV %		0%
Warrant [Member] | Non-affiliate [Member]
NAV %	7.20%	8.20%
Warrant [Member] | Non-affiliate [Member] | Healthcare Information and Services Segment [Member]
NAV %	0.60%	0.60%
Warrant [Member] | Non-affiliate [Member] | Life Science Segment [Member]
NAV %	1.80%
Warrant [Member] | Non-affiliate [Member] | Life Science [Member]
NAV %		1%
Warrant [Member] | Non-affiliate [Member] | Sustainability Segment [Member]
NAV %	0.50%	0.40%
Warrant [Member] | Non-affiliate [Member] | Technology Segment [Member]
NAV %	4.20%	6.20%
Other Long-Term Investments [Member] | Non-affiliate [Member]
NAV %	0.40%	0.10%
Other Long-Term Investments [Member] | Controlled Affiliate [Member] | Biotechnology Sector [Member]
NAV %		0%
Equity Securities [Member] | Non-affiliate [Member]
NAV %	0.70%	0.10%
Unrestricted Short Term Investments [Member]
NAV %	2.50%	3.20%
Restricted Short Term Investments [Member]
NAV %	0.50%	0.60%
Debt Securities [Member] | Non-affiliate [Member]
NAV %		178.30%
Debt Securities [Member] | Non-affiliate [Member] | Healthcare Information and Services Segment [Member]
NAV %	10%
Debt Securities [Member] | Non-affiliate [Member] | Life Science Segment [Member]
NAV %		77.30%
Debt Securities [Member] | Non-affiliate [Member] | Sustainability Segment [Member]
NAV %		18.80%
Debt Securities [Member] | Non-affiliate [Member] | Technology Segment [Member]
NAV %		77.20%
Debt Investments [Member] | Non-affiliate [Member]
NAV %	179.90%
Debt Investments [Member] | Non-affiliate [Member] | Healthcare Information and Services Segment [Member]
NAV %		5%
Debt Investments [Member] | Non-affiliate [Member] | Life Science Segment [Member]
NAV %	83%
Debt Investments [Member] | Non-affiliate [Member] | Sustainability Segment [Member]
NAV %	24.70%
Debt Investments [Member] | Non-affiliate [Member] | Technology Segment [Member]
NAV %	80.20%

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Mar. 14, 2022	Sep. 30, 2022	Sep. 30, 2021
Proceeds from Issuance of Common Stock		$ 67,525	$ 17,312
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,500,000
Shares Issued, Price Per Share (in dollars per share)	$ 14.35
Proceeds from Issuance of Common Stock	$ 34,300

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		5 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Apr. 29, 2022	Aug. 02, 2021	Jul. 30, 2020
Investments, Cost, Nonaccrual Status	$ 0		$ 0	$ 0
Investments, Fair Value, Nonaccrual Status	0		0	0
Investments, Nonaccrual, Interest Income	$ 0	$ 0		$ 0	$ 1,300
Investment, Nonaccrual, Income Not Received in Cash, Percent	7%	5.20%		7.50%	6.70%
Debt Issuance Costs, Net, Total	$ 5,600		5,600	$ 5,600		$ 4,300
Deferred Finance Costs, Accumulated Amortization	4,400		$ 4,400	4,400		3,200
Amortization of Debt Issuance Costs	$ 400	$ 200		$ 1,142	$ 744
Adjustments to Additional Paid in Capital, Non-deductible Excise Taxes Paid						400
Federal Excise Tax, Percent	4%		4%	4%
Excise and Sales Taxes	$ 100	$ 56		$ 306	174
Unrecognized Tax Benefits, Ending Balance	$ 0		$ 0	$ 0		0
Open Tax Year				2021 2020 2019
Proceeds from Issuance of Common Stock				$ 67,525	$ 17,312
Stock Repurchase Program, Remaining Authorized Repurchase Amount							$ 5,000
Stock Repurchased During Period, Shares (in shares)	0	0	167,465	0	0
Stock Repurchased During Period, Per Share (in dollars per share)			$ 11.22
Stock Repurchased During Period, Value			$ 1,900
The 2020 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value									$ 100,000
The 2021 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value								$ 100,000
Stock Issued During Period, Shares, New Issues (in shares)	1,523,519			2,641,920
Proceeds from Issuance of Common Stock	$ 19,000			$ 33,200
Payments of Stock Issuance Costs	400			600
Equity Sales Agreement, Remaining Amount Available for Issuance	$ 48,900		$ 48,900	$ 48,900
The 2020 Equity Distribution Agreement and the 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		395,068			1,122,516
Proceeds from Issuance of Common Stock		$ 6,600			$ 17,300
Payments of Stock Issuance Costs		$ 200			$ 500
One Investment [Member]
Investments, Cost, Nonaccrual Status						11,500
Investments, Fair Value, Nonaccrual Status						$ 6,900

Note 3 - Related Party Transa_2

Note 3 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Oct. 22, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Management Fee Payable		$ 1,870		$ 1,870		$ 706
Management Fee Expense		2,788	$ 1,997	7,555	$ 5,595
Performance Based Incentive Fee		2,784	2,012	6,353	5,040
Incentive Fee Payable		2,784		2,784		2,015
Administrative Fees Expense		412	251	1,147	829
Investment Management Agreement [Member]
Base Management Fee, Annual, Percent	2%
Base Management Fee, Annual, Percent, Gross Assets Exceeding $250 Million	1.60%
Management Fee Payable		1,900		1,900		700
Management Fee Expense		2,800	2,000	7,600	5,600
Incentive Fee to Pre-incentive Net Investment Income	20%
Pre-Incentive Fee Net Investment Income, Hurdle Rate	1.75%
Pre-Incentive Fee Net Investment Income, Hurdle Rate, Annualized	7%
Pre-Incentive Fee Net Investment Income, Catch-up, Percent	100%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up	2.1875%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up, Annualized	8.75%
Performance Based Incentive Fee		2,800	2,000	6,400	5,000
Incentive Fee Payable		2,800		2,800		$ 2,000
Administration Agreement [Member]
Administrative Fees Expense		$ 400	$ 300	$ 1,100	$ 800

Note 4 - Investments - Investme

Note 4 - Investments - Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Investments at cost	$ 629,216	$ 453,837
Investments at fair value	634,624	458,075
Biotechnology Sector [Member]
Investments at cost	148,952	109,899
Investments at fair value	147,442	107,902
Medical Device Sector [Member]
Investments at cost	114,364	88,681
Investments at fair value	116,967	84,567
Communications Sector [Member]
Investments at cost	22,883	22,853
Investments at fair value	26,070	25,920
Consumer-related Sector [Member]
Investments at cost	109,906	92,158
Investments at fair value	108,301	93,194
Data Storage Sector [Member]
Investments at cost	476	476
Investments at fair value	1,211	1,047
Internet and Media Sector [Member]
Investments at cost	329	569
Investments at fair value	1,299	3,305
Networking Sector [Member]
Investments at cost	13,551	17,390
Investments at fair value	13,413	17,964
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,254	2,609
Semiconductor Sector [Member]
Investments at cost	56	101
Investments at fair value	0	0
Software Sector [Member]
Investments at cost	108,910	60,902
Investments at fair value	107,441	60,807
Other Sustainability Sector [Member]
Investments at cost	77,024	46,595
Investments at fair value	77,700	47,011
Diagnostics Sector [Member]
Investments at cost	9,840	12,393
Investments at fair value	9,844	12,377
Other Sector [Member]
Investments at cost	7,621	175
Investments at fair value	8,682	1,177
Software, Healthcare Information and Service [Member]
Investments at cost	13,719	60
Investments at fair value	14,000	195
Debt [Member]
Investments at cost	612,478	441,885
Investments at fair value	609,032	437,317
Warrant [Member]
Investments at cost	11,971	10,023
Investments at fair value	22,113	20,200
Other Debt Obligations [Member]
Investments at cost	1,200	1,450
Investments at fair value	1,300	200
Equity Securities [Member]
Investments at cost	3,567	479
Investments at fair value	$ 2,179	$ 358

Note 5 - Transactions With Af_3

Note 5 - Transactions With Affiliated Companies - Investments in Controlled Affiliated Companies (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Net unrealized (depreciation) appreciation on investments		$ 3,442	$ 3,376	$ 1,169	$ 8,122
Net realized (loss) gain on investments		(8,585)	$ 1,344	(9,484)	(2,372)
HESP LLC [Member]
Fair value				0	1,500	$ 1,500
Purchases				0		0
Reductions				(300)		(50)
Transfers				0		0
Net unrealized (depreciation) appreciation on investments				1,450		(1,450)
Net realized (loss) gain on investments				(1,150)		0
Fair value		0		0		0
Dividend income				0		0
Dividends declared				0		0
Controlled Affiliate [Member]
Fair value				0	1,500	1,500
Purchases				0		0
Reductions				(300)		(50)
Transfers				0		0
Net unrealized (depreciation) appreciation on investments				1,450		(1,450)
Net realized (loss) gain on investments				(1,150)		0
Fair value		$ 0		0		0
Dividend income				0		0
Dividends declared				0		0
Other Affiliates [Member]
Fair value				0	7,547	7,547
Purchases						800
Reductions						(3,583)
Transfers						(3,538)
Discount accretion						12
Net unrealized (depreciation) appreciation on investments						(848)
Net realized (loss) gain on investments						(390)
Fair value						0
Dividend income						252
Other Affiliates [Member] | First Decisyon Inc. Investment [Member]
Fair value	[1]			0	1,181	1,181
Purchases	[1]					0
Reductions	[1]					0
Transfers	[1]					(1,181)
Discount accretion	[1]					0
Net unrealized (depreciation) appreciation on investments	[1]					0
Net realized (loss) gain on investments	[1]					0
Fair value	[1]					0
Dividend income	[1]					41
Other Affiliates [Member] | Second Decisyon Inc. Investment [Member]
Fair value	[1]			0	626	626
Purchases	[1]					0
Reductions	[1]					0
Transfers	[1]					(638)
Discount accretion	[1]					12
Net unrealized (depreciation) appreciation on investments	[1]					0
Net realized (loss) gain on investments	[1]					0
Fair value	[1]					0
Dividend income	[1]					21
Other Affiliates [Member] | Third Decisyon Inc. Investment [Member]
Fair value	[1]			0	227	227
Purchases	[1]					0
Reductions	[1]					0
Transfers	[1]					(227)
Discount accretion	[1]					0
Net unrealized (depreciation) appreciation on investments	[1]					0
Net realized (loss) gain on investments	[1]					0
Fair value	[1]					0
Dividend income	[1]					7
Other Affiliates [Member] | Fourth Decisyon Inc. Investment [Member]
Fair value	[1]			0	228	228
Purchases	[1]					0
Reductions	[1]					0
Transfers	[1]					(228)
Discount accretion	[1]					0
Net unrealized (depreciation) appreciation on investments	[1]					0
Net realized (loss) gain on investments	[1]					0
Fair value	[1]					0
Dividend income	[1]					7
Other Affiliates [Member] | Fifth Decisyon Inc. Investment [Member]
Fair value	[1]			0	685	685
Purchases	[1]					0
Reductions	[1]					0
Transfers	[1]					(685)
Discount accretion	[1]					0
Net unrealized (depreciation) appreciation on investments	[1]					0
Net realized (loss) gain on investments	[1]					0
Fair value	[1]					0
Dividend income	[1]					22
Other Affiliates [Member] | Sixth Decisyon Inc. Investment [Member]
Fair value	[1]			0	276	276
Purchases	[1]					0
Reductions	[1]					0
Transfers	[1]					(276)
Discount accretion	[1]					0
Net unrealized (depreciation) appreciation on investments	[1]					0
Net realized (loss) gain on investments	[1]					0
Fair value	[1]					0
Dividend income	[1]					9
Other Affiliates [Member] | Seventh Decisyon Inc. Investment [Member]
Fair value	[1]			0	183	183
Purchases	[1]					0
Reductions	[1]					0
Transfers	[1]					(183)
Discount accretion	[1]					0
Net unrealized (depreciation) appreciation on investments	[1]					0
Net realized (loss) gain on investments	[1]					0
Fair value	[1]					0
Dividend income	[1]					6
Other Affiliates [Member] | Eighth Decisyon Inc. Investment [Member]
Fair value	[1]			0	120	120
Purchases	[1]					0
Reductions	[1]					0
Transfers	[1]					(120)
Discount accretion	[1]					0
Net unrealized (depreciation) appreciation on investments	[1]					0
Net realized (loss) gain on investments	[1]					0
Fair value	[1]					0
Dividend income	[1]					0
Other Affiliates [Member] | First MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value				0	2,382	2,382
Purchases						0
Reductions						(2,783)
Transfers						0
Discount accretion						0
Net unrealized (depreciation) appreciation on investments						0
Net realized (loss) gain on investments						401
Fair value						0
Dividend income						139
Other Affiliates [Member] | Second MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value				0	0	0
Purchases						250
Reductions						(250)
Transfers						0
Discount accretion						0
Net unrealized (depreciation) appreciation on investments						0
Net realized (loss) gain on investments						0
Fair value						0
Dividend income						0
Other Affiliates [Member] | Third MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value				0	0	0
Purchases						70
Reductions						(70)
Transfers						0
Discount accretion						0
Net unrealized (depreciation) appreciation on investments						0
Net realized (loss) gain on investments						0
Fair value						0
Dividend income						0
Other Affiliates [Member] | Fourth MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value				0	0	0
Purchases						330
Reductions						(330)
Transfers						0
Discount accretion						0
Net unrealized (depreciation) appreciation on investments						0
Net realized (loss) gain on investments
Fair value						0
Dividend income						0
Other Affiliates [Member] | Fifth MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value				0	0	0
Purchases						150
Reductions						(150)
Transfers						0
Discount accretion						0
Net unrealized (depreciation) appreciation on investments						0
Net realized (loss) gain on investments						0
Fair value						0
Dividend income						0
Other Affiliates [Member] | Sixth MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value				$ 0	$ 1,639	1,639
Purchases						0
Reductions						0
Transfers						0
Discount accretion						0
Net unrealized (depreciation) appreciation on investments						(848)
Net realized (loss) gain on investments						(791)
Fair value						0
Dividend income						$ 0
[1]As of December 31, 2021, the Company no longer owns 5% or more of the portfolio company.

Note 6 - Fair Value (Details Te

Note 6 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total	$ (1,117)	$ 0	$ (1,117)	$ (120)
Unrealized Gain (Loss) on Investments	3,442	$ 3,376	1,169	8,122
Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total	(1,117)		(1,117)	(71)
Debt [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total	0		0	0
Equity Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total	0		0	(49)
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	40		40	100
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	$ 1,100		1,100
Fair Value, Inputs, Level 1 [Member] | Equity Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3				100
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Unrealized Gain (Loss) on Investments			1,200	6,300
Fair Value, Inputs, Level 3 [Member] | Debt [Member]
Unrealized Gain (Loss) on Investments			3,500	300
Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member]
Unrealized Gain (Loss) on Investments			$ 400	$ 1,500
The 2026 Notes [Member]
Debt Instrument, Share Price (in dollars per share) | $ / shares	$ 24.37		$ 24.37
The 2026 Notes [Member] | Fair Value, Inputs, Level 2 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 56,100		$ 56,100
The 2027 Notes [Member]
Debt Instrument, Share Price (in dollars per share) | $ / shares	$ 23.18		$ 23.18
The 2027 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 53,300		$ 53,300
Asset-Backed Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 43,500		$ 43,500
Measurement Input, Hypothetical Market Yields [Member] | Minimum [Member]
Debt Instrument, Measurement Input	0.03		0.03		0.03
Measurement Input, Hypothetical Market Yields [Member] | Maximum [Member]
Debt Instrument, Measurement Input	0.25		0.25		0.23

Note 6 - Fair Value - Significa

Note 6 - Fair Value - Significant Level 3 Fair Value Measurment Inputs (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Investments, fair value	$ 634,259	$ 457,557
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member]
Investments, fair value	$ 605,719	$ 430,417
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member] | Hypothetical Market Yield [Member]
Investments, measurement input	0.03
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member] | Hypothetical Market Yield [Member]
Investments, measurement input	0.25
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member] | Hypothetical Market Yield [Member]
Investments, measurement input	0.14	12
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value	$ 3,313	$ 6,900
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Probability Weighting [Member]
Investments, measurement input	0.25
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member]
Investments, measurement input		20
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member]
Investments, measurement input		50
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]
Investments, measurement input	0.25	33
Warrant [Member] | Black-scholes Valuation Model [Member]
Investments, fair value	$ 21,894	$ 19,837
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input	0.25	25
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input	0.20	20
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	0	0
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]
Investments, measurement input	1	1
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	1,899	980
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]
Investments, measurement input	4	4
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	64.53	20.35
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input	0.25	25
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input	0.20	20
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]
Investments, measurement input	2	2
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value	$ 1,300	$ 200
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Probability Weighting [Member]
Investments, measurement input	1
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Measurement Input, Discount Rate [Member]
Investments, measurement input	0.25	25
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]
Investments, measurement input	1	100
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Measurement Input, Discount Rate [Member]
Investments, measurement input	0.25	25
Equity Securities [Member] | Last Equity Financing [Member]
Investments, fair value	$ 2,033	$ 203
Equity Securities [Member] | Last Equity Financing [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	1	0
Equity Securities [Member] | Last Equity Financing [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	215.03	1
Equity Securities [Member] | Last Equity Financing [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	30.09	0.41

Note 6 - Fair Value - Assets at

Note 6 - Fair Value - Assets at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Recurring [Member]
Investments, fair value	$ 634,624	$ 458,075
Fair Value, Recurring [Member] | Money Market Funds [Member]
Investments, fair value	7,732	7,868
Fair Value, Recurring [Member] | Money Market Funds, Restricted Investments [Member]
Investments, fair value	1,617	1,359
Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	609,032	437,317
Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	22,113	20,200
Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	1,300	200
Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	2,179	358
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Investments, fair value	146	155
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Funds, Restricted Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	146	155
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Investments, fair value	219	363
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]
Investments, fair value	7,732	7,868
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Money Market Funds, Restricted Investments [Member]
Investments, fair value	1,617	1,359
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	219	363
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Investments, fair value	634,259	457,557
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Investments, fair value	634,259	457,557
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Money Market Funds, Restricted Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	609,032	437,317
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	21,894	19,837
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	1,300	200
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	$ 2,033	$ 203

Note 6 - Fair Value - Reconcili

Note 6 - Fair Value - Reconciliation of Level 3 Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Balance	$ 577,380	$ 402,853	$ 457,557	$ 350,048
Purchase of investments	94,627	98,592	348,347	217,252
Warrants and equity received and classified as Level 3	964	1,394	2,441	2,313
Principal payments received on investments	(26,960)	53,588	114,433	119,260
Proceeds from sale of investments	(6,126)	1,553	49,552	3,307
Net realized (loss) gain on investments	(8,195)	1,344	(9,094)	(2,469)
Unrealized appreciation (depreciation) included in earnings	4,227	3,925	2,720	8,894
Transfer out of Level 3	(1,117)	0	(1,117)	(120)
Transfer out of debt investments	0		0
Other	(541)	(1,606)	(2,610)	(1,990)
Balance	634,259	451,361	634,259	451,361
Principal payments received on investments	26,960	(53,588)	(114,433)	(119,260)
Proceeds from sale of investments	6,126	(1,553)	(49,552)	(3,307)
Debt [Member]
Balance	551,560	385,814	437,317	333,495
Purchase of investments	94,627	98,592	348,097	217,252
Warrants and equity received and classified as Level 3	0	0	0	0
Principal payments received on investments	(26,929)	53,588	114,120	119,260
Proceeds from sale of investments	(6,088)	34	49,088	135
Net realized (loss) gain on investments	(8,492)	(40)	(8,492)	(5,035)
Unrealized appreciation (depreciation) included in earnings	8,095	798	1,128	5,609
Transfer out of Level 3	0		0	0
Transfer out of debt investments	(3,200)		(3,200)
Other	(541)	(1,606)	(2,610)	(1,990)
Balance	609,032	429,936	609,032	429,936
Principal payments received on investments	26,929	(53,588)	(114,120)	(119,260)
Proceeds from sale of investments	6,088	(34)	(49,088)	(135)
Warrant [Member]
Balance	25,167	15,102	19,837	12,736
Purchase of investments	0	0	0	0
Warrants and equity received and classified as Level 3	964	1,394	2,441	2,313
Principal payments received on investments	0	0	0	0
Proceeds from sale of investments	(38)	1,519	464	3,159
Net realized (loss) gain on investments	266	1,384	535	2,566
Unrealized appreciation (depreciation) included in earnings	(3,348)	3,353	662	5,329
Transfer out of Level 3	(1,117)		(1,117)	(71)
Transfer out of debt investments	0		0
Other	0	0	0	0
Balance	21,894	19,714	21,894	19,714
Principal payments received on investments	0	0	0	0
Proceeds from sale of investments	38	(1,519)	(464)	(3,159)
Equity Securities [Member]
Balance	453	237	203	2,117
Purchase of investments	0	0	250	0
Warrants and equity received and classified as Level 3	0	0	0	0
Principal payments received on investments	0	0	0	0
Proceeds from sale of investments	0	0	0	0
Net realized (loss) gain on investments	0	0	0	0
Unrealized appreciation (depreciation) included in earnings	(420)	149	(420)	(1,682)
Transfer out of Level 3	0		0	(49)
Transfer out of debt investments	2,000		2,000
Other	0	0	0	0
Balance	2,033	386	2,033	386
Principal payments received on investments	0	0	0	0
Proceeds from sale of investments	0	0	0	0
Other Investments [Member]
Balance	200	1,700	200	1,700
Purchase of investments	0	0	0	0
Warrants and equity received and classified as Level 3	0	0	0	0
Principal payments received on investments	(31)	0	313	0
Proceeds from sale of investments	0	0	0	13
Net realized (loss) gain on investments	31	0	(1,137)	0
Unrealized appreciation (depreciation) included in earnings	(100)	(375)	1,350	(362)
Transfer out of Level 3				0
Transfer out of debt investments	1,200		1,200
Other	0	0	0	0
Balance	1,300	1,325	1,300	1,325
Principal payments received on investments	31	0	(313)	0
Proceeds from sale of investments	$ 0	$ 0	$ 0	$ (13)

Note 7 - Borrowings (Details Te

Note 7 - Borrowings (Details Textual) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended		9 Months Ended
	Feb. 25, 2022	Jun. 22, 2021	Apr. 24, 2021	Apr. 21, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 15, 2022	Dec. 31, 2021	Mar. 30, 2021	Sep. 15, 2019	Aug. 13, 2019	Oct. 11, 2017	Sep. 29, 2017
Asset Coverage to Borrowings, Ratio, Percent							185%
Debt Instrument, Face Amount					$ 483,461		$ 483,461			$ 353,000
Interest Paid, Excluding Capitalized Interest, Operating Activities							11,543	$ 7,785
Long-Term Debt, Gross					362,711		362,711			260,250
Restricted Investments					1,617		1,617			1,359
Money Market Funds [Member]
Restricted Investments					$ 600		$ 600			900
Key Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity, Accordian Feature		$ 150,000
Line of Credit Facility, Maximum Borrowing Capacity		$ 125,000
Line of Credit Facility, Advance Rate of Eligible Debt Investments		60%
Long-Term Debt, Weighted Average Interest Rate, over Time					5.60%	4.25%	4.75%	4.25%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage							0.50%
Line of Credit Facility, Current Borrowing Capacity					$ 57,500		$ 57,500			71,500
Line of Credit Facility, Remaining Borrowing Capacity					28,000		28,000			19,800
Debt Instrument, Face Amount					125,000		125,000			125,000
Long-Term Debt, Gross					$ 67,500		$ 67,500			$ 53,500
Key Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		3.25%
Key Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate							0.25%
Debt Instrument, Variable Rate					6.25%		6.25%			3.25%
The 6.25 % Notes Due 2022 [Member]
Debt Instrument, Face Amount															$ 32,500
Debt Instrument, Interest Rate, Stated Percentage															6.25%
Adittional 2022 Notes [Member]
Debt Instrument, Face Amount														$ 4,900
The 2022 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage												6.25%
Debt Instrument, Convertible, Conversion Price (in dollars per share)												$ 25
Repayments of Debt			$ 37,400
Interest Paid, Excluding Capitalized Interest, Operating Activities			300
Payments of Debt Issuance Costs			$ 400
The 2026 Notes [Member]
Debt Instrument, Face Amount					$ 57,500		$ 57,500			$ 57,500	$ 57,500
Debt Instrument, Interest Rate, Stated Percentage											4.875%
Long-Term Debt, Gross					57,500		57,500			57,500
The 2026 Notes Underwriter Option [Member]
Debt Instrument, Face Amount											$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)											$ 25
The 2027 Notes [Member]
Debt Instrument, Face Amount					57,500		57,500		$ 50,000	0
Debt Instrument, Interest Rate, Stated Percentage									6.25%
Long-Term Debt, Gross					57,500		57,500			0
The 2027 Notes Underwriter Option [Member]
Debt Instrument, Face Amount									$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)									$ 25
Asset-Backed Notes [Member]
Debt Instrument, Face Amount					43,461		43,461			70,500			$ 160,000
Debt Instrument, Interest Rate, Stated Percentage													4.21%
Long-Term Debt, Gross					43,461		43,461			70,500
NYL Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 200,000			$ 100,000
Line of Credit Facility, Current Borrowing Capacity					63,200		63,200			21,200
Line of Credit Facility, Remaining Borrowing Capacity					49,200		49,200			5,700
Debt Instrument, Face Amount					200,000		200,000			100,000
Long-Term Debt, Gross					136,750		136,750			78,750
Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature				$ 200,000
Line of Credit Facility, Advance Rate				67%
Line of Credit Facility, Change in Maximum Borrowing Capacity	$ 100,000
Long-Term Line of Credit, Total					$ 136,800		$ 136,800			$ 78,800
Line of Credit Facility, Interest Rate at Period End					5.11%		5.11%			4.62%
NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	3%
Minimum [Member]
Asset Coverage to Borrowings, Ratio, Percent							150%
Minimum [Member] | Key Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		1%
Minimum [Member] | Key Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate							4.25%
Minimum [Member] | NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				3.55%
Maximum [Member] | NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				5.15%

Note 7 - Borrowings - Borrowing

Note 7 - Borrowings - Borrowings (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 15, 2022	Dec. 31, 2021	Mar. 30, 2021	Aug. 13, 2019
Total commitment	$ 483,461		$ 353,000
Balance outstanding	362,711		260,250
Unused commitment	120,750		92,750
Unamortized debt issuance costs attributable to term borrowings	(3,700)		(2,637)
Total borrowings outstanding, net	359,011		257,613
Key Facility [Member]
Total commitment	125,000		125,000
Balance outstanding	67,500		53,500
Unused commitment	57,500		71,500
NYL Facility [Member]
Total commitment	200,000		100,000
Balance outstanding	136,750		78,750
Unused commitment	63,250		21,250
Asset-Backed Notes [Member]
Total commitment	43,461		70,500		$ 160,000
Balance outstanding	43,461		70,500
Unused commitment	0		0
The 2027 Notes [Member]
Total commitment	57,500	$ 50,000	0
Balance outstanding	57,500		0
Unused commitment	0		0
The 2026 Notes [Member]
Total commitment	57,500		57,500	$ 57,500
Balance outstanding	57,500		57,500
Unused commitment	$ 0		$ 0

Note 8 - Financial Instrument_3

Note 8 - Financial Instruments With Off-balance-sheet Risk (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Liability	$ 2,147
Commitments to Extend Credit [Member]
Other Commitment, Total	$ 214,500	$ 114,500

Note 8 - Financial Instrument_4

Note 8 - Financial Instruments With Off-balance-sheet Risk - Unfunded Commitments (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Unfunded commitments, principal balance	$ 214,500
Fair value of unfunded commitment liability	2,147
Better Place Forests Co. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	6
BrightInsight, Inc. [Member]
Unfunded commitments, principal balance	21,000
Fair value of unfunded commitment liability	278
Britecore Holdings, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	66
Canary Medical Inc. [Member]
Unfunded commitments, principal balance	2,500
Fair value of unfunded commitment liability	34
Castle Creek Biosciences [Member]
Unfunded commitments, principal balance	4,000
Fair value of unfunded commitment liability	72
Ceribell, Inc. [Member]
Unfunded commitments, principal balance	2,500
Fair value of unfunded commitment liability	4
Divergent Technologies, Inc. [Member]
Unfunded commitments, principal balance	30,000
Fair value of unfunded commitment liability	315
DropOff, Inc. [Member]
Unfunded commitments, principal balance	7,500
Fair value of unfunded commitment liability	188
Embody, Inc. [Member]
Unfunded commitments, principal balance	2,000
Fair value of unfunded commitment liability	20
Engage3, LLC [Member]
Unfunded commitments, principal balance	8,000
Fair value of unfunded commitment liability	40
Hound Labs, Inc. [Member]
Unfunded commitments, principal balance	7,500
Fair value of unfunded commitment liability	87
Interior Define, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	65
KSQ Therapeutics, Inc. [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	100
Lytics, Inc. [Member]
Unfunded commitments, principal balance	1,250
Fair value of unfunded commitment liability	0
Magnolia Medical Technologies, Inc [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	122
Native Microbials, Inc. [Member]
Unfunded commitments, principal balance	8,750
Fair value of unfunded commitment liability	64
Optoro, Inc. [Member]
Unfunded commitments, principal balance	15,000
Fair value of unfunded commitment liability	38
PDS Biotechnology Corporation [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	158
Scientia Vascular, Inc. [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	110
Slingshot Aerospace, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	64
Soli, Inc. [Member]
Unfunded commitments, principal balance	7,500
Fair value of unfunded commitment liability	147
Sonex Health, Inc. [Member]
Unfunded commitments, principal balance	2,500
Fair value of unfunded commitment liability	45
Swift Health Systems Inc. [Member]
Unfunded commitments, principal balance	25,500
Fair value of unfunded commitment liability	105
Temperpack Technologies, Inc [Member]
Unfunded commitments, principal balance	9,000
Fair value of unfunded commitment liability	$ 19

Note 9 - Concentrations of Cr_2

Note 9 - Concentrations of Credit Risk (Details Textual) - Debt Investments [Member] - Five Largest Debt Investments [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Investment Concentration Risk [Member]
Concentration Risk, Percentage			22%		26%
Investment Income Concentration Risk [Member]
Concentration Risk, Percentage	18%	21%	18%	13%

Note 10 - Distributions (Detail

Note 10 - Distributions (Details Textual) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.30	$ 0.30	$ 0.90	$ 0.90	$ 1.25
Earnings Per Share, Basic, Total (in dollars per share)	0.43	$ 0.40	$ 1.06	$ 1.02
Earnings Per Share, Basic, Undistributed (in dollars per share)	$ 0.67

Note 10 - Distributions - Distr

Note 10 - Distributions - Distribution Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 28, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Distributions declared per share (in dollars per share)		$ 0.30	$ 0.30	$ 0.90	$ 0.90	$ 1.25
Dividends, cash				$ 17,083		$ 25,067
Dividends, shares (in shares)				32,590		28,057
Dividends, stock				$ 392		$ 460
Dividend Paid December 15, 2022 [Member]
Distributions declared per share (in dollars per share)	$ 0.05
Dividend Paid January 13, 2023 [Member]
Distributions declared per share (in dollars per share)	0.11
Dividend Paid February 15, 2023 [Member]
Distributions declared per share (in dollars per share)	0.11
First 7/29/2022 Dividend [Member]
Record date				Nov. 17, 2022
Payment date				Dec. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 0
Dividends, shares (in shares)				0
Dividends, stock				$ 0
Dividend Paid March 15, 2023 [Member]
Distributions declared per share (in dollars per share)	$ 0.11
Second 7/29/2022 Dividend [Member]
Record date				Oct. 18, 2022
Payment date				Nov. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 0
Dividends, shares (in shares)				0
Dividends, stock				$ 0
Third 7/29/2022 Dividend [Member]
Record date				Sep. 19, 2022
Payment date				Oct. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,558
Dividends, shares (in shares)				7,703
Dividends, stock				$ 81
First 4/29/22 Dividend [Member]
Record date				Aug. 18, 2022
Payment date				Sep. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,528
Dividends, shares (in shares)				4,925
Dividends, stock				$ 60
Second 4/29/2022 Dividend [Member]
Record date				Jul. 19, 2022
Payment date				Aug. 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,484
Dividends, shares (in shares)				3,939
Dividends, stock				$ 55
Third 4/29/2022 Dividend [Member]
Record date				Jun. 17, 2022
Payment date				Jul. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,434
Dividends, shares (in shares)				4,286
Dividends, stock				$ 51
First 2/25/2022 Dividend [Member]
Record date				May 18, 2022
Payment date				Jun. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,378
Dividends, shares (in shares)				4,428
Dividends, stock				$ 50
Second 2/25/2022 Dividend [Member]
Record date				Apr. 19, 2022
Payment date				May 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,349
Dividends, shares (in shares)				4,088
Dividends, stock				$ 49
Third 2/25/2022 Dividend [Member]
Record date				Mar. 18, 2022
Payment date				Apr. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,352
Dividends, shares (in shares)				3,221
Dividends, stock				$ 46
First 10/22/21 Dividend [Member]
Record date						Feb. 18, 2022
Payment date						Mar. 16, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,100
Dividends, shares (in shares)						3,409
Dividends, stock						$ 46
Second 10/22/21 Dividend [Member]
Record date						Jan. 19, 2022
Payment date						Feb. 16, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,096
Dividends, shares (in shares)						2,680
Dividends, stock						$ 43
Third 10/22/21 Dividend [Member]
Record date						Dec. 17, 2021
Payment date						Jan. 14, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,031
Dividends, shares (in shares)						3,417
Dividends, stock						$ 56
Fourth 10/22/21 Dividend [Member]
Record date						Nov. 18, 2021
Payment date						Dec. 15, 2021
Distributions declared per share (in dollars per share)						$ 0.05
Dividends, cash						$ 1,013
Dividends, shares (in shares)						1,197
Dividends, stock						$ 20
First 7/23/21 Dividend [Member]
Record date						Nov. 18, 2021
Payment date						Dec. 15, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,027
Dividends, shares (in shares)						2,395
Dividends, stock						$ 38
Second 7/23/21 Dividend [Member]
Record date						Oct. 19, 2021
Payment date						Nov. 16, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,010
Dividends, shares (in shares)						1,907
Dividends, stock						$ 34
Third 7/23/21 Dividend [Member]
Record date						Sep. 17, 2021
Payment date						Oct. 15, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,008
Dividends, shares (in shares)						2,068
Dividends, stock						$ 36
First 4/23/21 Dividend [Member]
Record date						Aug. 18, 2021
Payment date						Sep. 15, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,996
Dividends, shares (in shares)						2,041
Dividends, stock						$ 34
Second 4/23/21 Dividend [Member]
Record date						Jul. 20, 2021
Payment date						Aug. 16, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,983
Dividends, shares (in shares)						1,937
Dividends, stock						$ 34
Third 4/23/21 Dividend [Member]
Record date						Jun. 17, 2021
Payment date						Jul. 16, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,964
Dividends, shares (in shares)						1,888
Dividends, stock						$ 33
First 2/26/21 Dividend [Member]
Record date						May 18, 2021
Payment date						Jun. 16, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,964
Dividends, shares (in shares)						1,671
Dividends, stock						$ 29
Second 2/26/21 Dividend [Member]
Record date						Apr. 20, 2021
Payment date						May 14, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,937
Dividends, shares (in shares)						1,794
Dividends, stock						$ 29
Third 2/26/21 Dividend [Member]
Record date						Mar. 18, 2021
Payment date						Apr. 16, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,938
Dividends, shares (in shares)						1,653
Dividends, stock						$ 28

Note 11 - Financial Highlight_2

Note 11 - Financial Highlights - Financial Highlights (Details) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) shares
Net asset value at beginning of period (in dollars per share)				$ 11.56	$ 11.02
Net investment income (in dollars per share)				1.06	1.02
Realized loss (in dollars per share)				$ (0.40)	$ (0.14)
Unrealized appreciation on investments (in dollars per share)				0.05	0.41
Net increase in net assets resulting from operations per common share (in dollars per share)		$ 0.23	$ 0.63	$ 0.71	$ 1.29
Distributions declared (in dollars per share)	[1]			$ (0.90)	$ (0.90)
From net investment income				(0.90)	(0.90)
From net realized gain on investments		0	0	0	0
Return of capital (in dollars per share)				$ 0	$ 0
Other	[2]			0.29	0.22
Net asset value at end of period (in dollars per share)		$ 11.66	$ 11.63	$ 11.66	$ 11.63
Per share market value, beginning of period (in dollars per share)				15.92	13.24
Per share market value, end of period (in dollars per share)		$ 10.01	$ 16.26	$ 10.01	$ 16.26
Total return based on a market value	[3]			(31.50%)	29.60%
Common stock, shares outstanding (in shares) | shares		26,393,773	20,425,175	26,393,773	20,425,175	21,217,460
Expenses without incentive value	[4]			11.40%	10.60%
Incentive fees	[4]			3%	3%
Net expenses	[4]			14.40%	13.60%
Net investment income with incentive fees	[4]			12.10%	12.10%
Net assets at the end of the period | $		$ 307,687	$ 237,590	$ 307,687	$ 237,590	$ 245,335
Average net asset value | $		$ 280,904	$ 223,031	$ 280,904	$ 223,031
Average debt per share (in dollars per share)				$ 13.32	$ 11.07
Portfolio turnover ratio	[5]			14.9	29
[1]Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.[2]Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.[3]The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.[4]Annualized.[5]Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance.

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($) $ in Thousands	Oct. 28, 2022	Oct. 21, 2022	Nov. 09, 2022	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument, Face Amount				$ 483,461	$ 353,000
Forecast [Member]
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized			$ 160,000
Transfer of Financial Assets Accounted for as Sales, Cash Proceeds Received for Assets Derecognized, Amount			98,800
Forecast [Member] | Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount			$ 100,000
Debt Instrument, Interest Rate, Stated Percentage			7.56%
Subsequent Event [Member] | Emalex Biosciences, Inc. [Member] | Equity Securities [Member]
Payments to Acquire Investments, Total		$ 400
Subsequent Event [Member] | Robin Healthcare, Inc. [Member] | Debt Investments [Member]
Payments to Acquire Investments, Total		$ 7,000
Subsequent Event [Member] | Sonex Health, Inc. [Member] | Debt Investments [Member]
Payments to Acquire Investments, Total	$ 2,500